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ABSTRACT 
 
 Acetaminophen (APAP) is a commonly used analgesic responsible for over 56,000 
overdose-related emergency room visits annually. A long asymptomatic period and limited 
treatment options result in a high rate of liver failure, generally resulting in either organ 
transplant or mortality. The underlying molecular mechanisms of injury are not well 
understood and effective therapy is limited. Identification of previously unknown genetic 
risk factors would provide new mechanistic insights and new therapeutic targets for APAP 
induced hepatocyte toxicity or liver injury.  
This study used a genome-wide CRISPR/Cas9 screen to evaluate genes that are 
protective against or cause susceptibility to APAP-induced liver injury. HuH7 human 
hepatocellular carcinoma cells containing CRISPR/Cas9 gene knockouts were treated with 
15mM APAP for 30 minutes to 4 days. A gene expression profile was developed based on 
the 1) top screening hits, 2) overlap with gene expression data of APAP overdosed human 
patients, and 3) biological interpretation including assessment of known and suspected 
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APAP-associated genes and their therapeutic potential, predicted affected biological 
pathways, and functionally validated candidate genes.  
This screen is the first genome-wide CRISPR/Cas9 knockout screen of APAP-
induced hepatocyte toxicity. The top hits from this screen included numerous genes 
previously not linked to liver injury. We further demonstrated the implementation of 
intermediate time points for the identification of early and late response genes. A negative 
selection screen identified genes involved in fundamental processes, including NAAA, 
ATG2B, and MYOZ3. A positive selection screen identified numerous genes potentially 
involved in pathogenic processes, including LZTR1, PGM5, and EEF1D. A top essential 
pathway at 24 hours of APAP treatment was Regulation of Skeletal Muscle Contraction. 
We additionally identified 6 genes, 3 novel and 3 known, that have drug-gene interactions 
favorable for re-purposing existing therapies to treat APAP-induced hepatotoxicity. 
Collectively, this line of research has illustrated the power of a genome-wide CRISPR/Cas9 
screen to systematically identify novel genes involved in APAP induced hepatocyte 
toxicity and to provide potential new targets to develop novel therapeutic modalities. 
  
 v 
 
APPROVAL PAGE 
 
The faculty listed below, appointed by the Dean of the School of Graduate Studies, have 
examined a thesis titled “Identification of Novel Regulatory Genes in Acetaminophen 
Induced Hepatocyte Toxicity by a Genome-Wide CRISPR/Cas9 Screen”, presented by 
Katherine Anne Shortt, candidate for the Doctor of Philosophy degree, and certify that in 
their opinion it is worthy of acceptance.  
 
Supervisory Committee 
Shui Qing Ye, M.D, Ph.D., Chair 
Division of Cell Biology and Biophysics, School of Biological Sciences 
Department of Biomedical and Health Informatics, School of Medicine 
 
Mary Gerkovich, Ph.D. 
Department of Biomedical and Health Informatics, School of Medicine 
 
Daniel P. Heruth, Ph.D. 
Department of Pediatrics, School of Medicine 
 
Saul Honigberg, Ph.D. 
Division of Cell Biology and Biophysics, School of Biological Sciences 
Gerald J. Wyckoff, Ph.D. 
Division of Molecular Biology and Biochemistry, School of Biological Sciences 
  
 vi 
 
CONTENTS 
 
ABSTRACT ....................................................................................................................... iii 
LIST OF ILLUSTRATIONS ...............................................................................................x 
LIST OF TABLES ............................................................................................................. xi 
GLOSSARY ..................................................................................................................... xii 
ACKNOWLEDGMENTS  .............................................................................................. xiv 
Chapter 
1. INTRODUCTION  .....................................................................................................1 
2. REVIEW OF THE LITERATURE  ...........................................................................4 
Candidate gene approaches for biomarker discovery in APAP-induced 
hepatotoxicity ...........................................................................................................4 
“Omics” approaches for biomarker discovery in APAP-induced hepatotoxicity ....7 
 Gene editing approaches for biomarker discovery in other diseases .....................10 
 Novel approach to APAP-induced hepatotoxicity biomarker discovery ...............11 
3. RESEARCH QUESTION .........................................................................................13 
4. METHODS  ..............................................................................................................15 
 Research design .....................................................................................................15 
sgRNA library amplification..................................................................................15 
Cell culture .............................................................................................................16 
Lentivirus production and concentration ...............................................................17 
Acetaminophen kill curve ......................................................................................18 
 vii 
 
In vitro hepatocellular carcinoma transduction using the GeCKOv2 sgRNA 
library .....................................................................................................................18 
CRISPR/Cas9 acetaminophen screen and sample collection ................................19 
CRISPR/Cas9 screen amplicon sequencing ..........................................................19 
CRISPR/Cas9 Screen deconvolution and analysis  ...............................................20 
Pathway analysis ....................................................................................................21 
Statistical analysis of gene expression datasets from the Gene Expression 
Analysis of overlapping data from Gene Expression Omnibus .............................21 
Human APAP induced liver injury data ....................................................21 
Mouse APAP induced liver injury data  ....................................................23 
Analysis of acetaminophen-associates SNPs in the literature ...............................24 
Drug-gene interaction analysis ..............................................................................25 
Functional validations in primary mouse hepatocytes ...........................................25 
Semi-quantitative PCR...........................................................................................27 
Western Blotting ....................................................................................................27 
Plasmids .................................................................................................................28 
5. RESULTS AND DISCUSSION PART 1: CRISPR/CAS9 SCREEN ......................29 
 Development of screening strategy and preparation of cell lines ..........................29 
 CRISPR/Cas9 knock-out screen and deconvolution..............................................29 
 Discussion ..............................................................................................................39 
6. RESULTS AND DISCUSSION PART 2: OUR SCREEN IN THE CONTEXT OF 
OTHER ACETAMINOPHEN DATA SETS ...........................................................42 
 viii 
 
 Overlapping analysis of our screen top hits with other gene expression 
acetaminophen datasets .............................................................................................42 
Analysis of RNA-sequence from mice with acetaminophen-induced acute liver 
injury ......................................................................................................................42 
Analysis of microarray of human liver biopsies from normal and acetaminophen-
induced acute liver failure patients ........................................................................43 
Analysis of microarray of human blood from normal and acetaminophen-dosed 
participants .............................................................................................................45 
Identification of candidate genes from overlapping gene sets ...............................48 
Discussion ..............................................................................................................49 
7. RESULTS AND DISCUSSION PART 3: ACETAMINOPHEN-ASSOCIATED 
SINGLE NUCLEOTIDE POLYMORPHISMS IN THE LITERATURE ...............52 
 Acetaminophen-associated single nucleotide polymorphisms in the literature .....52 
Functional in silico analyses of SNPs associated with acetaminophen-induced 
hepatotoxicity .........................................................................................................54 
Discussion ..............................................................................................................58 
8. RESULTS AND DISCUSSION PART 4: VALIDATIONS OF TOP CANDIDATE 
GENES ......................................................................................................................61 
 Validation of screening strategy ............................................................................61 
 Drug-gene interactions of candidate genes ............................................................62 
 Functional validations of candidate genes .............................................................64 
 Discussion ..............................................................................................................67 
9. CONCLUSIONS AND FUTURE DIRECTIONS....................................................71 
 ix 
 
 Conclusions ............................................................................................................71 
 Future directions ....................................................................................................72 
Appendix 
A. SUPPLEMENTARY FIGURES ...............................................................................74 
B. SUPPLEMENTARY TABLES ................................................................................79 
REFERENCE LIST .........................................................................................................154 
VITA ..............................................................................................................................166 
 
  
 x 
 
ILLUSTRATIONS 
 
 
Figure Page 
  
1. Genome-scale positive and negative screening using CRISPR/Cas9 ....................31 
2. Positive and negative screening reveal top gene and pathway candidates after 4 
days of APAP treatment.........................................................................................32 
3. Highly ranked genes and pathways after 24 hours of APAP treatment .................34 
4. Identification of gene hits across the APAP time course in the CRISPR/Cas9 
screen .....................................................................................................................37 
5. Overlapping analysis of significant CRISPR/Cas9 screen hits with mouse ALI 
(GSE110787) and human ALF gene expression data (GSE74000) ......................44 
6. Overlapping analysis of significant CRISPR/Cas9 screen hits with human ALI 
gene expression data (GSE70784)  ........................................................................47 
7. Validation experiments in primary mouse hepatocytes .........................................66 
 
 
  
 xi 
 
TABLES 
 
 
Table Page 
  
1. The top 100 genes for various APAP treatment times were queried in pubmatrix 
to determine novelty ..............................................................................................35 
2. Top canonical pathways predicted by Ingenuity Pathway Analysis ......................56 
3. Top diseases and disorders predicted by Ingenuity Pathway Analysis..................57 
4. Top candidate genes with known drug effects annotated by the DRUG Gene 
Interaction Database...............................................................................................63 
  
 xii 
 
GLOSSARY 
 
 
ALI: Acute Liver Injury.  
ALF: Acute Liver Failure. 
Allele: One of a number of alternate nucleotides of a specific locus on a strand of DNA.  
Amino acid: Organic acids that form the building blocks of proteins. Each of the 20 amino 
acids are coded by a 3 nucleotide DNA sequence. 
Cas9: DNA endonuclease guided by RNA. It is involved in CRISPR adaptive immunity 
in prokaryotes. 
CRISPR: Clustered Regularly Interspaced Palindromic Repeats 
Deoxyribonucleic Acid (DNA): Nucleic acids that encode genetic instructions of all living 
organisms. 
DILI: Drug-Induced Liver Injury. 
Exon: DNA sequence that remains in the mature RNA of a gene after introns are removed. 
Genome: The total genetic material of an organism. 
Genome-wide association study (GWAS): An approach that involves comprehensively 
scanning markers across the complete sets of DNA, or genomes, of many people to find 
genetic variations associated with a particular disease. 
Genotype: The set of alleles that an organism possesses for a given genetic locus. 
Normally a genotype contains 2 alleles due to the presence of 2 chromosomes.  
Hepatocellular carcinoma: A primary malignancy of the liver and the most common type of liver 
cancer in adults, and occurs commonly in people with liver disease 
Hepatocyte: The primary cell type in the liver. 
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Hepatotoxicity: Chemically-induced liver injury. 
Intron: DNA sequence in a gene but is not transcribed into the mature RNA. 
Linkage disequilibrium: When alleles for two genetic loci are not distributed randomly 
the loci are in linkage disequilibrium. 
Major allele: For a genomic position the allele that occurs most frequently in a population 
is the major allele. 
Mendelian disease: Diseases that have simple genetic inheritance patterns and are caused 
by a small number of genes.  
Minor allele: For a genomic position an allele that occurs in a population less frequently 
than a different allele at the same position is called a minor allele. 
Next generation sequencing (NGS): Current high throughput genetic sequencing 
technology that produces the order of nucleotides within a DNA molecule.  
Nonsynonymous mutation: A genetic variant that causes a change in amino acid coding. 
Single nucleotide polymorphism (SNP): Genetic variant that occurs at one nucleotide  
 (base pair). Different alleles are observed at one position across a population.  
Synonymous mutation: A genetic variant in a protein coding region that causes no change 
in amino acid coding. 
  
 xiv 
 
  
ACKNOWLEDGMENTS 
 
I would like to express my gratitude to my PhD committee for their guidance; the 
Ye lab for their support and excellent technical assistance; the students, staff and faculty 
of School of Biological Sciences and Department of Biomedical and Health Informatics in 
the School of Medicine, UMKC, for their tutelage, time, and advice in the completion of 
this project. Thanks to my friends and family for constantly encouraging and supporting 
me. I couldn’t have gotten here without all of you! 
This thesis was adapted with permission from the manuscripts Shortt et. al. (2018, 
under review) and Heruth et. al. (2018, under review). 
 
FUNDING 
 
Funding was provided in part by the start-up fund, William R Brown/Missouri State 
Endowment, The Children's Mercy Hospital, UMKC (Ye, SQ), a School of Graduate 
Studies Research Grant of UMKC School of Graduate Studies (Shortt, K), five UMKC 
GAF Awards of UMKC Women’s Council (Shortt, K), and a Sarah Morrison Student 
Research Award of UMKC School of Medicine (Singh, S). 
 
 
 1 
 
CHAPTER 1 
INTRODUCTION 
 
Acetaminophen (APAP) is a widely used medication and is responsible for ~50% 
of acute liver failure (ALF) cases in the United States (US) and Great Britain1-2. APAP is 
the top risk factor for acute liver injury (ALI) and ALF in the US and Great Britain and in 
the top 3 in China3. The recommended maximum daily dose of APAP is 4g for adults, with 
a single dose of just 7.5-10g causing acute toxicity4. Ultimately, 36% of cases of APAP 
induced ALF survive if no liver transplant occurs, and patients who receive a liver 
transplant have a 75% survival rate. 
At a therapeutic dosage about 90% of APAP is metabolized to glucoronate and 
sulfate conjugates by uridine 5’-diphoso-glucuronosyltransferases and sulfotransferases. 
Five to ten percent of APAP is processed in the liver by cytochrome-P450 enzymes (CYPs) 
to produce a highly toxic metabolite N-acetyl-p-benzo-quinone imine (NAPQI)5-7. 
Glutathione is conjugated with NAPQI by Glutathione-s-transferases (GST) to convert 
NAPQI to a non-toxic substrate. This mechanism, however, fails in cases of acute and 
chronic APAP overdose resulting in oxidant stress-induced liver injury8. When the 
enzymes responsible for glucuronidaiton (UDP-glucuronosyltransferases, e.g. UGT1A1, 
UGT1A6, UGT1A9, UGT287, UGT2815) and sulfation (sulfotransferases, e.g. SULT1A1, 
SULT1A3, SULT1A4, SULT1E1, SULT2A1) are saturated, APAP is metabolized by 
oxidation via the microsomal cytochrome P450 pathway into N-acetyl-p-benzoquinone 
imine (NAPQI) 9-10.  
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The cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2A6, CYP2D6, 
CYP2E1, and CYP3A4, convert acetaminophen into the highly reactive NAPQI metabolite 
11-15. At toxic acetaminophen levels, CYP3A4 presented with the highest relative capacity 
for acetaminophen bioactivation to NAPQI by oxidation, followed by CYP2E1, CYP2D6, 
and CYP1A2 16. At therapeutic acetaminophen levels, CYP3A4 again had the highest rate 
of conversion to NAPQI while the other CYP enzymes possessed significantly lower 
capacity for bioactivation 16.  
NAPQI, a strong oxidizer that is toxic to liver tissue, is reduced (inactivated) by 
conjugation with glutathione by glutathione S-transferases (GST), a family of enzymes 
(e.g. GSTT1, GSTP1) that detoxifies many hepatic drugs 17. The toxicity of NAPQI is 
associated with its ability to bind to cysteine residues in proteins to form NAPQI-protein 
adducts 18. At therapeutic doses, the small amount of NAPQI-protein adducts produced are 
removed effectively by autophagy 19-20. High levels of NAPQI deplete glutathione and 
accumulate in hepatocytes where excess NAPQI binds to cysteine residues on cellular and 
mitochondrial proteins, causing an immune response and necrosis, leading to ALI and 
ALF18, 21-22.  
The current model of acetaminophen-induced hepatic necrosis links the NAPQI-
protein adducts with amplified cascades of reactive oxygen and nitrogen species 
(ROS/RNS) resulting in the swift loss of hepatic cells and liver function 23-24. This model 
has been studied extensively 25-29, and the ROS/RNS induce increased mitochondrial 
permeability resulting in impaired mitochondrial function and necrotic cell death 30-31. 
Subsequently, necrotic hepatocytes release damage associated molecular patterns 
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(DAMPs) resulting in an immune response mediated by various cytokines and innate 
immune cells 32-34.  
The etiology of APAP-induced ALF is complex and is not fully understood, 
particularly for cases that present more than 8 hours post-ingestion5. These cases are 
extremely troublesome from a clinical perspective, because the liver injury can be 
asymptomatic for 24-48 hours4. When the canonical APAP clearance pathways including 
metabolism via CYPs are overwhelmed or low-functioning, redundant or accessory 
pathways may help to preserve function35. Current treatments of APAP-induced ALF focus 
on clearing excess APAP and replenishing glutathione and are only effective during a very 
short window of time post-overdose. Furthermore, there is evidence that APAP overdose 
may cause cell death by multiple mechanisms36. There is a demonstrated need for improved 
modalities of risk assessment, diagnosis, and therapeutics.  
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CHAPTER 2  
REVIEW OF THE LITERATURE 
 
Candidate gene approaches for biomarker discovery in APAP-induced hepatotoxicity 
 
Although acetaminophen is a dose-dependent hepatotoxin, elevated alanine 
aminotransferase (ALT) serum levels were measured in some healthy adults following a 7 
to 14 day administration of the maximum daily dose of 4 g per day 37-38. Additional case 
studies, although rare, have reported the development of ALI even at therapeutic doses 39-
40. These findings confirm that some healthy individuals experience mild to severe liver 
injury in response to therapeutic doses of acetaminophen suggesting that genetic 
components are involved in acetaminophen metabolism. Thus, several groups have 
proposed that NAPQI toxicity can be enhanced by alterations in the metabolism of 
acetaminophen due to genetic polymorphisms in the corresponding enzymes 29, 41-42. 
Since hepatic injury can occur at sub-therapeutic doses in some individuals genetic 
disposition may play a significant role in an individual susceptibility to APAP induced 
hepatotoxicity29, 41-43. Genetic variations, including single nucleotide polymorphisms 
(SNPs), can predict population and inter-individual differences in APAP degradation and 
hepatotoxicity 44-45. Currently several genome wide association studies (GWAS) in humans 
have identified pharmacogenetic SNPs associated with drug induced liver injury, including 
APAP-induced injury 46-47. Polymorphisms have been identified that alter the activity of 
the SULT, UGT, and CYP enzymes, all of that play important roles in APAP metabolism 
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29, 41, 46, however very few SNPs have been experimentally confirmed to be associated 
directly with acetaminophen-induced hepatotoxicity 48-50.  
Of the APAP-associated polymorphisms that have been identified, a number have 
resulted from candidate gene-based approaches. Homozygous carriers of the rs2031920 
variant T allele presented with a two-fold increase in the elimination rate of acetaminophen 
compared to CC and CT individuals in a study by Ueshima et. al.48, that correlated with 
increased promoter activity due to the homozygous minor genotype 51 and higher hepatic 
levels of CYP2E1 52. CYP2E1 is an isoform of Cytochrome P450, which is responsible for 
metabolizing APAP to NAPQI. 
Court et al. identified three 3’ UTR SNPs (rs8330, rs10929303, rs1042640) in the 
UGT1A gene that is associated with increased glucuronidation activity (more specifically 
it is a UDP glucouronosyl transferase) following acetaminophen exposure 49. The UGT1A 
rs8330 MAF (G) was significantly lower in the unintentional acetaminophen 
hepatotoxicity group (16%) compared with the other ALF subgroups (22%), with an OR = 
0.53 (0.30-0.94; P = 0.027) 50. This finding was consistent with a protective effect of the 
variant rs8330 G allele through enhancement of acetaminophen glucuronidation and 
detoxification, as demonstrated by a series of in vitro mechanistic studies by Court et al. 
49. rs8330 increased glucuronidation activity due to altered splicing of the primary UGT1A 
transcript resulting in the preferential retention of exon 5A versus exon 5B. Translation of 
UGT1A mRNA containing exon 5B produces a truncated UGT1A protein, termed isoform 
2 variant, which lacks enzymatic activity and further represses enzymatic activity through 
hetero-dimerization with the wild type isoform 49. Like rs776746, the rs8330 MAF varies 
among ethnic populations.  
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The CYP3A5 splice donor variant (rs776746) associated with acetaminophen-
induced hepatotoxicity. The minor A allele (also known as CYP3A5*1) encodes a 
functional Cytochrome P450 Family 3 Subfamily A Member 5 protein, while a non-
functional protein is produced from CYP3A5 genes containing the major G allele 
(rs776746; CYP3A5*3) 53. The CYP3A5*1 A allele was observed more frequently in 
intentional acetaminophen-overdose cases compared to all other acute liver failure patients 
50. The heterozygous GA genotype was an “at risk” genotype with an OR = 2.3 (1.1-4.9; P 
= 0.034) 50. The homozygous AA genotype was not observed in this cohort. Subsequently, 
the CYP3A5 diplotypes have been correlated with phenotypes for the metabolism of drugs, 
like tacrolimus: *1/*1, extensive metabolizer; *1/*3, intermediate metabolizer; *3/*3, poor 
metabolizer 54-55. However, the rs776746 MAF does not correlate with the incidence of 
acetaminophen-induced hepatotoxicity across different non-Caucasian ethnic groups 45, 56-
58.  
The CD44 rs1467558 TT minor allele genotype was over represented in the 
unintentional hepatotoxicity group with an OR = 4.0 (1.0-17.2; P = 0.045) 50, suggesting 
that rs1467558 TT is an “at risk” genotype. This observation was supported by previous 
studies that revealed that rs1467558 associated with elevated serum alanine 
aminotransferase (ALT) levels 37-38. In silico mechanistic structural analysis predicted that 
rs1467558 can alter many of the complex, alternative CD44 transcripts, including a 
potentially damaging amino acid change from threonine to isoleucine 38. Interestingly, 
CD44 is not an acetaminophen metabolizing enzyme, but rather a cell surface receptor 
involved in cell-cell interactions, cell adhesion, and cell migration in inflamed tissue 59. 
The rs1467558 MAF of 21% in the Caucasian unintentional hepatotoxicity cohort is higher 
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than in each of the ethnic populations determined by the 1000 Genomes Project: African 
(1%), American (11%), Asian (0%), European (19%), and Southern Asian (3%) 60.  
The rs1902023 missense polymorphism in UGT2B15 (termed UGT2B15*2) was 
associated with lower acetaminophen glucuronide-to-acetaminophen concentration ratios 
in urine 61 and blood 62. Court et al. demonstrated that UGT2B15*2 associated with 
increased plasma concentrations of NAPQI-protein adducts and that the plasma 
concentrations of the protein adducts negatively correlated with acetaminophen 
glucuronidation 63. Thus carriers of rs1902023 are slower metabolizers of acetaminophen 
glucuronidation resulting in increased availability of acetaminophen for oxidative 
metabolism to NAPQI and subsequent liver damage.  
 
“omics” approaches for biomarker discovery in APAP-induced hepatotoxicity 
 
Genomic approaches to biomarker discovery have had a small amount of success 
in identifying candidate polymorphisms and genes. To test the hypothesis that genetic 
polymorphisms downstream of NAPQI formation contribute to hepatotoxicity, Moyer et. 
al..tested 176 lymphoblastoid cell lines (HVP-LC) established from healthy donors for 
association of genetic polymorphisms downstream of NAPQI formation with 
hepatotoxicity 43. Initially, Moyer et al. examined the association of 716 SNPs, located in 
31 GSH pathway genes, with NAPQI-IC50. Only 45 SNPs had significant P values (<0.05), 
24 of which were located in the multidrug resistance ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3 (ABCC3) and member 4 (ABCC4) genes. Expression of Abcc3 
and Abcc4 in mice upon acetaminophen-induced hepatotoxicity have been shown to be 
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dependent upon the transcription factor, Nrf2 64. Nrf2 has been shown to play a protective 
role in acetaminophen-induced hepatotoxicity as Nrf2-/- knockout mice were more 
susceptible to acetaminophen-induced liver damage compared to their wild type Nrf2+/+ 
controls 65. The remaining significant SNPs were located in glutamate cysteine ligase 
(GCLC), glutathione peroxidase (GPX2, GPX3, GPX4 and GPX7), glutathione synthetase 
(GSS), and glutathione transferase (GSTA2, GSTA3 and GSTP1).  
When Moyer et. al. applied a genome-wide approach ninety-six SNPs (P < 1×10-4) 
associated with NAPQI-IC50. Interestingly, 15 of the top 20 significant SNPs mapped to 
intergenic regions. Ten of these 15 intergenic SNPs clustered in a region of chromosome 
3, between the C3orf38 and EPHA3 genes. Functional analysis of rs2880961, that lies 317 
kb downstream of C3orf38, demonstrated binding of transcription factors (TF), including 
NF-κB, HSF1, and HSF2, although significant differences in NF-κB, HSF1, and HSF2TF 
binding were not detected by chromatin immunoprecipitation (ChIP) assays between wild-
type and variant SNPs 43. However, this does not preclude differential binding of other TFs. 
The top 10 intragenic SNPs are canonical splicing variants located in the introns of genes 
involved in gene regulation (LMX1A), signal transduction (ETKN2, KCNJ3, MCPT1), 
immune response (IL23R, UBASH3A), extra-cellular matrix (SPAG16, LAMA4), and the 
detoxification of aldehydes generated by lipid peroxidation (ALDH1A3). To identify 
potential cis effects of SNPs on gene expression, Moyer et al. measured mRNA expression 
to identify 17 genes associated significantly with NAPQI IC50 with P < 0.0001, however 
none of these 17 genes overlapped with genes containing SNPs, suggesting that the SNPs 
may have a trans effect on the expression of these genes 43. 
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Two studies by Harrill et al. 38, 66 identified potential susceptibility targets using a 
panel of 36 inbred mouse strains to model genetic diversity. Haplotype-associated mapping 
and targeted sequencing revealed that polymorphisms in Ly86, Cd44, Cd59a, and Capn8 
correlated with increased ALT levels. To determine if the orthologous human genes were 
also associated with acetaminophen-induced liver injury, genomic DNA from two 
independent cohorts, UNC 38 and Purdue Pharma 37, were sequenced. Although Harrill et 
al. did not detect SNP associations within LY86 and CD59, rs3749166 in CAPN10 (the 
human orthologue of mouse Capn8) (P = 0.045) and rs1467558 in CD44 (P = 0.002) were 
associated with elevated ALT levels in both cohorts 38. To validate these findings further, 
liver damage was measured in C57BL/6J Cd44 knock-out mice administered 
acetaminophen. Cd44 knock-out mice presented with greater liver injury (61%±7% mean 
liver necrosis ± SE) compared to wild-type controls (40%±4%) following a 24 hour dose 
of acetaminophen (300 mg/kg). These results indicate a role for CD44 in modulation of 
susceptibility to acetaminophen hepatotoxicity, as supported by Court et al. 50. Further gene 
expression profiling identified 26 genes that associated significantly with liver damage. 
Similar with the Moyer et al. study, these genes did not overlap with the hepatotoxicity 
SNPs identified in their mouse panel. This observation supports the hypothesis that in 
addition to affecting protein-coding regions, SNPs may disrupt non-coding regulatory 
regions. An alternative explanation is that the 26 genes function either upstream or 
downstream of the SNP modified genes. 
Transcriptomic studies measure the changes in gene expression post-drug treatment 
using RNA sequencing or gene expression profiling, however the genes identified may not 
be causal. Although a major limitation of these studies is the absence of control populations 
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that ingested a similar dose of acetaminophen but did not develop ALF, the results are 
compelling. The association of these polymorphisms with acetaminophen-induced 
hepatotoxicity, along with their population variations, should be investigated further. To 
overcome the challenges of the candidate gene approach in human populations with ALF 
resulting from acetaminophen toxicity, additional studies have employed alternative 
approaches, such as GWAS, to identify SNPs that may serve as biomarkers for 
acetaminophen susceptibility. Further analysis of the candidate polymorphisms and genes 
identified by these methods will better elucidate their role as well as their diagnostic and 
therapeutic utility. 
 
Gene-editing approaches for biomarker discovery in other diseases 
 
Effective, reproducible screening methods for identification of disease-associated 
genes have long been sought. Microarray and omics approaches have widely been used to 
identify genes acting in APAP-induced injury43, 67-71. These studies measure the changes in 
gene expression post-drug treatment using RNA sequencing or gene expression profiling, 
however the genes identified may not be causal. Previous screens of various diseases were 
accomplished using gene knockdown by RNA interference (RNAi), resulting in 
incomplete gene knockout and limiting the applications of the method72-74. Gene-trap 
mutagenesis made genome-wide insertional mutagenesis studies possible, however it is 
only possible in haploid cell types, making it infeasible to study drug effects in diverse 
organ systems or in vivo75. Zinc finger nucleases (ZFNs) and transcription activator-like 
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effector nucleases (TALENs) produce double-stranded breaks, however it is difficult to 
target multiple targets simultaneously with these methods76-80.  
CRISPR/Cas9 pooled lentiviral libraries provide stable, genome-wide gene 
knockout alternative that makes possible direct assessment of gene function that previous 
methods have not achieved80-81. In addition to the CRISPR/Cas9 pooled gene knockout 
libraries, genome-wide CRISPR/Cas9 SAM (Synergistic Activation Mediator) and 
CRISPRi (CRISPR interference) sgRNA libraries enable robust, multi-approach CRISPR 
screens for human, mouse, and other model organisms82-86. Similarly to RNAi screens, in 
a CRISPR/Cas9 knockout library a positive screen identifies enriched gene knockouts after 
drug treatment. These genes potentially increase susceptibility to the treatment condition. 
A negative screen identifies depleted gene knockouts after drug treatment. These genes are 
potentially essential to survival of the treatment condition. The genome-wide 
CRISPR/Cas9 knockout screen has successfully identified genes contributing to a large 
variety of mechanisms, including essential genes and genes that conferred loss of resistance 
to vemurafenib in a melanoma model82, 87. 
 
Novel approach to APAP-induced hepatotoxicity biomarker discovery 
 
Genome wide association studies (GWAS) provide a powerful tool to scan for 
SNPs that associate with a disease phenotype, such as hepatotoxicity. Unfortunately, large 
scale GWAS and transcriptomic studies for acetaminophen-induced hepatotoxicity have 
not been performed in humans due to the lack of control populations consisting of 
individuals who ingested the same elevated doses of acetaminophen but did not develop 
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ALI. These “controls” are typically not captured since the need to pursue medical attention 
after their “overdose” is limited. 
This study builds on the existing CRISPR/Cas9 screening technology and applies 
it to a novel study of APAP-induced hepatotoxicity. We performed a genome-scale 
CRISPR/Cas9 screen of APAP toxicity (30 minutes-4 days) using the GeCKOv2 sgRNA 
library. We identified groups of genes and biological pathways that are protective against 
APAP and other genes that increase susceptibility to injury. An understanding of genes 
that act in protecting from or enhancing injury at different times can better inform better 
candidate gene discovery and elucidate the molecular pathways acting in response to 
APAP. By cross-referencing these data with existing gene expression data on APAP 
overdose in humans and mice, we validated findings from our screen and connected the 
effect of CRISPR/Cas9 gene knockout on drug metabolism with the effect of drug on 
gene expression. From these data we hypothesized the role of novel genes and validate 
the functional effect of knockdown of select candidate genes. These findings inform 
changes in the diagnostic and therapeutic modalities employed at the patient level, with 
the ultimate goal of improving outcomes of APAP-induced ALF.  
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CHAPTER 3 
RESEARCH QUESTION 
 
The purpose of this study is to discover new candidate genes for acetaminophen -
induced risk assessment, diagnosis, and treatment. The identification and validation of new 
biomarkers hold promise for mechanistic insights and novel therapeutic targets.  
We hypothesize that the mechanism of acetaminophen toxicity is more complex 
than is currently known, and expect to find novel genes associated with acetaminophen 
induced ALF. Our short-term goal is to identify new and robust candidate genes in APAP 
induced ALF. Our long-term goal is to expand and establish new genetic markers to better 
understand the physiology of the disease as well as direct the development of diagnostic, 
prognostic and therapeutic tools to address acetaminophen induced ALI and ALF. These 
aims advance our understanding of the molecular mechanisms underlying the pathogenesis 
of ALI/ALF and provide novel insights into effective prevention and treatment of 
acetaminophen induced liver injury. 
 
Aim 1: CRISPR/Cas9 gene knockout screen of Acetaminophen-induced 
hepatotoxicity 
 
Specific aim 1 was to identify novel genes associated with acetaminophen toxicity using a 
genome-wide CRISPR/Cas9 screen of acetaminophen-induced hepatotoxicity in a 
hepatocellular carcinoma cell line. We identified genes that are protective against 
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acetaminophen toxicity as well as genes that increase susceptibility to acetaminophen. The 
results of specific aim 1 are discussed in chapter 5. 
 
Aim 2: Overlapping analysis of post-Acetaminophen treated gene-expression data 
with our CRISPR/Cas9 screen top hits 
 
Specific aim 2 cross-evaluated the CRISPR/Cas9 screen gene list (+/- APAP) from specific 
aim 1 by a meta-analysis of 2 human microarray datasets (ALF and overdose) and 1 mouse 
RNA-seq dataset (+/- APAP). This analysis identified an overlapping and robust list of 
genes that are differentially expressed in APAP overdose and in APAP-induced ALF. The 
results of specific aim 2 are discussed in chapter 6. 
 
Aim 3: Exploration of candidate genes identified from the CRISPR/Cas9 screen and 
the literature 
 
Specific aim 3 analyzed the annotation and functional role of SNPs that are associated 
with APAP-induced hepatotoxicity in the literature. We additionally assessed overlap of 
genes containing SNPs with genes identified from our CRISPR/Cas9 screen strategy. We 
also explored top candidate genes identified from our screening strategy as well as from 
the literature. We validated selected genes, and began to investigate in-depth the 
molecular mechanisms underlying the roles of these genes and potential therapeutic 
targets in acetaminophen induced acute liver injury or acute liver failure. The results of 
specific aim 3 are discussed in chapters 7 and 8.
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CHAPTER 4 
METHODOLGY 
 
Research design 
 
 This study uses a novel genome-wide CRISPR/Cas9 knockout screening strategy 
to quantify the effect of specific, targeted gene knockouts on cellular survival of 
acetaminophen for a range of exposure times. Top enriched and depleted gene knockouts 
and pathways are assessed and placed in the context of other gene expression datasets 
representing acute overdose and chronic acetaminophen exposure. Selected candidate 
genes were knocked down in primary hepatocytes to validate screen findings.  
 
sgRNA library amplification 
 
The genome-wide CRISPR/Cas9 gene knockdown screen was accomplished using 
HuH7 human hepatoma cells and the GeCKOv2 gene knockout library82, 88-90. The human 
GeCKOv2 sgRNA library halves A and B contain 122,411 targeting sgRNA and 1,000 
non-targeting control sgRNA, of that 119,461 are unique sgRNAs (117,481 targeting 
sgRNAs). Library halves A and B were amplified in Endura competent cells (Lucigen cat. 
60242-1, Middleton, WI) and isolated using the Purelink HiPure plasmid midi prep kit 
(Invitrogen k210005, Carlsbad, CA) as previously described82, 89. 
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Cell culture 
 
HEK293FT cells (Thermo Fisher cat. R70007, Waltham, MA) were maintained in 
high-glucose DMEM (Thermo Fisher cat. 11965118) supplemented with 100 U/ml 
penicillin and streptomycin (Thermo Fisher cat. 15140122), non-essential amino acids 
(Thermo Fisher cat. 11140050), 2mM L-glutamine (Thermo Fisher cat. 25030081), 1mM 
sodium pyruvate (Thermo Fisher cat. 11360070), and 10% fetal bovine serum (Atlanta 
Biologicals cat. S11150, Atlanta, GA). Cells were detached with trypsin-EDTA (Thermo 
Fisher cat. 25200056). 
HuH7 was obtained from the Japanese Collection of Research Bioresources Cell 
Bank91. The HuH7 human hepatocellular carcinoma cell line (JCRB cat. 0403, Osaka, 
Japan) was chosen as a model for APAP toxicity studies because it is more robust than 
primary hepatocytes, allowing efficient lentiviral transduction, transfection, and genome 
editing with CRISPR/Cas992-96.  
Cells were maintained in DMEM (Thermo Fisher cat. 111885092) supplemented 
with 100 U/ml penicillin and streptomycin (Thermo Fisher cat. 15140122), non-essential 
amino acids (Thermo Fisher cat. 11140050), and 10% fetal bovine serum (Atlanta 
Biologicals cat. S11150) as previously described, with the addition of 2mM L-glutamine 
(Thermo Fisher cat. 25030081) and 1mM sodium pyruvate (Thermo Fisher cat. 
11360070)97. Cells were detached with trypsin-EDTA (Thermo Fisher cat. 25200056). All 
incubations were performed at 37°C and 5% CO2.  
  
  
 17 
 
Lentivirus production and concentration 
 
T-150 TPP flasks (18 T-150 flasks for the library, MidSci cat. TP0151, Valley Park, 
MO) of HEK293T cells were seeded at ~40% confluence the day before transfection in 
DMEM. One hour prior to transfection, media was removed and 18mL of pre-warmed 
reduced serum OptiMEM media (Thermo Fisher cat. 31985070) was added to each flask. 
Transfection was performed using Lipofectamine 2000 (Thermo Fisher cat. 11668019) and 
Plus reagent (Thermo Fisher cat. 11514015). For each flask, 200μl of Plus reagent was 
diluted in 3 ml OptiMEM with 20μg of lentiCRISPR plasmid library, 10μg of pVSVg, and 
15μg of psPAX2. 100μl of Lipofectamine 2000 was diluted in 3ml OptiMEM and, after 5 
min, it was added to the mixture of DNA and Plus reagent. The complete mixture was 
incubated for 20 min before being added to cells. After 6 h, the media was changed to 24ml 
D10 supplemented with 1% BSA (Sigma cat. A8412-100ML, St. Louis, MO). After 84h, 
the media was removed and centrifuged at 1,000 rpm at 4°C for 5 min to pellet cell debris. 
The supernatant was filtered through a 0.45 um low protein binding membrane (EMD 
Millipore Steriflip cat. SE1MO03MO0 or stericup cat. SCHVU05RE, Billerica, MA). To 
achieve concentration of the GeCKO v2 pooled library, the virus was ultracentrifuged 
(Beckman-Coulter, Brea, CA) at 32,800 rpm for 1h at 4°C and then re-suspended overnight 
at 4°C in D10 supplemented with 1% BSA. Aliquots were stored at –80°C. Lentiviruses 
were titrated by qRT-PCR (Clontech Lenti-X™ qRT-PCR Titration Kit cat. 631235, 
Mountain View, CA). 
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Acetaminophen kill curve 
 
The APAP concentration used for the screen was determined by measuring cell 
proliferation of HuH7 stably transduced with Cas9 and Guide-Puro (empty vector) in the 
presence of 0-20mM APAP (Sigma cat. A7085. St. Louis, MO) daily for 7 days. HuH7 
were seeded at 20,000 cells/96-well (MidSci cat. TP92696, Valley Park, MO) prior to 
APAP treatment. Titration of APAP concentrations ranging from 5mM-20mM was 
accomplished by measuring cell count at 24 hour intervals for seven days by trypan blue 
counting (Sigma cat. T8154-100ML, St. Louis, MO). Percent of cell death was determined 
as an average of the APAP-treated cell count divided (do you mean subtracted?, only dead 
cells stain, right?  I can’t see why you would divide) by untreated cell count (N=3). For the 
screen, 15mM APAP was chosen because there was 5% survival (95% cell death) at 3 days 
selection when APAP-treated cells were compared with untreated cells and 1% survival 
(99% cell death) at day 4 selection when APAP-treated cells were compared with untreated 
cells, based on the strategy of Wang et. al.86.  
 
In vitro hepatocellular carcinoma transduction using the GeCKOv2 sgRNA library 
 
HuH7 cells were detached using 0.25% Trypsin-EDTA (Thermo Fisher cat. 
25200056) and seeded the day prior to transduction at 6E6 cells per T-150 TPP flask 
(MidSci cat. TP0151, Valley Park, MO). The flasks were then transduced for 48h in culture 
media + 8µg/ml polybrene (Thermo Fisher cat. 107689-10G) + Cas9 lentivirus at an MOI 
<0.1. HuH7 underwent monoclonal selection by 1ug/ml blasticidin (Thermo Fisher cat. 
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A1113903) before Cas9 expression was confirmed by western blot. HuH7-Cas9 was 
transfected with the GeCKOv2 packaged lentiviral library as described above at 0.5 MOI. 
The pooled, transduced cells were selected with 1.5µg/ml puromycin (Invitrogen cat. Ant-
pr-1) for 3 days alongside cells transduced with the empty vector lentiGuidePuro, positive 
fluorescent control pLJM1-EGFP. pLJM1-EGFP fluorescence was verified 48h post-
transduction. 
 
CRISPR/Cas9 acetaminophen screen and sample collection 
 
After 8 days of transduction a T0 sample was collected (N=2) and the remaining 
library-transduced cells were treated with 15mM APAP for 30 minutes up to 4 days (2 
biological replicates for T0, 24 hour, and 4 day samples). Samples that underwent 4 days 
of APAP treatment were outgrown for 21 days prior to collection. Genomic DNA was 
isolated from samples of a minimum of 2x107 cells using the Blood and Cell Culture Midi 
Kit (Qiagen cat. 13343, Valencia, CA), resulting in a minimum of 136µg DNA per sample. 
DNA was quantified using the Qubit high-sensitivity DNA quantification assay (Thermo 
Fisher cat. Q32851) and Take3 microspot plate reader (BioTek Epoch, Winooski, VT).  
 
CRISPR/Cas9 Screen amplicon sequencing 
 
DNA amplification, library preparation, and sequencing were conducted using 
standard protocols. 3.33µg of the isolated genomic DNA was used to amplify the bar-coded 
amplicons in 39 Herculase II DNA polymerase (Agilent cat. 600679, Santa Clara, CA) 
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reactions per sample (primers described in supplementary table 1). 5µl amplicon or 1µl 
diluted plasmid library was used as template in 13 50µl Herculase II DNA polymerase 
reactions per sample to attach pooled variable-length spacers and Illumina indexes (primers 
described in supplementary table 1). 24 cycles were used to amplify DNA in the first and 
second PCR. The amplicon fragments after PCR 2 have the following sequence (354-362bp 
library with variable 20bp sgRNA sequence in the middle) (SF1). DNA was pooled by 
sample and purified using the Nucleospin Gel and PCR Clean-up kit (Clontech cat. 
740609.250, Mountain View, CA). DNA was quantified using a Qubit high-sensitivity 
DNA quantification assay (Thermo Fisher cat. Q32851) and Take3 microspot plate reader 
(BioTek). DNA quality was analyzed by Experion CHIP assay (BioRad cat. 7007-163, 
Hercules, CA). Clusters were generated on the flow cell using the HiSeq Rapid Duo CBot 
Sample Loading Kit (Illumina CT- cat. 403-2001, San Diego, CA). A single-read rapid run 
of 75 cycles was performed on a HiSeq 1500 (Illumina cat. GD-402-4002) using the HiSeq 
Rapid SBS kit (Illumina cat. FC-402-4022) with 10% PhiX.  
 
CRISPR/Cas9 screen deconvolution and analysis 
 
The sequence reads were demultiplexed and converted to fastQ with BCL2FastQ 
v2.17 (Illumina) and trimmed in cutadapt 1.7.1 (with Python 2.7.6) to include only the 
20bp sgRNAusing the 5’ sequence GTGGAAAGGACGAAACACCG and the 3’ sequence 
GTTTTAGAGCTAGA 98. Trimmed reads were aligned to the index in Bowtie2 v2.1 with 
a 1bp mismatch allowance99. Read counts were normalized to the median with T0 as 
control and analyzed using sgRNA and gene-level RRA (Robust Rank Aggregation) in 
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MaGeCK v0.5.6100. In comparisons between 2 time points the biological replicates were 
handled as independent replicates and in the pooled T0 vs. 30min-24h and 30min-4d the 
replicates were combined. Gene-level analysis was validated using Maximum Likelihood 
Estimate (MLE) in MaGeCK v0.5.6. Genes with fewer than 3 sgRNA were not included 
in the gene-level analysis but were included in the Gene Set Enrichment Analysis (GSEA) 
pathway analysis implemented in MaGeCK v0.5.6101. Scatter plots and heat maps were 
generated in R. Venn-diagrams were generated using 
http://bioinformatics.psb.ugent.be/webtools/Venn/. CRISPR/Cas9 screen data were 
submitted to the Gene Expression Omnibus (GSE112463, 
https://www.ncbi.nlm.nih.gov/geo/). 
 
Pathway analysis 
 
Analysis of pathway-level effects of APAP treatment in the 24h and 4d samples 
individually vs. T0 was accomplished using GSEA in Mageck v0.5.6 using the MsigDB 
“Kegg gene sets” and “all GO gene sets”. Ingenuity Pathway Analysis of 24h vs. T0 (genes 
with p<0.05) and 4d vs. T0 (genes with p<0.05) was also used to predict pathway-level 
effects of APAP treatment. 
 
Analysis of overlapping data from the Gene Expression Omnibus 
 
Human APAP-induced liver injury. We then analyzed samples from 2 publically 
available human datasets of acetaminophen overdose from the Gene Expression Omnibus, 
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GSE74000 and GSE7078467, 102. Gene candidates identified using the genome-wide 
CRISPR/Cas9 screen were cross-referenced with gens that were significantly correlated 
with APAP overdose from 2 human microarray datasets identified in the Gene Expression 
Omnibus (https://www.ncbi.nlm.nih.gov/geo/). These datasets were analyzed in GEO2R 
using the microarray data normalized and deposited by the original authors. 
Of the available gene expression datasets assessing the effect of APAP, these were 
selected because they address hepatotoxicity at a range of stages. These datasets were 
analyzed in GEO2R using the microarray data normalized and deposited by the original 
authors. GSE70784 contains gene-expression data from blood in patients receiving a daily 
dose of APAP or placebo. These data compare patients at a higher risk of injury 
(responders) to non-responders and placebo after 1 day and 8 days of dosing. Genes with 
differential expression in blood, especially early after dosing, are ideal diagnostic 
biomarkers. GSE7400 contains gene expression data from liver biopsies from healthy 
patients and patients APAP-induced-ALF. These data address differential gene expression 
in end-stage disease, and better inform the biological mechanisms active in APAP-induced 
ALF. 
In GEO2R, microarray data from 12 APAP responder blood samples were 
compared to 32 non-responders and 10 placebo controls on 1 day and 8 days of APAP 
treatment. Subjects were treated with 4g APAP or placebo for 7 days and were followed 
for 14 days. Responders were classified as patients with ALT (alanine aminotransferase). 
>2 times the upper limit of normal during days 4-9 after the start of APAP dosing. 
Background correction and normalization was completed by the depositing authors. Data 
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was log 2 transformed prior to analysis and the unadjusted p-values were used for 
comparison with the CRISPR screen. 
Microarray data from 3 APAP-induced ALF liver samples were compared to 2 
healthy liver samples were obtained from the GEO dataset GSE74000 and compared using 
GEO2R. Background correction, median polish summarization, and quantile normalization 
were completed by the depositing authors. Data was log 2 transformed prior to analysis 
and the FDR-adjusted p-values were used for comparison with the CRISPR screen. Heat 
maps were generated in R. Box plots were generated in GEO2R. 
 
Mouse APAP-induced liver injury. RNA-seq data from mice previously 
published by our lab (GSE110787, Zhang et al. Am J Pathol.  In press, 2018) evaluating 
the effect of APAP overdose on RNA expression changes in the liver was 7 male 11 week 
old C57BL/6 mice, 4 saline treated control mice and 3 mice 24h after 200mg/kg APAP 
(Sigma cat. A7085, St. Louis, MO) exposure via intraperitoneal injection, underwent RNA-
sequencing on an Illumina HiSeq1500. RNA was isolated from liver using the MirVana 
miRNA isolation kit (Thermo Fisher cat. AM1561, Waltham, MA).  
Samples were prepared using the TruSeq Stranded Total RNA Sample Preparation 
Kit (Illumina cat. RS-122-2201, San Diego, CA) and clusters were generated using the 
TruSeq Paired-End Cluster Kit v3-cBot-HS (Illumina cat. PE-401-3001, San Diego, CA). 
Paired –end sequencing (2x101 cycles) was completed using the TruSeq SBS kit v3-HS 
(Illumina cat. FC-401-3001, San Diego, CA). The raw base calling (.bcl) files were 
converted to demultiplexed compressed FASTQ files using Illumina’s bcl2fastq v2.17 
software. TopHat 2.0.9 was used to map RNA-seq reads against the mouse reference 
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genome (mm10) using default parameters103-104. Transcript assembly, abundance 
estimation, and comparison of expression were conducted with Cufflinks v2.2.1 and 
reported in Fragments Per Kilobase of exon per Million fragments mapped (FPKM)104. 
Cuffdiff, a part of the CuffLinks package, was used to calculate statistical significance 
changes of gene expression between treated and untreated mice105. Box plot and heat maps 
were generated in R. 
This RNA-seq study of APAP-induced ALI identified genes that were differentially 
expressed in a genetically and drug dosage controlled environment after liver injury has 
occurred, but prior to ALF. These data better illustrate the changes in gene expression due 
to the drug overdose absent of the variation that is unavoidable in human studies. 
 
Analysis of acetaminophen-associates SNPs in the literature  
 
 In this analysis we evaluate the 147 genetic polymorphisms that have been 
identified as associated with either protection against or susceptibility to APAP-induced 
hepatotoxicity and then provides functional interpretation of the biological relevance of 
these SNPs. The 147 SNPs analyzed in this analysis were identified from studies by 
Ueshima et. al., Court et. al., Harrill et. al., and Moyer et. al.38, 43, 48-50, 63, 66. Ueshima et al. 
described a CYP2E1 promoter SNP (rs2031920) that associated with altered 
acetaminophen metabolism48.  
To determine the potential biological processes and regulatory relationships for the 
SNPs discussed in previous studies of APAP and APAP metabolite-induced toxicity 38, 43, 
48, 50, we reanalyzed the 147 SNPs. Variant annotations were obtained from RefSeq, 
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GENCODE, and Ensembl106-108. Annotations of noncoding polymorphisms were assessed 
with HaploReg v4.1 109. Ingenuity Pathway Analysis (Qiagen) was used to predict 
functional consequences and PubMatrix was used to assess novelty of the gene associations 
with APAP-induced ALF110. Genome Wide Annotation of VAriants (GWAVA) was used 
to score the functional relevance of the 147 SNPs111. 
 
Drug-gene interaction analysis 
 
Genes in the top 10 of a CRISPR/Cas9 knockout screen list and overlapping a gene 
expression dataset (p<0.05), in a CRISPR/Cas9 knockout screen list (p<0.05) and involved 
in NAD metabolism, or in a CRISPR/Cas9 knockout screen list (p<0.05) and containing or 
nearest neighbor to APAP-associated SNPs were compared against the Drug Gene 
Interaction Database (http://www.dgidb.org/) to assess known drug interactions and 
potential re-purposing of existing drugs112. 
 
 
Functional validations in primary mouse hepatocytes: 
 
Cryopreserved hepatocytes (Lonza cat. MBCP01, Allendale, NJ) from 8-week old 
male C57/Bl6 mice were thawed in thawing media (Lonza. Cat. MCRT50) and 
immediately seeded at a density of 15,000 cells/96-well and 250,000 cells/12-well in 
Williams E media with thawing and plating supplement (Thermo cat. A1217601, cat. 
CM3000, respectively). After 4 hours the cells were transfected using the standard Polyplus 
INTERFERin protocol for 4 hours (VWR cat. 89129-930, Radnor PA) and 25nM TYE-
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563 fluorescent control (IDT cat. 51-01-20-19) or SmartPool scrambled siRNA or (Nampt, 
Lztr1, and Naaa) siRNA (Dharmacon, Lafayette, CO) or 50-100nM SmartPool siRNA 
(Pgm5, Dharmacon) in Williams E media with thawing and plating supplement (serum-
free, Thermo cat. A1217601, cat. CM4000, respectively). 20 hours after transfection TYE-
563 positive fluorescent controls were imaged and cells were treated with +/-7.5mM APAP 
for 3 hours beginning 22 hours post-transfection. Cell viability was measured by ATP 
luminescence read at 0.25 seconds with n=6 and the high and low values removed for a 
final n=4 (Promega CellTiter-Glo cat. G7571, Madison, WI) using a TriStar LB 941 
Multimode Microplate Reader (Berthold Technologies, Bad Wildbad, Germany). For each 
siRNA transfection, APAP-treated wells were normalized to untreated wells. Statistical 
significance was determined by a 2 sample 2-tailed Student’s t-test assuming equal 
variance (p<0.05). Gene expression was validated by sqPCR. 
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Semi-quantitative PCR 
 
RNA was isolated using the MirVana miRNA isolation kit (Thermo Fisher cat. 
AM1561, Waltham, MA) and quantified using the Epoch Take3 (BioTek, Winooski, VT). 
cDNA was amplified from 500ng mRNA by SuperScript IV (Thermo Fisher cat. 
18091200, Waltham, MA). 2µl CDNA was used as sqPCR template using Platinum Taq 
polymerase (Thermo Fisher cat. 10966-026, Waltham, MA) (primers are listed under 
sqPCR in supplementary table 1). A 2.5% agarose gel was run @100V to visualize 
knockdown of Lztr1, Nampt, and Pgm5 with ActB used as a loading control. 
 
Western blotting 
 
HuH7 cell lysates were collected on ice in RIPA buffer and isolated by 
centrifugation at 13,000 RPM for 10 minutes at 4°C. Protein was quantified by Pierce BCA 
(Thermo Fisher cat. 23225, Waltham, MA). 30µg protein (western) was boiled with sample 
buffer prior to loading on a polyacrylamide gel. Cas9 antibody diluted 1:2,000 in TBS-
T+3% milk (EMD Millipore cat. MAC133, Billerica, MA), vinculin antibody diluted 
1:1,000 in TBS-T+5% milk (Enzo cat. BML-VG6110, Farmingdale, NY). Goat anti-rabbit 
HRP antibody 1:10,000 in TBS-T + 5% milk (Vector Biolabs cat. PI-1000, Malvern, PA) 
and horse anti-mouse HRP antibody in TBS-T + 5% milk (vector Biolabs cat. P1-2000, 
Malvern, PA) were used to visualize westerns.  
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Plasmids 
 
The lenti Guide_puro backbone, lenti Cas9_blast, and the Human GeCKOv2 
CRISPR knockout pooled library were originally from Feng Zhang’s lab (Addgene pooled 
library #1000000048, #1000000049, plasmid #52962, 52963, respectively)89. psPAX2 was 
originally from Didier Trono’s lab (Addgene plasmid # 12260) and pCMV-VSV-G was 
originally from Bob Weinberg’s lab (Addgene plasmid # 8454) 113. pLJM1-EGFP was 
originally from David Sabatini’s lab (Addgene plasmid # 19319)114.  
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CHAPTER 5 
RESULTS PART 1 
 
Development of screening strategy and preparation of cell lines 
 
HuH7-Cas9 was monoclonally selected and expression of Cas9 was confirmed by 
western blot (figure 1 a). To determine the optimal dosage of APAP, HuH7-Cas9 cell count 
and viability were assessed daily (N=3) in the presence of 0-20mM APAP in growth media 
(figure 1 b). A screening strategy was developed based on the rate of cell death in 15mM 
APAP to assess the effect of the gene knockouts on cellular survival and proliferation with 
APAP treatment (figure 1 c). 
 
CRISPR/Cas9 knock-out screen and deconvolution 
 
HuH7-Cas9 cells (1.62x108 total) were transduced with the lentiviral sgRNA 
library at an MOI of 0.5 resulting in >630x total library coverage at the time of transduction. 
The first replicate contains plasmid and samples collected at 0h, 30min, 3h, 6h, 12h, 24h, 
and 4d (end) of APAP treatment. The second replicate contains samples collected at 0, 24h, 
and 4d of APAP treatment. A minimum of 2x107 cells were collected per sample, resulting 
in 160x library coverage per sample as template for the 1st PCR. The average library 
coverage of aligned reads calculated from amount of isolated DNA per sample was 205x 
and 284x, respectively for replicates 1 and 2. On average, 70% of the sequence reads 
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aligned to the reference sgRNA library resulting in 230.9x average library coverage per 
replicate (supplementary table 2). 
After 4 days of APAP treatment and 21 days outgrowth, the endpoint sample is 
significantly different from the plasmid library or T0 (p<10-10) by comparison via 
Wilcoxon Rank-Sum test and there is a noticeable increase in variation of read counts after 
4 days of drug treatment (figure 1 D-E, supplementary table 3). Scatter plots of the read 
counts between the untreated and 24h samples and the untreated and 4d samples show an 
increase in differential sgRNA count between 24h and 4d of drug treatment (supplementary 
figure 2 A-B). 
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Figure 1 | Genome-scale positive and negative screening using CRISPR/Cas9. A 
Expression levels of Cas9 in polyclonal and Monoclonal HuH7-Cas9 cell line. B Relative 
growth of HuH7-Cas9/GuidePuro when treated with and without APAP. C Timeline of 
APAP resistance screen in HuH7 hepatocellular carcinoma cells. D Box-plot showing the 
distribution of log2 median-normalized sgRNA read count frequencies of the plasmid 
library (plasmid) and post-lentiviral transduction for baseline (T0), early APAP treatment 
time points (T30min-24h), and the endpoint (4 days APAP treatment and 21 days 
outgrowth) conditions. E Rank correlation p-values of median-normalized sgRNA read 
counts between treatment conditions. 
 
sgRNA read counts were scored and ranked to determine the gene-level and 
protein-level negative and positive screen rankings of individual time points and combined 
time points using RRA (supplementary table 4-19). The 4 day APAP treated (end) samples 
were compared with the untreated sample, revealing a number of genes containing sgRNA 
that were significantly decreased with APAP treatment (negatively selected, potentially 
essential) and significantly increased with APAP treatment (positively selected, potentially 
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susceptible) (figure 2 A-B). These gene knock-outs were significantly differentially 
expressed in a sample where almost all of the Huh7 have been killed by APAP. The ranked 
gene lists underwent GSEA pathway analysis against the All Gene Ontology and KEGG 
pathway gene sets, that returned statistically significant, highly ranked essential pathways 
in the negative screen analysis as well as a number of novel pathways in both the negative 
and positive screen analysis (figure 2 C-E). Essential Kegg pathways are highly ranked in 
the negative screen after drug treatment, including ribosome and spliceosome pathways. 
Analysis of Gene Ontology pathways reveals other pathways important to cellular function 
are highly negatively selected and apoptotic processes are highly positively selected. 
 
 
Figure 2 | Positive and negative screening reveal top gene and pathway candidates 
after 4 days of APAP treatment. A Identification of top candidate genes using the p-
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values from positive RRA analysis of the 4d and T0 samples. Genes with the most 
positively selected sgRNAs are highlighted. B Identification of top candidate genes using 
the p-values from negative RRA analysis of the 4d and T0sample. Genes with the most 
negatively selected sgRNAs are highlighted. C Top 10 Kegg pathways negatively selected 
in the endpoint sample compared with the T0 sample. D Top 10 Gene Ontology pathways 
negatively selected in the endpoint sample compared with the T0 sample. E Top 10 Gene 
Ontology pathways positively selected in the endpoint sample compared with the T0 
sample. 
 
At 24h APAP treatment, we observed a significantly different distribution of genes 
representing highly significant positive and negative changes in sgRNA expression (figure 
3 A-B). Pathway analysis by GSEA using the KEGG and Gene Ontology gene sets returned 
a number of novel pathways (figure 3 C-E). The top negatively selected Gene Ontology 
pathway after 24 hours of APAP treatment was regulation of skeletal muscle contraction. 
The top biological network identified from this pathway by Ingenuity Pathway Analysis 
(Qiagen) was lipid metabolism, small molecule biochemistry and organ morphology, 
focusing around calcium signaling (figure 3 F). This correlates with existing literature 
suggesting that calcium imbalance may affect APAP-induced hepatotoxicity115-116. Our 
data provide new and previously unrevealed targets for further experimentation. 
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Figure 3 | Highly ranked genes and pathways after 24 hours of APAP treatment. A 
Identification of top candidate genes using the p-values from positive RRA analysis of the 
24h and T0 samples. Genes with the most positively selected sgRNAs are highlighted. B 
Identification of top candidate genes using the p-values from negative RRA analysis of the 
24h and T0 sample. Genes with the most negatively selected sgRNAs are highlighted. C 
Top 10 Kegg pathways negatively selected in the 24h sample compared with the T0 
sample. D Top 10 Gene Ontology pathways negatively selected in the 24h sample 
compared with the T0 sample. E Top 10 Gene Ontology pathways positively selected in 
the 24h sample compared with the T0 sample. F Top biological network identified by IPA 
from the top essential Gene Ontology pathway, regulation of skeletal muscle contraction, 
at 24h of APAP treatment. 
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We next sought to rank genes by time groups rather than specific time points with 
two main goals: 1) identify genes that were ranked highly (positive or negative) in early 
time points (30min-24h APAP exposure) vs. no treatment and 2) identify genes that were 
ranked highly (positive or negative) in all pooled APAP treated samples vs. no treatment. 
A literature search of the top 100 ranked genes (positively and negatively ranked, 
respectively) for each of these combinations of time points identified 44 unique genes (of 
716 total unique genes queried) that were already associated with APAP and a vast majority 
that do not have previous associations with acetaminophen in the literature (table 1). 
 
Table 1: The top 100 genes for various APAP treatment times were queried in 
pubmatrix to determine novelty. 
PubMatrix APAP acetaminophen hepatotoxic hepatotoxicity acute 
liver 
injury 
acute 
liver 
failure 
24h pos. top 100 genes + 
APAP 
7 7 6 14 11 8 
24h neg. top 100 genes + 
APAP 
5 5 5 5 5 5 
4d pos. top 100 genes + 
APAP 
7 6 6 8 6 8 
4d neg. top 100 genes + 
APAP 
7 7 2 8 8 4 
all pos. top 100 genes + 
APAP 
2 1 0 3 4 4 
all neg. top 100 genes + 
APAP 
6 6 4 7 6 4 
30min-24h pos. top 100 
genes + APAP 
7 7 2 5 5 5 
30min-24h neg. top 100 
genes + APAP 
6 6 4 7 5 5 
genes in all 8 top 100 lists 800  
unique genes in all 8 top 
100 lists 
716  
unique genes with APAP 
hits 
44(APAP), 
42(acetaminophen) 
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 We then grouped genes that were highly ranked at independent time points to 
isolate early and late acting genes. While a few genes contained sgRNA that are 
significantly enriched (or depleted) across all early time points, many were unique to the 
individual time points. While the sensitivity of the screen at very early times is likely lower 
than at later time points, early and late acting gene groups that were shared between time 
points or were unique to specific time points but represent statistically significant pathways 
may be important to drug response (figure 4 A-B). To identify knocked-out genes that have 
a global significance we compared all APAP-treated samples to the T0 samples (figure 4 
C-D). To identify knocked-out genes that were important for the early APAP response we 
compared the 30min-24h APAP treated samples to the T0 samples (figure 4 E-F). These 
comparisons resulted in a number of highly significant genes. 
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Figure 4 | Identification of gene hits across the APAP time course in the CRISPR/Cas9 
screen. A, B Venn diagrams of differently expressed genes in HuH7 cells treated with 15 
mM APAP for 5 early time points. The diagrams show the number of gene knockouts 
significantly enriched by the treatment (A) and depleted by the treatment (B) for 5 time 
points (P<0.05). The diagrams show the number of genes significantly modulated by the 
treatments. C Identification of top candidate genes using the p-values from positive RRA 
analysis based on all APAP time points vs. T0. Genes with the most positively selected 
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sgRNAs are highlighted. D Identification of top candidate genes using the p-values from 
negative RRA analysis based on all APAP time points vs. T0. Genes with the most 
negatively selected sgRNAs are highlighted. E Identification of top candidate genes using 
the p-values from positive RRA analysis based on intermediate (30min-24h) APAP time 
points vs. T0. Genes with the most positively selected sgRNAs are highlighted. F 
Identification of top candidate genes using the p-values from negative RRA analysis based 
on intermediate (30min-24h) APAP time points vs. T0. Genes with the most negatively 
selected sgRNAs are highlighted. 
 
The RRA statistical method was chosen to rank gene knockouts because of its 
superior performance when compared with RSA and RIGER100. To validate our choice of 
statistical analysis method, we compared the RRA to the Maximum Likelihood Estimate 
algorithm (MLE), which has been shown to produce comparable gene ranking to RRA117. 
In a MLE analysis of all APAP time points compared with the T0 sample, 683 genes were 
statistically significant (p<0.05), of that 442 (65%) were also statistically significant 
(p<0.05) using the RRA method (v0.5.6) (supplementary table 20).  
We suspect that NAD metabolism may play an important role in survival of 
acetaminophen injury and to this end we identified a number of genes involved in NAD 
metabolism that are also highly ranked in the CRISPR screen time points. A list of 48 genes 
identified based on Nikiforov et al., 2015 was compared with statistically significant 
CRISPR hits (p<0.05)118. We identified 9 NAD metabolism genes in our screen data 
(supplementary table 21). Notably, NMNAT1 knockout is significantly depleted across all 
APAP-treated samples and individually at 24h and 4d treatments. Additionally, data from 
our lab suggest overexpression of NAMPT, a gene involved in NAD salvage, is protective 
against APAP-induced hepatotoxicity in vivo105. 
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Discussion 
 
This study has identified a number of novel and previously unrevealed regulators 
of APAP-induced hepatotoxicity by employing state of the art genome-wide CRISPR/Cas9 
screen in a hepatocyte cell line. Selected targets have been validated in primary hepatocytes 
and cross-referenced in other available data sets of human and mouse involvement. Our 
study has illustrated the power of a genome-wide CRISPR/Cas9 screen to systematically 
identify novel genes involved in APAP induced hepatocyte toxicity and most importantly, 
it provide a rich resources for further experimentation to identify potential new diagnostic 
targets or to develop novel therapeutic modalities to APAP induced hepatocyte toxicity. 
Genes containing sgRNA that are significantly and consistently enriched or depleted across 
the gene are candidates for further study, both as biomarkers and as contributors to larger 
disease mechanisms. Gene knockouts that are extremely enriched or depleted are more 
likely to function in APAP mechanism without a redundant mechanism, as opposed to gene 
knockouts with little to no differential read count.  
It is widely accepted that the cytochrome P450 isoform play an important role in 
APAP metabolism to NAPQI. While we expected to see the cytochrome P450 isoforms 
higher in the gene rankings of the negative screen, it is unsurprising that they are not highly 
ranked because HuH7 has low expression of some CYPs. It is suspected that multiple 
isoforms can regulate the metabolism of APAP, so it is possible that others are 
compensating for the knocked out isoform. The low expression of some CYPs in HuH7 
arguably increases the potential for this system to reveal non-canonical mechanisms of 
survival and susceptibility.  
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Although there are always concerns when using a cell line to study a biological 
mechanism, HuH7 has been used successfully for studies of drug metabolism95, 119. To 
carry out the CRISPR/Cas9 screen it was necessary to use a cell line that could be 
transduced and didn’t require differentiation. Whenever possible, we validated our findings 
in primary mouse hepatocytes.  
Although few genes were completely removed from the pooled mutant cell 
population prior to APAP treatment, thousands were missing after 4 days of APAP 
treatment. Based on the kill curve 4 days of APAP treatment results in about 1% surviving 
cells, indicating a majority of the cells being killed. The survival of cells with low numbers 
of sgRNAs is only statistically important if the proportion within the surviving population 
is significantly different than the starting population consistently across multiple sgRNAs 
per gene. The early time points (30 minutes to 24 hours of APAP treatment) in this screen 
are based on traditional gene expression screening techniques. By considering the impact 
of drug selection at early time points we can better assess the early and late response genes 
involved in drug toxicity. We propose that a Wilcoxon Rank-Sum value of p<10-10 may be 
too stringent for addressing finer scale effects of gene knockout. 
Using GSEA pathway analysis our screen identified WNT signaling (Kegg gene 
set) as a very strongly depleted pathway and also identified positive regulation of Notch 
Signaling (GO, Gene Ontology gene set) as a significantly depleted pathway (p<0.05). 
Notch signaling has been previously identified as essential to survival of APAP120. To 
further validate our screening methodology, both spliceosome and ribosome Kegg 
pathways are among the most strongly depleted pathways after 4 days of APAP treatment. 
Our top negatively selected GO pathway after 24h APAP treatment, regulation of skeletal 
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muscle contraction, corroborates some existing work, suggesting that intracellular calcium 
may be important to response to APAP. However, the role of this pathway in APAP-
induced hepatotoxicity is unclear. 
The other top pathways included a variety of functions. At 24h APAP treatment the 
top GO pathway based on the positive (enriched) gene knockout ranking is viron. This 
could be resultant of the lentiviral process used to incorporate the sgRNA and Cas9 
genomic sequence. At 4d APAP treatment the top pathway from the positive gene knockout 
ranking is T-cell apoptotic process. The top pathway from the negative gene knockout 
ranking at 4d APAP treatment is sodium ion export.  
Based on Zhang et al. (Am J Pathol.  In press, 2018) we identified NAD salvage, 
specifically the gene NAMPT, as a potentially important in protection against APAP-
induced injury105. We extended this hypothesis to the genome-wide CRISPR screen of 
APAP-induced hepatotoxicity, assessing the presence of NAD metabolism genes among 
the top ranked genes (p<0.05). This analysis revealed that a number of NAD metabolism 
genes are represented in our highly enriched or depleted gene knockouts. NMNAT1 
knockout was significantly depleted across the APAP screen, suggesting an important 
function in cell survival after APAP treatment. These genes that have known functions in 
NAD metabolism and whose knockout impacts survival of drug exposure in our 
CRISPR/Cas9 screen warrant additional mechanistic and population-based evaluation of 
their utility as biomarkers for liver injury.  
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CHAPTER 6 
RESULTS PART 2 
 
Overlapping analysis of our screen top hits with other gene expression acetaminophen 
datasets 
 
 In order to validate our results, we performed the overlapping analysis of our screen 
top hits with other gene expression acetaminophen datasets. We analyzed 2 human 
microarray datasets and 1 mouse RNA-sequence data set, all of that were collected after 
APAP exposure. In order to better understand the effect of APAP on the transcriptome and 
place this information within the context of our CRISPR/Cas9 knockout screen, we 
identified genes that were significantly enriched or depleted (p<0.05) in the CRISPR screen 
and in the transcriptome data. 
 
Analysis of RNA-sequence from mice with acetaminophen-induced acute liver injury 
 
In cuffdif, RNA-seq data from mice with and without APAP exposure 
(GSE110787) were compared to assess the effect of APAP exposure on gene transcription. 
1,626 of 46,073 genes were statically, significantly and differentially expressed genes after 
APAP exposure with an unadjusted p-val <0.05. 1,025 genes have – log2 fold change with 
p<0.05 and 601 genes have + log2 fold change with P<0.05 (supplementary figure 3 A, 
supplementary table 22). Overlap between the genes that were highly ranked in the 
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CRISPR screen (p<0.05) and this analysis (p<0.05) represent genes that were validated in 
vivo. (figure 5 A-B, supplementary table 22). 
 
Analysis of microarray of human liver biopsies from normal and acetaminophen-
induced acute liver failure patients 
 
Secondary data from human sources was used to cross-validate the CRISPR screen 
findings. In GEO2R, microarray data from 3 APAP-induced ALF liver samples were 
compared to 2 healthy liver samples (GSE74000). 1,679 of 54,675 probes have an FDR-
adjusted p-value of <0.05. 1,251 probes have – log2 fold change with p<0.05 and 428 
probes have + log2 fold change with p<0.05 (supplementary figure 3 B). We compared 
genes with p<0.05 to genes that were significantly enriched and depleted in our CRISPR 
screen (p<0.05) to identify overlap and ascertain the relationship between sgRNA depletion 
or enrichment and gene expression (figure 5 C-D). 
 
 44 
 
 
Figure 5 | Overlapping analysis of significant CRISPR/Cas9 screen with mouse ALI 
(GSE110787) and human ALF gene expression data (GSE74000). A Overlap of top 
positive CRISPR/Cas9 screen hits (p<0.05) at 24h with mouse RNA-Seq top hits at 24h 
APAP treatment (p<0.05), with heat map of the differential log2 fold change of the top 10 
genes with the most positively selected sgRNAs (left to right). B Overlap of top negative 
CRISPR/Cas9 screen hits (p<0.05) at 24h with mouse RNA-Seq top hits at 24h APAP 
treatment (p<0.05), with heat map of the differential log2 fold change of the top 10 genes 
with the most negatively selected sgRNAs (left to right). C Overlap of top positive 
CRISPR/Cas9 screen hits (p<0.05) at 24h with ALF microarray dataset GSE74000 top hits 
at 24h (p<0.05), with hea tmap of the differential log2 fold change of the top 10 genes with 
the most positively selected sgRNAs (left to right) GSE74000; ALF healthy liver sample 
microarray data. D Overlap of top negative CRISPR/Cas9 screen hits (p<0.05) at 24h with 
ALF microarray dataset GSE74000 top hits at 24h (p<0.05), with heat map of the 
differential log2 fold change of the top 10 genes with the most negatively selected sgRNAs 
(left to right). 
 
  
 45 
 
Analysis of microarray of human blood from normal and acetaminophen-dosed 
participants 
 
A second dataset, GSE70748 was chosen to filter genes identified in the CRISPR 
screen that have also been identified in blood in humans who have been dosed with APAP 
(supplementary table 23). In GEO2R, microarray data from 12 APAP responder blood 
samples were compared to 32 non-responders using days 1 and 8 independently 
(GSE70784). This data represents a population of individuals who were dosed with APAP 
over a course of days, during that blood was collected daily. No probes had an FDR-
adjusted p-value <0.05, so the unadjusted p-values were referenced. After 1 day of APAP 
dosing 362 of 20,173 probes have an unadjusted p-value <0.05, of that 148 probes have – 
log2 fold change with p<0.05 and 214 probes have + log2 fold change with P<0.05 
(supplementary figure 4 A). After 8 days of APAP dosing 2445 of 20,173 probes had an 
unadjusted p-value <0.05, of that 314 probes have – log2 fold change with p<0.05 and 2,131 
probes have + log2 fold change with P<0.05 (supplementary figure 4 B). We compared 
genes with p<0.05 to genes that were significantly enriched and depleted in our CRISPR 
screen (p<0.05) to identify overlap and ascertain the relationship between sgRNA depletion 
or enrichment and gene expression (figure 6 A-D). 
Using the same GSE70784 dataset in GEO2R, microarray data from 12 APAP 
responder blood samples were compared to 10 placebo controls using days 1 and 8 
independently. After 1 day of APAP dosing 697 of 20,173 probes had an unadjusted p-
value <0.05. Of these, 244 probes have – log2 fold change with p<0.05 and 453 probes 
have + log2 fold change with P<0.05 (supplementary figure 4 C). After 8 days of APAP 
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dosing 1,801 of 20,173 probes had an unadjusted p-value <0.05, of that 1248 probes have 
– log2 fold change with p<0.05 and 553 probes have + log2 fold change with P<0.05 
(supplementary figure 4 D). We compared genes with p<0.05 to genes that were 
significantly enriched and depleted in our CRISPR screen (p<0.05) to identify overlap and 
ascertain the relationship between sgRNA depletion or enrichment and gene expression 
(figure 6 E-H). 
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Figure 6 | Overlapping analysis of significant CRISPR/Cas9 screen hits with human 
ALI gene expression data (GSE70784). A Top positive CRISPR/Cas9 screen hits 
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(p<0.05) at 24h overlapping APAP overdose microarray dataset GSE70784 responders vs. 
Non-responders (1 day) (p<0.05). Heat map of differential log2 fold change of the top 10 
genes with the most positively selected sgRNAs (left to right). B Top negative 
CRISPR/Cas9 screen hits (p<0.05) at 24h overlapping APAP overdose microarray dataset 
GSE70784 responders vs. Non-responders (1 day) (p<0.05). Heat map of differential log2 
fold change of the top 10 genes with the most negatively selected sgRNAs (left to right). 
C Top positive CRISPR/Cas9 screen hits (p<0.05) at 24h overlapping APAP overdose 
microarray dataset GSE70784 responders vs. Non-responders (8 days) (p<0.05). Heat map 
of differential log2 fold change of the top 10 genes with the most positively selected 
sgRNAs (left to right). D Top negative CRISPR/Cas9 screen hits (p<0.05) at 24h 
overlapping APAP overdose microarray dataset GSE70784 responders vs. Non-responders 
(8 days) (p<0.05). Heat map of differential log2 fold change of the top 10 genes with the 
most negatively selected sgRNAs (left to right). E Top positive CRISPR/Cas9 screen 
hits(p<0.05) at 24h overlapping APAP overdose microarray dataset GSE70784 responders 
vs. Placebo (1 day) (p<0.05). Heatmap of differential log2 fold change of the top 10 genes 
with the most positively selected sgRNAs (left to right). F Top negative CRISPR/Cas9 
screen hits (p<0.05) at 24h overlapping APAP overdose microarray dataset GSE70784 
responders vs. Placebo (1 day) (p<0.05). Heatmap of differential log2 fold change of the 
top 10 genes with the most negatively selected sgRNAs (left to right). G Top positive 
CRISPR/Cas9 screen hits (p<0.05) at 24h overlapping APAP overdose microarray dataset 
GSE70784 responders vs. Placebo (8 days) (p<0.05). Heatmap of differential log2 fold 
change of the top 10 genes with the most positively selected sgRNAs (left to right). H Top 
negative CRISPR/Cas9 screen hits (p<0.05) at 24h overlapping APAP overdose 
microarray dataset GSE70784 responders vs. Placebo (8 days) (p<0.05). Heatmap of 
differential log2 fold change of the top 10 genes with the most negatively selected sgRNAs 
(left to right).  
 
Identification of candidate genes from the overlapping gene sets 
 
We then isolated only genes (or gene knockouts in the case of the CRISPR screen) 
that were significantly differentially expressed across the CRISPR, mouse, and human 
studies. 523 genes (369 unique) overlapped the mouse RNA-seq GSE110787 and CRISPR 
“top lists” (4d, 24h, Int, and All, p<0.05). 57 of the 67 unique genes overlapping CRISPR, 
Mouse, and GSE74000 p<0.05 lists were not previously reported to have a role in APAP 
metabolism, and 51/67 had consistent expression in mouse and GSE74000 and within 
CRISPR lists. When we compared the GSE70784 1 day responder vs. placebo to the 
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CRISPR and mouse RNA-seq datasets, 12 of the 16 overlapping unique genes were novel 
(p<0.05 overlap the main CRISPR analyses and the mouse RNA-seq) and 10 of the 16 had 
consistent expression between CRISPR analysis or between gene expression dataset. When 
we compared the GSE70784 8 day responder vs. placebo to CRISPR/Cas9 and mouse 
datasets 36 of the 38 overlapping unique genes were novel (p<0.05 overlap the main 
CRISPR analyses and the mouse RNA-seq) and 22 of the 38 have consistent expression 
between CRISPR analysis or between gene expression dataset The largest overlap with the 
CRISPR/Cas9 screen data was observed with the GSE70784 8d day responder vs. non-
responder dataset (supplementary table 24). A number of the genes with significantly 
differential expression in the in vivo datasets had known relationships with APAP (top 100 
genes per data set, analyzed using PubMatrix), although as previously seen with the 
CRISPR screen, many are novel findings (supplementary table 25). 
 
Discussion 
 
 The analysis method used to rank genes from the genome-wide CRIPSR-Cas9 
screen based significance and rank on a combination of highly differential sgRNA counts 
that are consistent across a gene. However it is still possible that the genes identified by 
this method may have poor clinical utility. To better identify genes that could have good 
utility as biomarkers, we cross-referenced 3 different studies of APAP-induced liver injury 
and failure.  
The 3 gene expression datasets all used distinct sampling methodologies, that when 
combined, produced a comprehensive picture of changes in gene expression after APAP 
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overdose. GSE70784 consists of blood samples from participants that are dosed with the 
daily maximum of APAP daily for an extended time. These data reflect a more chronic 
drug exposure, and response to the drug is measured by ALT. GSE74000 consisted of liver 
biopsies from Livers being replaced after APAP-induced ALF and liver biopsies obtained 
from non-ALF donors. This dataset, although it contains few samples, represents 
differential gene expression in humans at the 4d-point of the disease. The mouse RNA-seq 
data GSE110787 provided an extremely controlled population with controlled APAP 
dosage, avoiding issues of inter-population variabilities that may affect studies in human 
populations. 
This approach addresses APAP-induced liver injury in 2 distinct ways. First, we 
identified genes with a role in APAP metabolism by assessing the effect of gene 
knockouts on cell proliferation and survival. Next, we identified genes that were 
differentially expressed in response to APAP. The combination helps us to build 
hypotheses about the role of these genes in the disease process. This cross-validation with 
other APAP datasets is targeted at identifying genes that are important to APAP 
metabolism and may be novel diagnostic or therapeutic biomarkers. Genes that are highly 
ranked in the CRISPR screen (p<0.05) and whose RNA are expressed differentially at 
high enough levels that a blood sample (preferable) or liver biopsy (less preferable) could 
be used to detect changes in expression levels resultant from APAP overdose rapidly in 
clinic. Novel genes identified by this method that were highly ranked in the CRIPSR-
Cas9 screen and in the gene expression data are the strongest candidates for further study. 
This method of candidate gene discovery was validated by the presence of genes that 
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already have known association with APAP metabolism among the top candidate genes. 
Selection of specific candidate genes is discussed in more detail in chapter 8. 
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CHAPTER 7 
RESULTS PART 3 
 
Acetaminophen-associated single nucleotide polymorphisms in the literature 
 
We explored the candidate gene and genome-wide approaches that have identified 
147 SNPs associated with either protection against or susceptibility to acetaminophen-
induced hepatotoxicity (supplementary table 26). We then provided a reanalysis of the 
published SNP data using in silico tools to further uncover the biological relevance of the 
coding and non-coding variants (Heruth et. al. 2018, under review).  
Court et al. evaluated the association with acetaminophen-induced hepatotoxicity 
in a panel of polymorphisms from genes encoding known acetaminophen metabolizing 
enzymes, including UGT1A, UGT1A1, UGT1A6, UGT1A9, UGT2B15, SULTA1, CYP2E1, 
and CYP3A5 50. They also analyzed a polymorphism in CD44 that associated with elevated 
serum alanine aminotransferase (ALT) levels in healthy volunteers who consumed the 
maximum recommended dose of acetaminophen for up to 2 weeks 37-38. Three genes, 
CYP3A5, UGT1A, and CD44, contained SNPs with relatively weak associations with 
acetaminophen-induced liver injury in an Acute Liver Failure Study Group cohort of 260 
Caucasian individuals that consists of 78 patients with intentional acetaminophen-
overdose, 79 patients with unintentional acetaminophen-overdose, and 103 patients with 
ALF due to non-acetaminophen associated causes.  
Moyer et al. utilized a human variation panel of 176 lymphoblastoid cell lines 
(HVP-LC) established from healthy donors 43. The growth inhibitory effect of NAPQI 
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(IC50) was determined for each cell line following 24 hours of treatment with 7 doses (0-
100µM) of NAPQI. Initially, Moyer et al. examined the association of 716 SNPs, located 
in 31 GSH pathway genes, with NAPQI-IC50. Moyer et al. extended their study to a 
genome-wide SNP analysis in that 1,008,202 SNPs were screened for association with 
NAPQI-IC50.To identify SNPs associated with NAPQI-induced hepatotoxicity, GWAS 
was performed using Illumina Infinium HumanHap 550K and 510S bead chips and 
Affymetrix 6.0 GeneChips.  
Two studies by Harrill et al. 38, 66 identified potential susceptibility targets using a 
panel of 36 inbred mouse strains to model genetic diversity. Fasting mice were treated with 
300 mg/kg acetaminophen by intragastric dosing. Food was reintroduced after three hours 
of acetaminophen dosing. After 24 hours the mice were euthanized for analysis. The extent 
of liver injury was quantified by serum ALT levels. Haplotype-associated mapping and 
targeted sequencing were used to evaluate relationships of polymorphisms with ALT. 
Harrill et al. also performed mRNA microarray analyses on an Agilent Mouse Toxicology 
Array (#4121A) to identify gene expression biomarkers for acetaminophen hepatotoxicity 
in their panel of 36 inbred mouse strains 66.  
To begin to understand the molecular mechanisms by that SNPs associate with a 
disease state, it is important to analyze the data at the gene level 121. Here we analyzed 
coding and non-coding genes that contain or nearest neighbors to SNPs that have a 
significant association with acetaminophen sensitivity (supplementary tables 27-28). 
Genes positioned outside of protein-coding genes may be positioned in regulatory elements 
that have functional consequences on nearby genes. In total, Refseq, GENCODE, and 
Ensembl annotations predicted the 147 SNPs to be in or nearest neighbor to a combined 97 
 54 
 
unique genes, including 60 protein-coding genes and 37 non-coding RNA genes. The 
newly compiled data are presented in supplementary tables 26-31. 
 
Functional in silico analyses of SNPs associated with acetaminophen-induced 
hepatotoxicity 
 
Analysis with HaploReg 4.1 (RefSeq) classified 84 intergenic and 63 intragenic 
SNPs, with 58 of the intragenic SNPs annotated functionally as 5’-UTR, intronic, or 3’-
UTR (supplementary table 29). GENCODE annotation identified 79 and 68 intergenic and 
intragenic SNPs, respectively. 71 SNPs (48.3%) are associated with two or more 
transcripts, while 21 (14.3%) are within a single transcript (supplementary table 27). 55 
SNPs (38.2%) are not located within a known transcript. 7 SNPs are located in the 
proximity of 5 miRNAs. In total, 58 SNPs are within or in the proximity of non-coding 
RNA genes.   
Interestingly, several of the SNPs overlap regulatory regions including promoter 
and enhancer histone marks, DNases, and bound proteins. Several of the SNPs are 
predicted to alter TF binding sites (Supplementary Table 29). Genome Wide Annotation 
of VAriants (GWAVA) was used to score the functional relevance of the 147 SNPs 
(supplementary table 30) 111. Five of the SNPs (rs2031920, rs8330, rs2524290, rs10929303 
and rs1042640) have a high functional significance prediction using a model that accounts 
for nearby transcriptional start sites (TSS score >0.7) 122. These predictions support the 
previous findings that rs2031920 and rs8330 effect the transcriptional regulation of 
CYP2E1 and UGT1A, respectively 48-49. rs2524290 is located in the promoter region of 
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RAB3IL1, that encodes RAB3A Interacting Protein Like 1, a guanine nucleotide exchange 
factor. rs10929303 and rs1042640 are located in the 3’ UTR of UGT1A1 but are predicted 
to disrupt protein binding motifs. An additional 20 SNPs have a moderate functional 
significance with a TSS score >0.4. Further investigation of these SNPs is warranted to 
determine the roles of these potential regulatory regions and the corresponding genes in 
acetaminophen-induced hepatotoxicity. 
The 72 protein-coding genes were assessed further for functional associations using 
Ingenuity Pathway Analysis (IPA)123 in 2 steps. First, the 44 protein-coding genes 
corresponding to 84 intragenic SNPs were analyzed for biological significance. Next, 
following the lead of Zhang and Lupski 124, the list was expanded to include the 28 protein-
coding genes that were nearest to the 63 intergenic SNPs. Inclusion of the additional genes 
enhanced the predicted associations with several canonical pathways that play a key role 
in hepatotoxicity and drug metabolism. The number of genes associated with Glutathione 
redox reactions I, Xenobiotic metabolism signaling, LPS/IL-1 mediated inhibition of RXR 
function and Glutathione Biosynthesis were enriched significantly when the intragenic 
SNPs were included in the analysis (table 2).  
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Table 2: Top canonical pathways predicted by Ingenuity Pathway Analysis. 
Pathway* 
Ratio of 44 genes 
containing SNPs# 
P-value 
Ratio of 72 genes 
containing or near 
SNPs& 
P-value 
Glutathione Redox Reactions I 8.33E-02 
1.07E-
03 
2.50E-01 1.21E-10 
Xenobiotic Metabolism Signaling 2.41E-02 
1.68E-
06 
3.79E-02 2.32E-09 
LPS/IL-1 Mediated Inhibition of 
RXR Function 
2.25E-02 
8.13E-
05 
3.15E-02 7.71E-06 
Nicotine Degradation III 7.27E-02 
4.50E-
06 
7.27E-02 3.06E-05 
Glutathione Biosynthesis NA NA 6.67E-01 3.11E-05 
*, Top 5 pathways for ratio of genes containing or near 
SNPs    
#, number of genes with intragenic SNPs divided by total genes in the pathway  
&, number of genes with intragenic and intergenic SNPs divided by total number of genes 
in pathway  
NA, not applicable, no genes discovered in the pathway    
 
For example, the Glutathione redox reactions I pathway included two genes (GPX2 
and GSTP1) with intragenic SNPs and an additional four genes (GPX3, GSTA1, GPX4, 
GPX7) near intergenic SNPs, while Glutathione Biosynthesis included no genes with 
intragenic SNPs and two genes (GCLC, GSS) near intragenic SNPs. As evidence that the 
enriched associations were not a random result of including an increased number of genes, 
the Nicotine degradation III pathway was not altered when the additional 28 genes were 
included in the analysis. The number of genes associated with Diseases and Disorders also 
increased significantly when both the intragenic and intergenic SNPs were considered 
(table 3).  
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Table 3: Top diseases and disorders predicted by Ingenuity Pathway Analysis. 
Diseases and Disorders* Genes# Range of P-values# Genes& 
Range of P-
values& 
Metabolic Disease 6 6.02E-03 - 8.44E-06 13 9.70E-03 - 
4.74E-07 
Gastrointestinal Disease 39 1.00E-02 - 6.06E-06 63 9.70E-03 - 
4.37E-06 
Hepatic System Disease 25 1.00E-02 - 6.06E-06 39 9.70E-03 - 
4.37E-06 
Organismal Injury and Abnormalities 41 1.00E-02 - 6.06E-06 67 9.70E-03 - 
4.37E-06 
Inflammatory Disease 12 8.02E-03 - 2.67E-05 14 7.17E-03 - 
1.29E-05 
*, Top 5 diseases and disorders for combined genes with intragenic and intergenic SNPs  
#, number of genes containing intragenic SNPs    
&, number of genes containing intragenic and intergenic SNPs   
 
Remarkably, 24 and 26 of the 28 protein-coding genes nearest to intragenic SNPs 
were associated with Gastrointestinal Disease and Organismal Injury and Abnormalities, 
respectively. These observations suggest strongly that the intragenic SNPs play a 
significant role in regulating cellular and molecular functions associated with 
acetaminophen-induced hepatotoxicity.  
To determine what genetic associations have already been identified, a PubMatrix 
literature query 110 of the 72 protein-coding genes (supplementary table 29) against the 
terms “acetaminophen,” “disease,” “drug,” “hepatotoxicity,” “liver” and “metabolism” 
revealed that 56 and 55 of the genes have not been associated previously with 
“acetaminophen” or “hepatotoxicity,” respectively. Conversely, 67 and 51 genes have been 
linked previously to “disease” and “liver” (supplementary table 31).  
We then cross-referenced the genes containing the147 APAP-associated SNPs with 
the findings of the genome-wide CRISPR/Cas9 knockout screen of APAP hepatotoxicity. 
133 gene names were identified from the literature as nearest-neighbors or containing the 
147 APAP injury-associated single nucleotide polymorphisms (SNPs). Of the genes 
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containing the 147 SNPs, 22 of the 133 gene names identified from RefSeq, GENCODE, 
and Ensembl (non-coding RNA genes) were significantly enriched or depleted in the 
CRISPR/Cas9 screen time points (p<0.05) (supplementary table 32, Shortt et. al. 2018, 
under review). Interestingly, ALCAM and RAP1GAP2 knockouts were both highly ranked 
at 4d and across all time points (p<0.05, enriched and depleted, respectively) of the 
CRISPR/Cas9 knockout screen. GSS and CPA6 knockouts were both highly ranked at 24h 
and across early time points (30min-24h) (p<0.05, enriched and depleted, respectively). 
STAB1 knockout was not significantly enriched at 24h or 4d, but emerged as significantly 
enriched across early time points (30min-24h, p<0.05) and all time points (30min-4d, 
p<0.05). These findings, in combination with known APAP-associated polymorphisms in 
these genes, suggest a direct role of these genes in APAP-induced liver injury.  
 
Discussion 
 
Non-coding SNPs (SNPs not located in a protein encoding gene) are commonly 
identified in GWAS, but have been under studied because of the difficulty in elucidating 
their biological function. Non-coding SNPs may be in linkage disequilibrium with the 
causal coding variant(s), however it is also possible they are positioned within regulatory 
regions, such as chromatin marks, enhancer elements, and DNase hypersensitivity regions, 
that have functional consequences on nearby genes 124. They may also be located in non-
protein encoding genes. Non-coding RNA genes produce functional RNAs (e.g., LINC, 
antisense, snRNA, miRNA) rather than mRNAs that encode proteins. Non-coding RNAs 
are associated with multiple biological functions, including the regulation of transcription, 
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mRNA processing, and translation 125. Although several miRNAs have been associated 
with liver injury 126 and the interaction with 3’UTR SNPs 127, the mechanisms by which 
the non-coding RNA influence acetaminophen-induced hepatotoxicity remain to be 
elucidated further.  
HaploReg 4.1, GWAVA, Ingenuity Pathway and PubMatrix analyses complement 
the genetic association studies and supports the need for further investigation into the 
biological processes and regulatory roles effected by the SNPs and the corresponding genes 
discussed here. The non-coding RNA genes described above have not been linked 
previously to APAP-induced hepatotoxicity. Interestingly, several of the SNPs overlap 
regulatory regions including promoter and enhancer histone marks, DNases, and bound 
proteins (supplementary table 29). Several of the SNPs are predicted to alter TF binding 
sites.  
The pathways and networks obtained from the smaller, intragenic gene list, along 
with the expanded set that incorporates nearest neighbor intergenic SNP genes, support the 
idea that noncoding, intergenic SNPs may hold important predictive value when 
considering APAP-induced hepatotoxicity. In summary, similar pathways were predicted 
with the expanded gene list but with increased significance.  
Although the application of genetic information has not yet been applied formally 
to acetaminophen dosing, the studies presented here provide the foundation for critical 
translational research in DILI. The identification of SNPs associated with a significant risk 
for acetaminophen-induced hepatotoxicity will provide potential targets for improved 
prognosis, prevention, and treatment. However, there remains very little human data 
investigating acetaminophen-induced hepatotoxicity. The majority of data has been 
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generated using either in vitro or animal models. The studies reviewed in this article 
provide a strong starting point for the validation of these findings and the further 
investigation of potentially promising acetaminophen susceptible biomarkers. The in silico 
analyses suggest that these 147 SNPs are present at biologically significant locations that 
may regulated and modify biological functions, including gene expression and alternative 
splicing. In addition, the identification of 41 novel non-coding RNA genes provides 
intriguing targets for further exploration.  
Ultimately, these 147 SNPs will have to be examined experimentally to determine 
if they are intricately involved in acetaminophen metabolism or simply false-positives due 
to experimental limitations. The SNPs that were also identified in the CRISPR/Cas9 screen 
are extremely promising candidates for further evaluation. Further study of the 
polymorphisms in these genes could result in a diagnostic or prognostics SNP panel. 
Further study of the role of these genes could inform their use in targeted therapies. 
The identification of SNPs associated with acetaminophen-induced hepatotoxicity 
will provide novel insights into the mechanisms of acetaminophen metabolism and the 
potential for therapeutic interventions. Additional GWAS studies, including whole genome 
sequencing and SNP-array assays, on larger cohorts of acetaminophen-induced ALI or 
ALF, and the inclusion of control populations that ingested the same dose of 
acetaminophen but did not develop ALI or ALF, are critical for the identification of 
additional biomarkers. Furthermore, the complex, and perhaps redundant, biochemical 
metabolism of acetaminophen in the liver suggests that it might be necessary to perform 
multi-loci, transcriptomic, or epigenetic analyses to identify regions associated with 
acetaminophen-induced hepatotoxicity rather than a single polymorphic allele. 
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CHAPTER 8 
RESULTS PART 4 
 
Validation of screening strategy 
 
We considered genes for functional validation that were in the top 10 of a CRISPR 
list and were also significantly differentially expressed in the GEO or mouse RNA-seq 
datasets (p<0.05), with a preference for genes with a p<0.05 in multiple positive or negative 
ranked lists. Novelty was assessed by literature search and essentiality was determined 
from essentialgene.org. A number of genes that were highly ranked in the CRISPR screen 
(positive or negative) and overlapped with the other gene sets (human and mouse gene 
expression with and without APAP, p<0.05) are identified as essential genes 
(http://www.essentialgene.org/). These genes include PGM5, KIF23, C19orf60, BMPR1A, 
PDSS2, CXADR, SSR2, TMCC2, RDH13, and EGR1 (Supplementary Table 33). 
Additional genes that ranked highly in the CRISPR screen and overlapped with the other 
gene sets (human and mouse gene expression with and without APAP) have previously 
published relationships with APAP metabolism (pubmatrix.irp.nia.nih.gov). These genes 
include EGR1, VNN1, NR1I3. Genes that are highly ranked in our screen and previous 
publications support the selection method used to filter candidate genes. Novel, non-
essential genes identified by this study for further study include LZTR1, NAAA, ATG2B, 
MYOZ3, EFNB3, OR5M11, FCGR3A, PROZ, EEF1D, ACAD11, and TMCC2 
(supplementary table 33). These genes are pathogenic (positively ranked) or protective 
 62 
 
(negatively ranked) and have potential for utility in development of diagnostic, risk-
assessment, or therapeutic biomarkers. 
 
Drug-gene interactions of candidate genes 
 
Further analysis of top candidate genes described in this study (Supplementary 
Tables 21, 32, 33) identified a number of candidate drugs that may be suitable for re-
purposing to treat APAP-induced hepatotoxicity. Of the 54 unique candidate genes that 
were analyzed, 153 drug-gene interactions were identified for 19 genes (supplementary 
table 34). Of these, 14 genes were annotated with drug-gene interactions of known effects 
(table 4).  
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Table 4: Top candidate genes with known drug effects annotated by the DRUG 
Gene Interaction Database (www.dgidb.org). 
Gene Gene Effect on ALF Known Drug Drug 
Effect 
Drug Effect 
matches 
Gene Effect? 
BMPR1A susceptible (CRISPR screen) CHEMBL3186227 inhibitor yes 
FCGR3A protective (CRISPR screen) GLOBULIN, IMMUNE antagonist no 
NAAA protective (CRISPR screen) CARBENOXOLONE inhibitor no 
NAAA protective (CRISPR screen) FLUFENAMIC ACID inhibitor no 
NR1I3 susceptible (PMID: 12376703,  
and CRISPR screen) 
PRASTERONE activator no 
NR1I3 susceptible (PMID: 12376703,  
and CRISPR screen) 
CHEMBL458603 agonist no 
NR1I3 susceptible (PMID: 12376703,  
and CRISPR screen) 
CLOTRIMAZOLE antagonist yes 
NR1I3 susceptible (PMID: 12376703,  
and CRISPR screen) 
MECLIZINE antagonist 
modulator 
yes 
PROZ protective (CRIPSR screen) MENADIONE activator yes 
HSD11B1 susceptible (CRISPR screen) CARBENOXOLONE inhibitor yes 
HSD11B1 susceptible (CRISPR screen) CHEMBL222670 inhibitor yes 
HSD11B1 susceptible (CRISPR screen) CHEMBL2153191 inhibitor yes 
HSD11B1 susceptible (CRISPR screen) CHEMBL2177609 inhibitor yes 
HSD11B1 susceptible (CRISPR screen) PHENYLARSINE OXIDE inhibitor yes 
HSD11B1 susceptible (CRISPR screen) PREDNISONE ligand unknown 
SIRT1  protective (PMID 29084443), 
susceptible (CRISPR screen) 
CHEMBL257991 activator unknown 
SIRT1  protective (PMID 29084443), 
susceptible (CRISPR screen) 
SODIUM LAURYL 
SULFATE 
inhibitor unknown 
SIRT1  protective (PMID 29084443), 
susceptible (CRISPR screen) 
CHEMBL420311 inhibitor unknown 
SIRT1  protective (PMID 29084443), 
susceptible (CRISPR screen) 
SPLITOMICIN inhibitor unknown 
SIRT3 susceptible (PMID 21720390, 
CRISPR screen) 
SODIUM LAURYL 
SULFATE 
inhibitor yes 
GPX2 protective (CRISPR screen) GLUTATHIONE cofactor unknown 
GPX4 protective (PMID 25962350), 
susceptible (CRISPR screen) 
GLUTATHIONE cofactor unknown 
GSS protective (PMID 11287661), 
susceptible (CRISPR screen) 
ACETYLCYSTEINE stimulator no 
GSTP1 susceptible (PMID 11058152; 
CRIPSR screen) 
EZATIOSTAT 
HYDROCHLORIDE 
inhibitor yes 
KCNJ3 protective (CRISPR 4d), 
susceptible (CRISPR all 
APAP samples) 
CHEMBL2409106 activator unknown 
KCNJ3 protective (CRISPR 4d), 
susceptible (CRISPR all 
APAP samples) 
CHEMBL116590 channel 
blocker 
unknown 
KCNJ3 protective (CRISPR 4d), 
susceptible (CRISPR all 
APAP samples) 
HALOTHANE inhibitor unknown 
NAMPT protective (Zhang et al. 2018, 
CRISPR screen) 
TEGLARINAD 
CHLORIDE 
inhibitor no 
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Notably, 3 novel genes are targets of existing drugs that may be suitable re-
purposed therapeutics against APAP-induced hepatotoxicity. BMPR1A, identified as a 
susceptible gene by the CRISPR/Cas9 screen, is inhibited by CHEMBL3186227. PROZ, 
identified as a protective gene by the CRISPR/Cas9 screen, is activated by Menadione. 
HSD11B1, a gene that was shown to be susceptible in the CRISPR/Cas9 screen, is inhibited 
by Carbenoloxone, CHEMBL222670, CHEMBL2153191, CHEMBL2177609, and 
Phenylarsine Oxide. An additional 3 genes, NR1I3, SIRT3, and GSTP1, have known roles 
in APAP hepatotoxicity that were correctly predicted by our CRIPSR-Cas9 screen and are 
targets of existing drugs that may be suitable for re-purposing128-130. These 6 genes are 
excellent candidate targets for re-purposing existing drugs to treat APAP-induced ALI and 
ALF. An additional 3 genes, SIRT1, GPX4, and GSS, were identified as targets of drugs 
with known gene interactions, however the CRISPR/Cas9 screen did not agree with the 
published gene role (protective or susceptible) in APAP-induced hepatotoxicity131-133.  
 
Functional validation of candidate genes 
 
The screening strategy employed in the study resulted in the discovery of genes that 
were ranked among the 10 enriched or depleted knockouts at specific APAP treatment 
times or across the screen, and were also significantly enriched or depleted in APAP-
treated gene expression data. From these genes, we selected LZTR1, PGM5, and NAAA 
for in vitro tests of gene knockdown. Lztr1, Nampt, Pgm5, and Naaa were knocked down 
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in vitro in primary mouse hepatocytes that were subsequently treated with and without 
APAP to assess relative changes in cellular survival.  
Nampt knockdown by siRNA, measured by sqPCR, resulted in a significant 
decrease in cellular survival when compared with a scramble control after 3h APAP 
treatment (figure 7 A-B). Lztr1 knockdown by siRNA, measured by sqPCR, resulted in a 
significant increase in cellular survival when compared with a scramble control after 3h 
APAP treatment (figure 7 C-D). Pgm5 knockdown by siRNA resulted in a significant 
increase in cellular survival after 3h of APAP treatment when compared with the scrambled 
control (figure 7 E-F).  
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Figure 7 | Validation experiments in primary mouse hepatocytes. 
A Viability of primary mouse hepatocytes transfected with 25Mm 
scrambled or Lztr1 siRNA after treatment with 7.5mM APAP for 3h, 
normalized to Lztr1 siRNA transfected, untreated cells, measured by 
luminescent ATP assay. N=4 and error bars represent standard 
deviation. *, p<0.05. B sqPCR from cDNA prepared from RNA 
collected 25h post-transfection with 25Mm scrambled or Lztr1 
siRNA. C Viability of primary mouse hepatocytes transfected with 
25Mm scrambled or Nampt siRNA after treatment with 7.5mM 
APAP for 3h, normalized to Nampt siRNA transfected, untreated 
cells, measured by luminescent ATP assay. N=4 and error bars 
represent standard deviation. *, p<0.05. D sqPCR from cDNA 
prepared from RNA collected 25h post-transfection with 25Mm 
scrambled or Nampt siRNA. E Viability of primary mouse 
hepatocytes transfected with 50-100Mm scrambled or Pgm5 siRNA 
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after treatment with 7.5mM APAP for 3h, normalized to Pgm5 siRNA 
transfected, untreated cells, measured by luminescent ATP assay. 
N=4 and error bars represent standard deviation. *, p<0.05. F sqPCR 
from cDNA prepared from RNA collected 25h post-transfection with 
50Mm scrambled or Pgm5 siRNA. 
 
Although Naaa knockdown was confirmed, no effect on cellular survival of APAP 
was observed (data not shown). It is also possible that a complete NAAA knockout, rather 
than knockdown, is responsible for the protective effect and that low NAAA expression is 
enough for normal function. Overall, NAMPT, LZTR1, and PGM5 are strong candidate 
biomarkers of APAP-induced ALI and ALF. Additional studies are needed to confirm the 
roles of these genes in APAP-induced hepatotoxicity. 
 
Discussion 
 
Validation of the screen findings was sought at multiple steps in the analysis and 
by siRNA in primary hepatocytes. Inspection of the significant genes revealed overlap of 
the CRISPR/Cas9 knockout screen (p<0.05) with human microarray and mouse RNA-seq 
studies of APAP overdose (p<0.05). Several top genes identified from the screen for further 
study already had known associations with APAP in the literature. The presence of genes 
that are already known to be associated with acetaminophen hepatotoxicity in the overlap 
between the CRISPR/Cas9 gene knockouts and the expression datasets validates this 
method of candidate gene discovery.  
Some of the genes identified from the screen for further study have been previously 
identified as essential. The presence of essential genes among the top candidates identified 
from both highly enriched and depleted gene knockouts suggests a number of essential 
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cellular functions may be affected by APAP overdose and toxicity. While these genes were 
not essential in our study, their relationship with APAP treatment would support their roles 
in critical cellular functions that, when disrupted, result in cell death. 
We tested the effect of siRNA knockdown of Lztr1, Nampt, and Pgm5 in primary 
mouse hepatocytes to validate our screen findings. We demonstrate that Leucine Zipper 
Like Transcription Regulator 1 (LZTR1) knockout and knockdown increase cellular 
survival of APAP-induced injury. LZTR1 has a positive LFC in the APAP-exposed human 
microarray data GSE70784, suggesting that the while the gene knockout increases survival 
of APAP, it is also elevated in APAP-treated subjects (supplementary table 29). LZTR1 
mutations are associated with Noonan Syndrome 10, Schwannomatosis-2, gastric cancer, 
ventricular septal defects, and deletion of the gene may be associated with DiGeorge 
syndrome134-138. The GO annotations for LZTR1 include transcription factor activity and 
sequence-specific DNA binding. The protein localizes to the golgi, where it is thought to 
have a stabilizing effect. 
Nicotinamide Phosphoribosyltransferase (NAMPT, PDB ID 4LVF.A) was selected 
for further study because although it is not significant in this screen, other lab data 
demonstrates a protective effect of overexpression against APAP-induced hepatotoxicity 
and Nampt has reduced expression in APAP-treated mice (LFC=-0.476, p<0.05)105. This 
in combination with the number of other NAD metabolism genes that are significantly 
ranked in this screen led us to validate the effect of NAMPT knockdown, which we found 
to increase susceptibility to APAP-induced injury. NAMPT protein is involved in the 
catalysis of the biosynthesis of the nicatinomide adenine dinucleotide. NAMPT’s role in 
NAD salvage is thought to be important to a number of metabolism and aging-related 
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conditions139-146. It is involved in the NAD metabolism and Common Cytokine Receptor 
Gamma-Chain Family Signaling pathways. GO annotations include protein 
homodimerization activity and drug binding.  
Phosphoglucomutase 5 (PGM5) knockdown increased cellular survival of APAP 
treatment, validating our CRISPR/Cas9 screen finding that knockout of the gene is 
protective. PGM5 has a negative LFC in the APAP-exposed human microarray data 
GSE70784, suggesting that the gene knockout increases survival of APAP exposure and 
gene expression is decreased after APAP exposure. PGM5 does not exhibit 
phosphoglucomutase activity and is a component of cell-cell and cell-matrix junctions. It 
is expressed at high levels in smooth muscle and is essential in the metabolism of galactose 
and glycogen and is involved in the Porphyrin and chlorophyll metabolism pathway. GO 
annotations include structural molecule activity, intramolecular transferase activity, and 
phosphotransferase activity. Abnormal expression and mutation of PGM5 are associated 
with a number of diseases, including Duchenne’s Muscular Dystrophy and colorectal 
tumorigenesis, 147-148.  
 We attempted to validate the increased susceptibility of NAAA knockdown, 
however we were not able to reproduce this result in primary mouse hepatocytes. Although 
we were able to confirm knockdown of Naaa in vitro, we were not able to validate the 
increase in susceptibility observed in the CRISPR/CAS9 screen. It is possible that the effect 
is too small in the conditions used for the validation experiments. Further mechanistic 
studies are needed to evaluate the biological pathways in that these genes are acting to alter 
APAP metabolism. Further population studies of polymorphisms in these genes could yield 
susceptibility SNP panels. mRNA or protein expression of these genes, especially genes 
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that are also identified in GSE70784 in blood after APAP dosing, could have utility as 
biomarkers for diagnosis and prognosis.  
To better control for potential differences in drug metabolism across systems and 
to identify the most promising candidate genes, the CRIPSR-Cas9 gene knockout rankings 
were cross-referenced with multiple human and mouse datasets to select the most 
promising candidate genes. We also identified genes with likely and known associations 
with APAP-induced hepatotoxicity (NAD metabolism and genes containing 
polymorphisms). These candidate genes were assessed for drugability by existing drugs as 
a means to more quickly bring forward new therapies. Indeed, 6 candidate genes (3 novel 
and 3 known) are targets for existing drugs that have an interaction predicted to be 
protective against APAP-induced hepatotoxicity. 
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CHAPTER 9 
 
Conclusions 
 
Collectively, this study has illustrated the power of a genome-wide CRISPR/Cas9 
screen to systematically identify novel genes involved in APAP-induced hepatocyte 
toxicity and to provide potential new targets to develop novel therapeutic modalities. A 
negative selection screen for essential genes identified gene sets involved in fundamental 
processes, and a positive selection screen identified numerous genes potentially involved 
in pathogenic processes. These results inform the complex heterogenic nature of APAP 
toxicity and provide new targets for new mechanistic explorations and novel therapeutic 
modality developments. Combined with functional validations, this screening technique 
offers a robust and dynamic way to identify candidate genes for a variety of disease models. 
In this study we demonstrate that LZTR1 and PGM5 knockout and knockdown are 
protective against APAP–induced hepatotoxicity. Further experiments are warranted to 
evaluate the specific roles of these genes in the disease process.  
The gene NAMPT is protective against APAP-induced ALI in vivo, although not 
identified directly by the sgRNA screen, we show knockdown increases susceptibility to 
APAP-induced hepatotoxicity. NAMPT has a known role in NAD salvage that warrants 
further study to identify if its protective effect is resultant of increased NAD supporting 
glutathione production and CYP function, or if it is protective by a novel mechanism.  
These genes represent novel diagnostic and therapeutic targets for improving the 
care of acetaminophen overdose. Gene expression could be used to determine susceptibility 
 72 
 
to APAP-hepatotoxicity as well diagnose and predict disease severity and outcome. 
Expression and function-associated variants in these genes could be used in risk-
assessment genotyping panels. Furthermore, these genes represent novel biomarkers for 
personalized therapeutics. In silico analysis of candidate genes identified a number of the 
candidate genes that are targets for existing drugs. These existing drugs could be quickly 
re-purposed to treat and prevent APAP-induced ALF. Further studies are needed to better 
understand the functional role of the genes and pathways highlighted in this study.  
 
Future Directions 
 
This study identifies genetic components of acetaminophen-induced hepatocyte 
toxicity. Further studies are needed to better understand the functional role of the genes 
and pathways highlighted in this study. More validations in primary hepatocytes, animal 
models, patient populations and further investigation of the underlying molecular 
mechanisms are needed. Further research on the topic can include biological validation in 
cellular and mouse models, as well as in-depth study of the roles of the genes and pathways 
proposed in this study. Specifically, studies of the effects of overexpression of the 
functionally validated candidate genes in-vitro and of overexpression and 
knockdown/knockout in-vivo will further define the role of these genes. Larger-scale 
genome-wide studies as well as candidate gene approaches in human populations can 
contribute to our understanding of genetic variation that alters acetaminophen metabolism. 
Additional CRISPR/Cas9 knockout screening of non-coding RNAs associated with APAP-
induced hepatotoxicity will advance our understanding of non-coding contributors to 
susceptibility to and pathogenesis of the disease process. 
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Possible implications of the study described here could include novel diagnostic 
and therapeutic targets or susceptibility and prognosis markers for acetaminophen-induced 
ALF. Drugable gene candidates also warrant further study as it is faster and cheaper to re-
purpose existing drugs. This research has the potential to make a valuable contribution to 
the body of medical research by adding to our understanding of acute liver failure and 
acetaminophen metabolism. The findings in this study provide rich novel targets for further 
experimentation, which could lead to development of new and better diagnostic and 
therapeutic modalities to potentially enhance the frequency of good outcomes of 
acetaminophen-induced ALF.  
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APPENDIX A 
SUPPLEMENTARY FIGURES 
 
 
Supplementary Figure 1 | Amplicon sequencing strategy. 
The sequence of the sgRNA cassette labeled with the 
binding sites of the sequencing primers with different 
colors:pink, Illumina forward primer (P5 and seq); green, 
binding site of forward indexing primer; yellow, binding site 
of reverse indexing primer; red, Illumina reverse primer 
(seq); blue, Illumina P7 sequence. 
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Supplementary Figure 2 | Scatterplots describing the distribution of read counts 
between samples. A Scatterplot showing enrichment and depletion of Log2 sgRNA read 
counts after 24h APAP treatment. B Scatterplot showing enrichment and depletion of Log2 
sgRNA read counts after 4d APAP treatment and 21d outgrowth. 
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Supplementary Figure 3 | Box plots of mouse RNA-seq (GSE 110787) and human 
microarray samples (GSE74000) used to validate CRISPR/Cas9 screen hits. A Log2 
read counts of samples with and without APAP treatment from RNA-sequenced mice. B 
Log2 read counts for GSE74000, healthy liver control and APAP overdose samples.  
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Supplementary Figure 4 | Box plots of human microarray samples (GSE70784) used 
to validate CRISPR/Cas9 screen hits. A Log2 read counts from day 1 responder and 
nonresponder samples in GSE70784. B Log2 read counts from day 8 responder and 
nonresponder samples in GSE70784. C Log2 read counts from day 1 responder and placebo 
 78 
 
samples in GSE70784. D Log2 read counts from day 8 responder and placebo samples in 
GSE70784. 
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APPENDIX B 
SUPPLEMENTARY TABLES 
 
Supplementary Table 1: Primers used for sequencing, cloning, and sqPCR. 
Name Sequence Details 
PCR1 F1 
primer 
AATGGACTATCATATGCTTACCGTAACTTGAA
AGTATTTCG 
primer for readout PCR1 
PCR1 R1 
primer 
CTTTAGTTTGTATGTCTGTTGCTATTATGTCTA
CTATTCTTTCC 
primer for readout PCR1 
PCR2 F01 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTttcttgtggaaa
ggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F02 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTattcttgtggaa
aggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F03 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTgattcttgtgga
aaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F04 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTcgattcttgtgg
aaaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F05 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTtcgattcttgtg
gaaaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F06 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTatcgattcttgt
ggaaaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F07 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTgatcgattcttg
tggaaaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F08 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTcgatcgattctt
gtggaaaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F09 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTacgatcgattct
tgtggaaaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F10 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTttcttgtggaaa
ggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F11 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTattcttgtggaa
aggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 F12 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCTgattcttgtgga
aaggacgaaacaccg 
Illumina F (P5 & Illumina seq) 
with variable-length stagger for 
readout PCR2 
PCR2 R01 CAAGCAGAAGACGGCATACGAGATAAGTAGA
GGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
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Supplementary Table 1. –Continued. 
PCR2 R02 CAAGCAGAAGACGGCATACGAGATACACGAT
CGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R03 CAAGCAGAAGACGGCATACGAGATCGCGCGG
TGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R04 CAAGCAGAAGACGGCATACGAGATCATGATC
GGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R05 CAAGCAGAAGACGGCATACGAGATCGTTACC
AGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R06 CAAGCAGAAGACGGCATACGAGATTCCTTGGT
GTGACTGGAGTTCAGACGTGTGCTCTTCCGAT
CTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R07 CAAGCAGAAGACGGCATACGAGATAACGCAT
TGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R08 CAAGCAGAAGACGGCATACGAGATACAGGTA
TGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R09 CAAGCAGAAGACGGCATACGAGATAGGTAAG
GGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R10 CAAGCAGAAGACGGCATACGAGATAACAATG
GGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R11 CAAGCAGAAGACGGCATACGAGATACTGTATC
GTGACTGGAGTTCAGACGTGTGCTCTTCCGAT
CTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
PCR2 R12 CAAGCAGAAGACGGCATACGAGATAGGTCGC
AGTGACTGGAGTTCAGACGTGTGCTCTTCCGA
TCTtctactattctttcccctgcactgt 
Illumina R (P7  & Illumina  seq) 
with barcode for readout PCR2 
Nampt-
Mouse-F 
TGGCGCTTTGCTACAGAAGT mouse qPCR, amplicon position: 
exon 9-10 (CDS), length: 117 
Nampt-
Mouse-R 
TTGGGATCAGCAACTGGGTC mouse qPCR, amplicon position: 
exon 9-10 (CDS), length: 117 
mLztr1-
set8-F 
GCCCGTTCTAGCTACTTTGAG mouse qPCR, amplicon position: 
exon 17/18-21 (CDS), length: 
436bp 
mLztr1-
set8-R 
GCTTGTCAGAGATGTGGGAG mouse qPCR, amplicon position: 
exon 17/18-21 (CDS), length: 
436bp 
mPgm5-
set5-F 
ACCGTTATATGATCCTTGGCC mouse qPCR, amplicon position: 
exon 6-9 (CDS), length: 428bp 
mPgm5-
set5-R 
CTCCAGTCCCTCGTAATCAAAC mouse qPCR, amplicon position: 
exon 6-9 (CDS), length: 428bp 
ActB-F CTTTGCAGCTCCTTCGTTGC mouse qPCR, amplicon position: 
5'UTR-exon 1, length: 79bp 
ActB-R GTCGACGACCAGCGCA mouse qPCR, amplicon position: 
5'UTR-exon 1, length: 79bp 
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Supplementary Table 2: Alignment metrics for the CRISPR/Cas9 APAP screen. 
Label 
Total reads 
/sample 
Total mapped 
reads /sample 
Freq mapped genes 
/sample 
Zerocounts 
/sample 
Plasmid_rep1 46103448 35778757 0.78 1 
Plasmid_rep2 47102021 37808035 0.80 0 
T0_rep1 36989846 20480799 0.55 12 
T0_rep2 45321323 36048480 0.80 2 
T30min 36441473 24184285 0.66 15 
T3h 42968606 34715794 0.81 2 
T6h 41412350 33900076 0.82 5 
T12h 35096028 27235534 0.78 4 
24h_rep1 40517754 14730530 0.36 19 
24h_rep2 40473783 32073043 0.79 2 
4d_rep1 31545812 10868034 0.34 4957 
4d_rep2 42953904 34098492 0.79 1257 
Total_rep1 311075317 201893809 0.65  
Total_rep2 175851031 140028050 0.80  
Total 486926348 341921859 0.70  
 
 
  
 
Supplementary Table 3: Wilcoxon Rank-Sum Test p-values for the CCRISPR/Cas9 screen samples. 
Label 
Plasmid 
rep. 1 
Plasmid 
rep. 2 T0 rep. 1 T0 rep. 2 T30min T3h T6h T12h 24h rep. 1 24h rep. 2 4d rep. 1 4d rep. 2 
Plasmid 
rep. 1 1.00E+00 9.59E-01 3.83E-03 2.47E-02 5.44E-03 1.96E-01 1.33E-01 1.07E-03 4.16E-01 3.92E-02 7.51E-211 2.63E-66 
Plasmid 
rep. 2 9.59E-01 1.00E+00 4.07E-03 2.62E-02 6.13E-03 2.08E-01 1.39E-01 1.06E-03 3.92E-01 4.18E-02 1.77E-211 1.62E-66 
T0 rep. 1 3.83E-03 4.07E-03 1.00E+00 5.44E-01 8.87E-01 1.34E-01 1.90E-01 5.91E-08 1.37E-03 4.05E-01 3.05E-198 1.86E-56 
T0 rep. 2 2.47E-02 2.62E-02 5.44E-01 1.00E+00 6.37E-01 3.77E-01 4.69E-01 8.80E-07 8.69E-03 8.41E-01 1.58E-200 4.49E-58 
T30min 5.44E-03 6.13E-03 8.87E-01 6.37E-01 1.00E+00 1.74E-01 2.31E-01 8.54E-08 2.25E-03 4.83E-01 4.59E-199 5.74E-57 
T3h 1.96E-01 2.08E-01 1.34E-01 3.77E-01 1.74E-01 1.00E+00 8.52E-01 3.15E-05 6.26E-02 4.81E-01 7.40E-203 3.07E-60 
T6h 1.33E-01 1.39E-01 1.90E-01 4.69E-01 2.31E-01 8.52E-01 1.00E+00 1.55E-05 4.27E-02 6.03E-01 3.79E-203 1.23E-59 
T12h 1.07E-03 1.06E-03 5.91E-08 8.80E-07 8.54E-08 3.15E-05 1.55E-05 1.00E+00 2.23E-02 1.38E-06 2.95E-218 5.30E-70 
24h rep. 
1 4.16E-01 3.92E-01 1.37E-03 8.69E-03 2.25E-03 6.26E-02 4.27E-02 2.23E-02 1.00E+00 1.22E-02 3.81E-206 1.74E-62 
24h rep. 
2 3.92E-02 4.18E-02 4.05E-01 8.41E-01 4.83E-01 4.81E-01 6.03E-01 1.38E-06 1.22E-02 1.00E+00 8.10E-203 1.49E-58 
4d rep. 1 7.51E-211 1.77E-211 3.05E-198 1.58E-200 4.59E-199 7.40E-203 3.79E-203 2.95E-218 3.81E-206 8.10E-203 1.00E+00 3.50E-73 
4d rep. 2 2.63E-66 1.62E-66 1.86E-56 4.49E-58 5.74E-57 3.07E-60 1.23E-59 5.30E-70 1.74E-62 1.49E-58 3.50E-73 1.00E+00 
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Supplementary Table 4: Enriched gene knockouts ranked by RRA analysis 
of the CRISPR/Cas9 screen 30min-4d APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
PDSS2 6 7.75E-06 5.56E-05 1 3 0.9457 
KIF23 6 1.48E-05 9.76E-05 2 4 0.59281 
hsa-mir-4484 4 1.70E-05 6.71E-05 3 1 2.9828 
CXADR 6 1.70E-05 0.0001077 4 5 0.60028 
CNNM1 6 2.77E-05 0.00016466 5 4 0.55475 
PGM5 6 3.84E-05 0.0002207 6 5 0.56592 
NR1I3 6 5.27E-05 0.0002802 7 5 0.45067 
RS1 6 7.11E-05 0.00035216 8 2 0.80817 
CCDC51 6 7.66E-05 0.00036968 9 1 1.4295 
NEK4 6 8.26E-05 0.00040059 10 4 0.6183 
TM4SF5 6 9.81E-05 0.00047669 11 2 0.74329 
NETO1 6 0.00011428 0.00055141 12 5 0.35556 
WFIKKN2 6 0.00011712 0.00056617 13 2 0.94383 
GLYATL3 6 0.00012513 0.00059385 14 3 0.64176 
CTNND2 6 0.00012767 0.00060815 15 2 1.1465 
RXFP1 6 0.00013562 0.00064689 16 4 0.47969 
hsa-mir-3667 4 0.00015321 0.00061506 17 3 0.33794 
PLP1 6 0.0001724 0.00081686 18 5 0.34928 
CHST4 6 0.00017874 0.00084753 19 1 1.4723 
TMEM229B 6 0.00018836 0.00089642 20 4 0.61343 
KPNA7 6 0.00022854 0.0010532 21 4 0.48639 
GUCY2F 6 0.00024923 0.0011469 22 3 0.71776 
IQCE 6 0.00025408 0.0011686 23 4 0.47943 
DET1 6 0.00026497 0.0012161 24 5 0.38933 
TM2D2 6 0.00027997 0.0012876 25 2 0.75432 
ZNF2 6 0.00028086 0.0012926 26 2 1.1893 
TRIM37 6 0.00030257 0.0013793 27 3 0.55012 
TMEM60 6 0.00030447 0.0013867 28 2 0.9665 
XRN2 6 0.00032385 0.0014688 29 4 0.53972 
PIGV 6 0.00033192 0.0015011 30 2 0.93384 
HOXD12 6 0.00033951 0.0015343 31 2 0.87919 
KHDRBS3 6 0.00034392 0.00155 32 5 0.39681 
HTR3A 6 0.00035572 0.0016058 33 5 0.48482 
SLITRK4 6 0.00036497 0.0016422 34 4 0.67464 
RAB41 6 0.00037236 0.0016773 35 4 0.47937 
TFIP11 6 0.00038298 0.001729 36 2 1.1676 
CBFA2T3 6 0.00038485 0.0017359 37 4 0.45563 
FAF2 6 0.00039675 0.0017862 39 4 0.38135 
TRPV6 6 0.00039963 0.0017949 40 4 0.55701 
  
84 
 
Supplementary Table 5: Depleted gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 30min-4d APAP treatment vs. T0. 
ID sgRNA Neg score Neg p-value Neg rank Neg good 
sgRNA 
Neg lfc 
PKD2 6 4.51E-06 3.25E-05 1 3 -1.5917 
C19orf60 6 2.55E-05 0.00014829 2 1 -1.7353 
HERC6 6 5.94E-05 0.00031526 3 4 -0.78428 
KIAA1737 6 6.23E-05 0.00032633 4 5 -0.55801 
SENP3 6 6.65E-05 0.00034524 5 3 -0.89267 
TTC29 6 7.66E-05 0.00038168 6 2 -1.3568 
AK7 6 0.00011033 0.00055187 7 5 -0.59964 
hsa-mir-8088 4 0.00011567 0.00046239 8 4 -0.81305 
TMCC2 6 0.00011568 0.00057079 9 5 -0.46257 
HIST1H3I 6 0.00011761 0.00058047 10 4 -0.81016 
C5orf34 6 0.00011854 0.00058508 11 3 -1.0994 
CYB5B 6 0.00012767 0.00062014 12 3 -0.71493 
H3F3B 6 0.00012922 0.0006289 13 3 -0.88598 
TAT 6 0.00017355 0.00083369 14 3 -1.1348 
GLB1L3 5 0.00017609 0.00083231 15 5 -0.38086 
WDR25 6 0.00017874 0.0008586 16 2 -1.2777 
OAZ1 6 0.0001804 0.0008669 17 5 -0.6531 
CENPA 6 0.00018117 0.00087151 18 3 -0.79542 
SSFA2 6 0.00018359 0.00088904 19 4 -0.71874 
PEX11A 6 0.00018498 0.00089504 20 3 -0.7544 
ANKRD13B 6 0.00019191 0.00092317 21 3 -1.0923 
hsa-mir-6839 4 0.00019627 0.00076727 22 3 -0.88662 
TIGD2 6 0.00019763 0.00094485 23 5 -0.58574 
ADAMTS15 6 0.0002298 0.0010698 25 3 -1.479 
SNRPD1 6 0.00024615 0.0011423 26 3 -1.1914 
KLHL2 6 0.00025963 0.0012013 27 2 -0.92905 
NUBPL 6 0.00027857 0.0012903 28 3 -1.0675 
EIF4ENIF1 6 0.00028086 0.0013019 29 2 -1.1856 
hsa-mir-498 4 0.00028087 0.0010814 30 2 -0.78968 
MNX1 6 0.00028982 0.0013374 31 5 -0.43006 
DICER1 6 0.00029364 0.0013554 32 3 -0.62626 
KRT85 6 0.00033046 0.0015034 33 4 -0.77437 
SMAP2 6 0.00033186 0.0015094 34 5 -0.34947 
ADCY9 6 0.00033192 0.0015099 35 1 -1.2071 
SSPO 6 0.00034304 0.0015525 36 5 -0.55715 
hsa-mir-3929 4 0.00036053 0.0013849 37 3 -0.97941 
ALPPL2 6 0.00036267 0.0016413 38 3 -0.81703 
GPR107 6 0.00037868 0.0017128 39 5 -0.46629 
RAB24 6 0.00038012 0.0017197 40 4 -0.87477 
  
85 
 
Supplementary Table 6: Enriched gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 30min-24h APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
CATSPERD 6 1.20E-06 8.53E-06 1 4 0.87111 
GATS 6 7.21E-06 5.14E-05 2 3 0.63212 
OR10J5 6 7.55E-06 5.37E-05 3 5 0.4469 
BMPR1A 6 1.64E-05 0.00010493 4 5 0.29969 
hsa-mir-4484 4 1.70E-05 6.71E-05 5 1 2.6355 
TIMP4 6 2.79E-05 0.0001672 6 3 0.67637 
ESYT1 6 3.49E-05 0.00021148 7 4 0.51038 
STYX 6 4.03E-05 0.00023408 8 6 0.32595 
PGM5 6 5.68E-05 0.00031849 9 6 0.30323 
hsa-mir-496 4 6.14E-05 0.00023869 10 4 0.26194 
EMC8 6 7.55E-05 0.00040289 11 4 0.40301 
LOC643669 6 7.66E-05 0.00040704 12 2 1.2731 
RETNLB 6 9.00E-05 0.00048961 13 3 0.44105 
RPL13A 6 9.15E-05 0.00049629 14 6 0.28236 
AP5S1 6 9.57E-05 0.00052189 15 3 0.41817 
RASSF4 6 9.60E-05 0.00052282 16 5 0.42009 
AIM2 6 9.99E-05 0.00054496 17 5 0.46325 
FRYL 6 0.0001017 0.0005551 18 5 0.37196 
FAM194B 6 0.00010702 0.00058647 19 3 0.5383 
MPV17L 6 0.00011014 0.00060538 20 2 0.93129 
DCN 6 0.00012767 0.00069071 21 2 0.69049 
NUCB1 6 0.00013616 0.00073775 22 6 0.20616 
SLC43A1 6 0.0001527 0.00083139 24 4 0.38929 
ATXN3L 6 0.00015596 0.00085214 25 6 0.21101 
NDUFS5 6 0.00016076 0.00087705 26 6 0.30749 
TM4SF5 6 0.00017361 0.00094762 27 3 0.49386 
SESN2 6 0.00017874 0.00097898 28 4 0.19759 
ITIH2 6 0.00018493 0.001021 29 6 0.20532 
GSTP1 6 0.00019946 0.0010851 30 2 0.5513 
TP53I13 6 0.00021365 0.0011575 31 6 0.24655 
PFKFB1 6 0.0002298 0.001234 32 2 1.2147 
FBXL20 6 0.00023294 0.0012525 33 5 0.28205 
QRSL1 6 0.0002394 0.0012852 34 5 0.3129 
NUDT2 6 0.00024602 0.0013171 35 5 0.24332 
KHDRBS3 6 0.00024836 0.0013323 36 5 0.29467 
CD55 6 0.00026429 0.0014185 37 3 0.42614 
TES 6 0.00026491 0.0014218 38 3 0.51684 
GLYATL3 6 0.00026678 0.0014296 39 3 0.44454 
NR1I3 6 0.00028086 0.0014983 40 4 0.28284 
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Supplementary Table 7: Depleted gene knockouts ranked by RRA analysis of 
the CRISPR/Cas9 screen 30min-24h APAP treatment vs. T0. 
ID sgRNA Neg score Neg p-value Neg 
rank 
Neg good 
sgRNA 
Neg lfc 
PROZ 6 1.52E-05 9.85E-05 1 3 -0.55952 
OR5M11 6 1.91E-05 0.00011739 2 4 -0.6621 
FCGR3A 6 2.55E-05 0.00014829 3 3 -0.34113 
C5orf47 6 6.10E-05 0.00033325 4 3 -0.52808 
PKD2 6 7.66E-05 0.00040704 5 4 -0.58533 
hsa-mir-4466 4 8.37E-05 0.00033279 6 4 -0.39367 
SOHLH2 6 9.05E-05 0.00049191 7 3 -0.54426 
NAAA 6 0.00010807 0.00059108 8 4 -0.50403 
CIAPIN1 6 0.00012767 0.00069071 9 3 -0.2787 
NR1D1 6 0.00013891 0.00075021 10 4 -0.5877 
SH3D21 6 0.00014111 0.00076451 11 5 -0.55614 
ZNF776 6 0.00015003 0.00082032 12 4 -0.67762 
hsa-mir-3201 4 0.00016173 0.00064781 13 4 -0.36678 
PPP1R26 6 0.00017838 0.0009776 14 6 -0.22734 
PLXDC1 6 0.00017874 0.00097898 15 3 -0.4942 
RASGEF1B 6 0.00020879 0.0011326 16 2 -0.72315 
hsa-mir-4521 4 0.00022551 0.00088673 17 4 -0.37679 
EFNB3 6 0.0002298 0.001234 18 2 -0.56097 
hsa-mir-331 4 0.00024601 0.00095454 19 3 -0.45414 
GAL3ST4 6 0.00024972 0.0013401 20 5 -0.36374 
CCDC19 6 0.00028086 0.0015108 21 4 -0.37326 
RAB3GAP2 6 0.00029997 0.0015989 22 5 -0.35747 
CABIN1 6 0.00031478 0.0016755 23 3 -0.60778 
PSRC1 6 0.00031826 0.0016902 24 4 -0.38892 
SOX6 6 0.00033086 0.0017525 26 6 -0.22492 
OLFM4 6 0.00033192 0.0017585 27 3 -0.49955 
hsa-mir-4281 4 0.00035512 0.0013637 28 3 -0.86949 
hsa-mir-8063 4 0.00035746 0.0013733 29 2 -0.68673 
MUC4 6 0.00036599 0.0019231 30 4 -0.32442 
HMMR 6 0.00036766 0.0019305 31 4 -0.36554 
NLRP5 6 0.00037541 0.0019674 32 4 -0.3908 
HSDL2 6 0.00037826 0.001979 33 5 -0.29211 
CCDC169-SOHLH2 5 0.00037996 0.0017608 34 3 -0.40926 
WRAP53 6 0.00038082 0.0019928 35 3 -0.40888 
RCN3 6 0.00038277 0.0020016 36 3 -0.76598 
AP4B1 6 0.00038298 0.002002 37 3 -0.32839 
PPM1G 6 0.00038502 0.0020089 38 4 -0.37103 
PXDN 6 0.00039281 0.0020417 39 5 -0.26842 
SLC35D3 6 0.00039783 0.0020578 40 5 -0.307 
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Supplementary Table 8: Enriched gene knockouts ranked by RRA analysis 
of the CRISPR/Cas9 screen 30min APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
hsa-mir-629 4 1.31E-05 5.19E-05 1 2 1.1437 
KAT7 6 1.93E-05 0.00011785 2 5 0.82194 
SRSF1 6 2.55E-05 0.00014829 3 3 0.51229 
CATSPERD 6 4.88E-05 0.00027744 4 4 0.95801 
F8 6 5.54E-05 0.00031018 5 5 0.66691 
CCNY 6 7.66E-05 0.00040704 6 3 0.24045 
hsa-mir-6831 4 9.24E-05 0.00036323 7 4 0.4178 
KIF2B 6 9.75E-05 0.00052789 8 3 0.68703 
ANK1 6 0.00010535 0.0005754 9 4 0.60448 
SFTPA1 6 0.00011544 0.00062936 10 5 0.6241 
OR2AG1 6 0.00011942 0.00065104 11 5 0.73872 
AXIN1 6 0.00012767 0.00069071 12 4 0.36959 
SAT1 6 0.00013246 0.00071608 13 3 0.94749 
OR2T33 6 0.00013785 0.0007456 14 6 0.34869 
ATP7B 6 0.00014873 0.00081109 15 4 0.8474 
TSC22D1 6 0.0001651 0.00089873 16 3 0.69373 
CDK18 6 0.00016874 0.0009181 17 6 0.44218 
LOC643669 6 0.00017874 0.00097898 18 2 1.6648 
SETMAR 6 0.00020346 0.0011005 19 6 0.4566 
MSRA 6 0.00020451 0.0011072 20 5 0.46454 
hsa-mir-671 4 0.00020826 0.00081386 21 4 0.43091 
CPQ 6 0.00021258 0.0011515 22 2 0.89045 
hsa-mir-1283-1 4 0.00022408 0.00088305 23 3 0.53965 
C5orf64 6 0.0002298 0.001234 24 3 0.33194 
TMEM165 6 0.00024959 0.0013397 25 6 0.26639 
SLC2A12 6 0.00025306 0.0013581 26 5 0.5113 
CD163 6 0.00026405 0.0014167 27 4 0.58326 
ZNF257 6 0.00027228 0.0014591 28 4 0.63291 
PCED1B 6 0.00028086 0.0015108 29 3 0.36349 
STXBP2 6 0.00029129 0.0015597 30 6 0.34082 
SESN2 6 0.00031363 0.0016713 31 4 0.76548 
AAED1 6 0.00032051 0.0017017 32 4 0.66596 
hsa-mir-4484 4 0.00032342 0.0012437 33 3 0.52471 
RAB7L1 6 0.00033192 0.0017585 34 4 0.59309 
RAB3B 6 0.00034332 0.0018148 35 4 0.63844 
FBXL20 6 0.00036933 0.001949 36 5 0.47368 
C5orf51 6 0.00037181 0.0019665 37 4 0.58045 
CREB3L3 6 0.00038298 0.0020278 38 3 0.21435 
USP25 6 0.00039139 0.0020689 39 5 0.59887 
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Supplementary Table 9: Depleted gene knockouts ranked by RRA analysis 
of the CRISPR/Cas9 screen 30min APAP treatment vs. T0. 
ID sgRNA Neg score Neg p-value Neg rank Neg good 
sgRNA 
Neg lfc 
CRYBB1 6 2.13E-05 0.00012892 1 5 -0.77782 
HAUS8 6 2.44E-05 0.00014644 2 6 -0.42961 
TNFRSF10C 6 2.55E-05 0.00014829 3 3 -0.34479 
NHEJ1 6 2.89E-05 0.00017273 4 6 -0.50827 
hsa-mir-6775 4 3.62E-05 0.0001386 5 4 -0.52897 
HIP1R 6 4.62E-05 0.00026637 6 5 -0.5242 
SRP19 6 5.03E-05 0.0002862 7 5 -0.40136 
COL9A3 6 7.32E-05 0.00038998 8 6 -0.38037 
MAPK11 6 7.66E-05 0.00040704 9 2 -0.57421 
C17orf105 6 0.00010542 0.00057632 10 5 -0.49927 
hsa-mir-6846 4 0.00011213 0.0004504 11 4 -0.57785 
OAZ1 6 0.00012767 0.00069071 12 3 -0.46701 
hsa-mir-4788 4 0.00013378 0.00054034 13 2 -0.84262 
GSDMC 6 0.00014477 0.00078941 14 3 -0.8266 
TTC9 6 0.00017874 0.00097898 15 2 -0.5821 
IRF2BPL 6 0.00018144 0.00099697 16 4 -0.38708 
hsa-mir-7850 4 0.00018725 0.00072945 17 2 -0.6255 
ASAH2 6 0.00019729 0.0010781 18 6 -0.33131 
AZGP1 6 0.0002298 0.001234 19 1 -1.109 
ANKRD66 6 0.00023819 0.0012793 20 4 -0.58655 
RAP2A 6 0.00024452 0.0013078 21 5 -0.54024 
SPANXF1 5 0.00024562 0.0011556 22 4 -0.52934 
hsa-mir-4270 4 0.00024978 0.00096607 23 3 -0.61801 
PRLR 6 0.0002747 0.001473 24 4 -0.62035 
ARHGEF2 6 0.00029689 0.0015846 25 3 -0.58824 
GUCY2C 6 0.00032762 0.0017373 26 5 -0.42311 
GMDS 6 0.00033116 0.0017543 27 2 -1.0905 
CYP26C1 6 0.00033192 0.0017585 28 1 -0.86341 
ACTR3B 5 0.00034747 0.001627 29 3 -0.50374 
TXNRD3NB 6 0.00034956 0.0018489 30 3 -0.72464 
OR10G8 6 0.00035528 0.0018823 31 4 -0.65745 
CSNK1A1 6 0.00036565 0.0019296 32 3 -0.76362 
PSENEN 6 0.00037695 0.0019942 33 5 -0.43933 
SOHLH2 6 0.00038023 0.0020112 34 4 -0.84114 
ZFP30 6 0.00038298 0.0020278 35 2 -0.55655 
RNMTL1 6 0.00040071 0.0021081 36 4 -0.47957 
TCL1B 6 0.00041106 0.0021708 37 6 -0.239 
CPXM2 6 0.00041237 0.0021801 38 3 -0.47961 
CYP2S1 6 0.00041496 0.0021897 39 4 -0.49216 
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Supplementary Table 10: Enriched gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 3h APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
CPE 6 1.11E-05 7.91E-05 1 6 0.35521 
HES6 6 2.31E-05 0.00014137 3 6 0.35138 
C5orf64 6 2.55E-05 0.00014829 4 3 0.26997 
RTBDN 6 2.59E-05 0.00015013 5 3 0.7885 
IQCE 6 5.69E-05 0.00031872 6 4 0.50013 
POLR2C 6 6.05E-05 0.00033094 7 6 0.31181 
SLITRK1 6 6.30E-05 0.00034339 8 2 0.93917 
GP9 6 6.76E-05 0.00036507 9 6 0.42265 
CDHR4 6 7.66E-05 0.00040704 10 5 0.371 
KPNA3 6 8.47E-05 0.00045686 11 6 0.48675 
GTF2E2 6 8.96E-05 0.0004873 12 4 1.0284 
AKR7A2 6 9.58E-05 0.00052189 13 6 0.316 
ANKRD7 6 0.00011641 0.00063674 14 4 0.88174 
hsa-mir-4484 4 0.00011916 0.000479 15 2 1.7943 
LCMT2 6 0.00012767 0.00069071 16 2 1.7217 
CLCN6 6 0.00012836 0.0006944 17 5 0.39548 
TEX33 6 0.00014663 0.00080002 18 3 0.61369 
RDH13 6 0.00015194 0.00082908 19 3 1.2339 
STAMBPL1 6 0.00015845 0.00086506 20 4 0.55147 
BGLAP 5 0.00019151 0.00090242 21 2 1.9002 
AP3M1 6 0.00021252 0.0011515 22 5 0.41577 
AFF1 6 0.00021364 0.0011575 23 4 0.48661 
FAM194B 6 0.00021413 0.0011621 24 4 0.61065 
PIGO 6 0.00021504 0.0011662 25 6 0.26571 
LEFTY1 6 0.00022883 0.0012271 26 4 0.55873 
ZNF524 6 0.00023056 0.0012373 27 4 0.68207 
ST8SIA5 6 0.00023402 0.0012592 28 3 0.56604 
PDSS2 6 0.00024005 0.0012899 29 3 0.79873 
PRPS1L1 6 0.00024601 0.0013171 30 4 0.51425 
SPATA31A1 3 0.00025007 0.00073222 31 3 0.45463 
CSN3 6 0.00026374 0.0014158 32 3 0.60568 
TNNT3 6 0.00027631 0.0014813 33 6 0.44574 
CPNE5 6 0.00028086 0.0015108 34 2 1.1177 
C16orf71 6 0.00028212 0.0015149 35 5 0.45673 
PTPRT 6 0.00028321 0.0015205 36 5 0.47812 
GDPD3 6 0.0002963 0.0015823 37 4 0.52214 
MAST4 6 0.00029994 0.0015989 38 3 0.78261 
KCNA1 6 0.00031931 0.0016958 39 5 0.71872 
hsa-mir-106b 4 0.00032543 0.0012502 40 2 0.55078 
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Supplementary Table 11: Depleted gene knockouts ranked by RRA analysis 
of the CRISPR/Cas9 screen 3h APAP treatment vs. T0. 
ID sgRNA Neg score Neg p-value Neg rank Neg good 
sgRNA 
Neg lfc 
GDF15 6 5.55E-06 4.13E-05 1 3 -0.92515 
RAD51AP2 6 1.92E-05 0.00011739 2 5 -0.66697 
BLID 6 2.55E-05 0.00014829 3 3 -0.26669 
EIF2S3 6 2.58E-05 0.00015013 4 5 -0.44464 
FAM63A 6 3.31E-05 0.00019949 5 5 -0.33166 
DPM1 6 3.54E-05 0.00021332 6 4 -0.47327 
ACMSD 6 3.56E-05 0.00021425 7 5 -0.5557 
STK19 6 4.29E-05 0.00024976 8 4 -0.66472 
UROD 6 4.31E-05 0.00025022 9 4 -0.55998 
FOXG1 6 5.68E-05 0.00031849 10 6 -0.55571 
STARD7 6 5.69E-05 0.00031849 11 5 -0.64105 
TMSB15B 3 6.38E-05 0.00019303 12 3 -0.2882 
PRPF31 6 7.66E-05 0.00040704 13 2 -0.81686 
ITLN2 6 9.38E-05 0.00051175 14 4 -0.615 
RAB3GAP2 6 0.00010196 0.00055695 15 5 -0.39493 
RAPSN 6 0.00011232 0.00061553 16 5 -0.47682 
NEB 6 0.00012258 0.00066442 17 6 -0.2515 
ZNF611 4 0.00014182 0.00057401 18 4 -0.60071 
FAM167B 6 0.00014242 0.00077442 19 4 -0.56612 
AP4B1 6 0.00014953 0.00081663 20 4 -0.49354 
ARL5B 6 0.00015106 0.00082493 21 6 -0.25585 
CD84 6 0.00015219 0.00083092 22 6 -0.30523 
SPANXF1 5 0.00015543 0.00073176 23 4 -0.3949 
LAPTM5 6 0.00016981 0.0009241 24 4 -0.56437 
IFNG 6 0.00017209 0.00093886 25 3 -0.56892 
SIVA1 6 0.00017818 0.00097622 26 3 -0.66867 
HDGFRP2 6 0.00017874 0.00097898 27 2 -1.0114 
TBC1D21 6 0.00019212 0.0010542 28 6 -0.31215 
C1orf43 6 0.00022074 0.0011921 29 5 -0.33197 
GINS4 6 0.0002298 0.001234 30 4 -0.54694 
DNM1 6 0.00023825 0.0012797 31 5 -0.45568 
AUP1 6 0.00026264 0.0014102 32 3 -0.60157 
hsa-mir-4681 4 0.00027224 0.0010519 33 4 -0.37647 
CMTM1 4 0.00027303 0.0010551 34 4 -0.39637 
EIF1AD 6 0.00027997 0.0015053 35 3 -0.742 
SERPINF1 6 0.00028086 0.0015108 36 5 -0.3583 
STK38L 6 0.00028865 0.0015435 37 6 -0.25919 
LDOC1 6 0.00029041 0.0015537 38 3 -0.45134 
hsa-mir-942 4 0.0002956 0.00114 39 3 -0.47037 
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Supplementary Table 12: Enriched gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 6h APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
LOC643669 6 3.84E-06 2.74E-05 1 3 0.96959 
RAB41 6 1.03E-05 7.45E-05 2 4 0.51956 
SNRNP70 6 1.21E-05 8.42E-05 3 3 0.89968 
SRSF1 6 2.55E-05 0.00014829 4 3 0.38277 
STYX 6 3.16E-05 0.00019211 5 4 0.69453 
AKR7A2 6 4.37E-05 0.00025253 6 5 0.36009 
SPATS1 6 4.97E-05 0.00028251 7 6 0.29516 
CCDC71 6 6.70E-05 0.00036184 8 6 0.34472 
RETNLB 6 7.51E-05 0.00039966 9 3 0.56409 
CCNY 6 7.66E-05 0.00040704 10 3 0.35893 
NPFF 6 9.17E-05 0.00050114 11 6 0.46028 
hsa-mir-4800 4 9.89E-05 0.00039459 12 3 0.57866 
CTNND2 6 0.00010271 0.00055972 13 3 0.49469 
NUDCD3 6 0.00010338 0.00056294 14 2 1.2832 
WDR24 6 0.00010476 0.00057125 15 6 0.36501 
SMARCA2 6 0.00011143 0.00061045 16 4 0.54585 
PDP2 6 0.00011559 0.00062982 17 5 0.57918 
SIRT1 6 0.0001253 0.00067503 18 5 0.56079 
GPS2 6 0.00012767 0.00069071 19 2 1.9818 
ASXL1 6 0.00013614 0.00073775 20 5 0.63292 
TSPAN13 6 0.00014346 0.00078065 21 6 0.26872 
SPAG6 6 0.00015658 0.00085675 22 6 0.29197 
OR52I2 6 0.00017189 0.00093747 23 3 0.66348 
R3HDM1 6 0.00017201 0.00093793 24 4 0.44622 
SOGA3 6 0.00017361 0.00094762 25 3 1.1267 
NPTX1 6 0.00017874 0.00097898 26 4 0.26695 
hsa-mir-150 4 0.0001891 0.00073775 27 4 0.64051 
LYG1 6 0.00021232 0.0011506 28 6 0.31616 
SSTR2 6 0.00021725 0.0011773 29 3 0.5415 
FASTKD3 6 0.00021736 0.0011778 30 4 0.44421 
ARHGAP27 6 0.00021867 0.0011847 31 5 0.46813 
FMNL2 6 0.00022289 0.0012008 32 5 0.55852 
BAX 6 0.00022795 0.0012257 33 4 0.46007 
HIST1H2AM 6 0.0002298 0.001234 34 1 3.3758 
BGLAP 5 0.00023406 0.0010994 35 3 0.60159 
PGGT1B 6 0.00024455 0.0013078 36 6 0.43196 
ME1 6 0.00024701 0.0013226 37 6 0.3376 
TIMP4 6 0.00026703 0.0014324 38 3 0.75619 
CARM1 6 0.00026787 0.0014352 39 4 0.40124 
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Supplementary Table 13: depleted gene knockouts ranked by RRA analysis 
of the CRISPR/Cas9 screen 6h APAP treatment vs. T0. 
ID sgRNA Neg score Neg p-value Neg 
rank 
Neg good 
sgRNA 
Neg lfc 
ASB10 6 8.47E-06 6.07E-05 1 5 -0.54332 
DRAP1 6 1.37E-05 9.29E-05 3 5 -1.1001 
ACOT1 6 1.65E-05 0.00010585 4 2 -0.84258 
PNMAL1 6 2.55E-05 0.00014829 5 3 -0.35088 
LMTK3 6 3.15E-05 0.00019165 6 2 -0.68178 
OR5AU1 6 4.72E-05 0.00027052 7 3 -0.43634 
CSF2 6 6.68E-05 0.00036184 8 3 -0.49177 
FIGN 6 6.82E-05 0.00036876 9 6 -0.31215 
C1orf43 6 6.93E-05 0.00037614 10 5 -0.48234 
hsa-mir-1248 4 7.08E-05 0.00027836 11 3 -0.65237 
BZW2 6 7.33E-05 0.00038998 13 3 -0.48134 
GPR37L1 6 8.71E-05 0.00047162 14 5 -0.57205 
hsa-mir-196a-2 4 0.00011916 0.000479 15 3 -0.58026 
TRIM33 6 0.00012698 0.00068702 16 5 -0.29048 
HIST1H2BD 6 0.00012767 0.00069071 17 2 -0.79881 
MGAT4A 6 0.00012798 0.00069163 18 4 -0.52264 
YIPF7 6 0.00012872 0.00069809 19 2 -0.6191 
LRRN1 6 0.00015582 0.00085122 20 6 -0.36718 
IL1R2 6 0.00018182 0.0010011 21 3 -0.71554 
hsa-mir-548ab 4 0.00018428 0.00072184 22 2 -0.68659 
TMEM215 6 0.00020403 0.0011044 23 5 -0.3895 
CD84 6 0.00020598 0.001116 24 5 -0.42474 
ATP1A1 6 0.00020936 0.0011363 25 4 -0.44064 
DYNC1LI2 6 0.0002298 0.001234 26 1 -1.0698 
GALNT5 6 0.00023033 0.0012364 27 4 -0.51196 
TSSK6 6 0.00024467 0.0013083 28 5 -0.39479 
IFI27 6 0.00025937 0.0013899 29 5 -0.45498 
hsa-mir-372 4 0.00026635 0.0010288 30 3 -0.68708 
ZBTB38 6 0.00028086 0.0015108 31 3 -0.24388 
STOX2 6 0.00033192 0.0017585 32 4 -0.50216 
PROCA1 6 0.00033362 0.0017686 33 3 -0.68802 
ZNF609 6 0.00035161 0.0018636 34 2 -0.75098 
MTX2 6 0.00035346 0.0018747 35 6 -0.2695 
hsa-mir-302d 4 0.00035833 0.0013761 36 3 -0.53077 
MBD2 6 0.00036395 0.0019236 37 3 -0.52941 
DAW1 6 0.00038298 0.0020278 38 1 -0.68703 
TBP 6 0.0003896 0.002062 39 6 -0.35758 
RPN1 6 0.00040224 0.0021155 40 5 -0.52792 
KDELR2 6 0.00040864 0.0021565 41 4 -0.41677 
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Supplementary Table 14: Enriched gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 12h APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
OTUD3 6 1.56E-05 0.00010032 1 3 0.83868 
GATS 6 1.79E-05 0.00011231 2 4 0.77141 
BMPR1A 6 1.93E-05 0.00011785 3 6 0.41848 
CUL4B 6 1.96E-05 0.00012015 4 6 0.36531 
SCUBE2 6 2.14E-05 0.00012892 5 5 0.68204 
NR3C1 6 2.52E-05 0.00014783 6 4 0.80561 
C14orf159 6 2.55E-05 0.00014829 7 3 0.237 
PIK3R1 6 2.78E-05 0.00016674 8 4 0.66259 
TES 6 5.91E-05 0.00032679 9 3 0.72636 
ZW10 6 6.08E-05 0.00033279 10 6 0.48035 
C5orf64 6 7.66E-05 0.00040704 11 4 0.20738 
ZNF613 6 8.02E-05 0.00042826 12 6 0.60179 
DEFB114 6 0.00010702 0.00058647 13 4 0.5274 
LIX1 6 0.00011211 0.00061414 14 6 0.466 
HIST1H2AM 6 0.00012767 0.00069071 15 1 3.7898 
DUSP2 6 0.00014087 0.00076405 16 3 0.8838 
CD1B 6 0.00014721 0.00080371 17 5 0.64858 
KCNJ3 6 0.00015128 0.00082585 18 6 0.32044 
KLHL15 6 0.00015275 0.00083139 19 5 0.59454 
KIAA0895 6 0.00015518 0.00084707 20 5 0.48535 
SSBP2 6 0.00015763 0.00085952 21 5 0.52499 
EVI5L 6 0.00016031 0.00087428 22 3 0.85075 
GRB7 6 0.00016553 0.00090242 23 5 0.75454 
IRF1 6 0.0001694 0.00092225 24 6 0.37856 
MTA1 6 0.00017874 0.00097898 25 1 3.2361 
FSTL1 6 0.00018744 0.0010334 26 4 0.70639 
WRB 6 0.00018815 0.0010348 27 5 0.62386 
ATPAF2 6 0.00019034 0.001044 28 2 0.98707 
PGM5 6 0.00019139 0.0010491 29 6 0.48176 
RREB1 6 0.00019572 0.0010698 30 4 0.76125 
VIT 6 0.00019583 0.0010708 31 6 0.36793 
GAREM 6 0.0001967 0.0010758 32 3 0.74914 
PRDM11 6 0.00020842 0.0011293 33 5 0.60209 
MICAL3 6 0.00021313 0.0011538 34 5 0.61197 
AIM2 6 0.00022164 0.0011939 35 5 0.67795 
EZH1 6 0.00023319 0.0012539 36 6 0.38361 
GOLGA2 6 0.00024713 0.0013231 37 4 0.67385 
PSMB11 6 0.00026098 0.0013983 38 6 0.40166 
ARID3A 6 0.00026827 0.0014361 39 4 0.5301 
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Supplementary Table 15: Depleted gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 12h APAP treatment vs. T0. 
ID sgRNA Neg score Neg p-value Neg 
rank 
Neg good 
sgRNA 
Neg lfc 
QRFP 6 7.00E-06 5.10E-05 1 6 -0.71124 
hsa-mir-6840 4 1.21E-05 4.82E-05 2 4 -0.58806 
hsa-mir-6805 4 1.33E-05 5.28E-05 3 4 -0.69571 
hsa-mir-4449 4 2.23E-05 9.06E-05 5 3 -0.99791 
FAM110D 6 2.55E-05 0.00014829 6 2 -1.021 
RPL3L 6 4.79E-05 0.00027329 8 4 -1.1242 
hsa-mir-3201 4 6.35E-05 0.00024653 9 4 -1.0169 
hsa-mir-6772 4 6.65E-05 0.00026037 10 4 -0.57996 
RNF25 6 6.83E-05 0.00036922 11 5 -0.70265 
EPB42 6 7.66E-05 0.00040704 12 2 -1.039 
hsa-mir-1180 4 7.70E-05 0.00030511 13 3 -0.89839 
ABI1 6 8.07E-05 0.00043057 14 6 -0.50071 
hsa-mir-4674 4 8.83E-05 0.00034893 15 4 -0.52824 
HOOK2 6 9.29E-05 0.00050852 16 6 -0.56762 
MAGEH1 6 9.35E-05 0.00051129 17 6 -0.4293 
ILKAP 6 0.00010968 0.00060215 18 5 -0.71864 
CBX8 6 0.00012637 0.00068148 19 5 -0.75639 
ZNF776 6 0.00013183 0.00071377 20 6 -0.43882 
LPL 6 0.00013757 0.00074513 21 6 -0.47907 
hsa-mir-3128 4 0.00016674 0.00066303 22 2 -1.1344 
hsa-mir-6068 4 0.00016996 0.00067318 23 2 -1.0814 
ATAD3B 6 0.00017874 0.00097898 24 3 -0.90913 
TC2N 6 0.00019991 0.001086 26 5 -0.50035 
hsa-mir-4532 4 0.00020684 0.00080971 27 3 -1.6694 
C1orf56 6 0.0002187 0.0011852 28 6 -0.48476 
TMC4 6 0.0002214 0.0011935 29 6 -0.73446 
NOL3 6 0.0002298 0.001234 30 5 -0.44867 
UBXN7 6 0.00024216 0.0012995 31 6 -0.56121 
hsa-mir-4469 4 0.00025373 0.00098267 32 4 -0.66196 
HDGFRP3 6 0.00025498 0.001365 33 5 -0.59283 
hsa-mir-4324 4 0.00025629 0.00099282 34 3 -0.59911 
TACSTD2 6 0.00026402 0.0014162 35 3 -1.0601 
BRAP 6 0.00028086 0.0015108 36 3 -0.37861 
MAPK13 6 0.00028769 0.0015399 37 5 -0.71997 
H2AFJ 6 0.00029098 0.0015569 38 5 -0.83708 
hsa-mir-4466 4 0.0003011 0.001157 41 3 -1.2671 
ZNF768 6 0.0003037 0.001621 42 6 -0.33605 
UGT2B15 4 0.00030925 0.0011875 43 2 -0.96415 
RAC2 6 0.00032657 0.0017317 45 5 -0.56381 
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Supplementary Table 16: Enriched gene knockouts ranked by RRA analysis 
of the CRISPR/Cas9 screen 24h APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
PAGE4 6 3.80E-07 3.00E-06 1 6 0.50966 
BGLAP 5 4.12E-06 1.91E-05 2 2 1.6481 
PGM5 6 1.34E-05 9.13E-05 3 6 0.39874 
EEF1D 6 2.55E-05 0.00014829 4 2 1.6816 
FAM98B 6 3.61E-05 0.00021701 5 3 0.617 
EGR1 6 7.66E-05 0.00040704 6 2 1.4603 
ZBTB21 6 9.87E-05 0.00053481 7 5 0.79106 
RAP1A 6 0.00012767 0.00069071 8 2 0.86814 
HDC 6 0.00013846 0.0007479 9 5 0.37985 
SULT2B1 6 0.00014774 0.00080556 10 6 0.26799 
RFPL3 6 0.00015617 0.00085353 11 6 0.2974 
OR10J5 6 0.00017189 0.00093747 12 4 0.63468 
HIST1H2AM 6 0.00017874 0.00097898 13 2 1.5416 
PDCD5 6 0.00018409 0.0010163 14 4 0.64129 
SLC43A1 6 0.0001928 0.0010592 15 5 0.44453 
REST 6 0.0001964 0.0010731 16 3 0.46524 
HBE1 6 0.0002102 0.0011432 17 6 0.23558 
RBM10 6 0.0002298 0.001234 18 2 1.6083 
FAM120A 6 0.00023414 0.0012603 19 4 0.49317 
CSGALNACT1 6 0.0002408 0.0012949 20 5 0.31133 
ADCY9 6 0.00025774 0.0013784 21 3 0.61489 
TSNAX 6 0.0002633 0.0014139 22 6 0.26452 
UQCRC1 6 0.00027027 0.0014462 23 4 0.48922 
PCED1B 6 0.00028086 0.0015108 24 1 2.811 
TMEM60 6 0.00029838 0.0015901 25 4 0.51151 
RASSF4 6 0.00031826 0.0016902 26 5 0.35433 
ENAM 6 0.00033192 0.0017585 27 4 0.2781 
USP10 6 0.00035221 0.0018659 28 5 0.2809 
RRP9 6 0.00037015 0.0019582 29 4 0.52246 
C4orf22 6 0.00037197 0.0019674 30 5 0.3168 
HES5 6 0.00037573 0.0019886 31 5 0.37072 
AKAP9 6 0.00038298 0.0020278 32 4 0.38815 
PECR 6 0.00041903 0.0022091 33 4 0.41854 
XPR1 6 0.00042456 0.0022363 34 4 0.48323 
SDS 6 0.00043403 0.0022815 35 5 0.42734 
hsa-mir-4804 4 0.00044577 0.0016925 36 4 0.2922 
FMO5 6 0.0004667 0.0024383 37 6 0.23512 
CIDEC 6 0.00047506 0.0024785 38 6 0.33006 
NTN5 6 0.00047801 0.0024912 39 5 0.42811 
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Supplementary Table 17: Depleted gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 24h APAP treatment vs. T0. 
ID sgRNA Neg score Neg p-value Neg 
rank 
Neg good 
sgRNA 
Neg lfc 
TIPRL 6 5.52E-06 4.08E-05 1 5 -0.42208 
VNN1 6 1.06E-05 7.73E-05 2 4 -0.51134 
OR11L1 6 1.35E-05 9.20E-05 3 5 -0.43335 
ACAD11 6 1.71E-05 0.00010816 4 5 -0.40344 
EFNB3 6 2.55E-05 0.00014829 6 2 -0.6828 
MYOZ3 6 3.94E-05 0.00022993 7 4 -0.43961 
FAM227B 6 4.77E-05 0.0002719 8 4 -0.57481 
SSR2 6 5.64E-05 0.0003171 10 6 -0.23165 
GPSM1 6 7.66E-05 0.00040704 11 2 -0.48187 
EOMES 6 7.96E-05 0.00042457 12 5 -0.47969 
RCL1 6 9.10E-05 0.00049376 13 4 -0.47733 
POFUT1 6 0.00010169 0.0005551 14 5 -0.34436 
SDC1 6 0.00013778 0.0007456 15 2 -0.76185 
BABAM1 6 0.00017628 0.00096284 16 5 -0.45825 
hsa-mir-3140 4 0.00017768 0.00070454 17 3 -0.45661 
GKN2 6 0.00017874 0.00097898 18 3 -0.34985 
SUZ12 6 0.00017977 0.00098544 19 6 -0.38846 
hsa-mir-4449 4 0.00019735 0.00077189 20 3 -0.48835 
GLI3 6 0.0002068 0.001122 21 5 -0.38439 
IP6K1 6 0.00022379 0.0012036 22 5 -0.51206 
PPM1M 6 0.00022415 0.0012055 23 3 -0.5059 
NSUN5 6 0.00022709 0.0012225 24 2 -0.87854 
OR2T34 6 0.0002298 0.001234 25 2 -0.54416 
TNFRSF1A 6 0.00024106 0.0012959 26 3 -0.55964 
TGFBR3L 6 0.00024836 0.0013323 27 5 -0.50034 
BTG3 6 0.00024944 0.0013378 28 6 -0.25213 
hsa-mir-4707 4 0.00025534 0.00098959 29 2 -0.73793 
CAMK1 6 0.00025664 0.0013729 30 5 -0.41143 
SHPRH 6 0.00028086 0.0015108 31 3 -0.28086 
TACSTD2 6 0.00029994 0.0015989 33 3 -0.62317 
TSPAN2 6 0.00030333 0.0016187 34 2 -0.89357 
FOXF1 6 0.00033434 0.0017737 35 4 -0.38978 
GSDMB 6 0.00033858 0.0017931 36 6 -0.36549 
MAPK8IP2 6 0.00033942 0.0017981 37 3 -0.61229 
KCTD11 6 0.00039433 0.0020472 39 5 -0.36608 
TMEM41A 6 0.00040652 0.0020984 40 4 -0.36943 
hsa-mir-1324 4 0.00040662 0.0015542 41 2 -0.49281 
HIST1H2AL 6 0.00041091 0.0021192 42 4 -0.46954 
PELI2 6 0.00041523 0.0021353 43 3 -0.5315 
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Supplementary Table 18: Enriched gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 4d APAP treatment vs. T0. 
ID sgRNA Pos score Pos p-value Pos rank Pos good 
sgRNA 
Pos lfc 
ATXN2 6 7.01E-07 5.77E-06 1 4 2.8779 
FAM57A 6 1.26E-05 8.74E-05 2 4 2.5453 
SEMG2 6 1.97E-05 0.00012015 3 6 1.3511 
KIR3DL3 6 2.55E-05 0.00014829 4 3 0.6228 
MYOM3 6 2.69E-05 0.00016074 5 5 1.888 
EYA4 6 5.74E-05 0.00031895 6 4 2.1426 
LZTR1 6 7.32E-05 0.00038998 7 5 1.9547 
CDK5RAP1 6 7.51E-05 0.00040013 8 5 1.7195 
UVRAG 6 7.66E-05 0.00040704 9 3 1.6195 
FEZF2 6 8.06E-05 0.00043057 10 5 1.6874 
C1QTNF5 6 8.26E-05 0.0004421 11 4 1.8882 
TNFRSF25 6 8.47E-05 0.00045686 12 3 2.1064 
NLRC3 6 9.73E-05 0.00052789 13 6 1.5065 
SMIM4 6 0.00011389 0.00062014 14 6 1.7844 
hsa-mir-3683 4 0.00011916 0.000479 15 2 1.9545 
TMPRSS6 6 0.00012767 0.00069071 16 5 0.48736 
hsa-mir-4327 4 0.00015321 0.00061506 17 2 2.6477 
SIK2 6 0.000156 0.0008526 18 5 0.83149 
ENPP7 6 0.00016992 0.0009241 19 6 1.3272 
C12orf77 6 0.0001762 0.00096284 20 3 2.6334 
DEFB118 6 0.00017861 0.00097852 21 6 1.2257 
FEM1C 6 0.00020342 0.0011001 22 4 1.9684 
CRISP1 6 0.00020503 0.0011095 23 4 1.5127 
C9orf91 6 0.00020746 0.0011252 24 5 1.651 
ESRRA 6 0.00021269 0.0011519 25 5 2.1654 
PSMC5 6 0.00022442 0.0012064 26 5 1.6159 
HLA-DPB1 6 0.00023005 0.001235 27 3 2.1053 
LPXN 6 0.00027024 0.0014458 28 4 1.7911 
SOD2 6 0.00028086 0.0015108 29 3 0.58993 
hsa-mir-4752 4 0.00028949 0.0011169 30 3 1.6833 
B3GALT5 6 0.00029928 0.0015938 31 3 1.8816 
SLCO2A1 6 0.00030233 0.0016123 32 6 1.6761 
LGALS3 6 0.00030789 0.0016422 33 3 2.5551 
IL1RL1 6 0.00031723 0.0016861 34 5 1.9972 
NADK2 6 0.00033192 0.0017585 35 2 3.2826 
TAS2R20 6 0.00035363 0.0018752 37 5 1.7274 
ABCB10 6 0.00037015 0.0019582 38 4 1.8988 
hsa-mir-504 4 0.00037244 0.0014361 39 3 2.4877 
IQCB1 6 0.00037517 0.001984 40 4 1.5882 
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Supplementary Table 19: Depleted gene knockouts ranked by RRA 
analysis of the CRISPR/Cas9 screen 4d APAP treatment vs. T0 
ID sgRNA Neg score Neg p-value Neg 
rank 
Neg good 
sgRNA 
Neg lfc 
INO80C 6 2.99E-08 2.31E-07 1 5 -2.0821 
CALHM1 6 1.07E-05 7.77E-05 2 6 -3.3159 
LCE5A 6 2.01E-05 0.00012108 3 5 -2.2661 
KLHL21 6 2.55E-05 0.00014829 4 2 -1.8677 
NTRK2 6 7.66E-05 0.00040704 5 3 -3.8148 
CXorf21 6 8.68E-05 0.00047116 6 4 -1.1478 
NFAT5 6 0.00011624 0.00063444 7 4 -2.4115 
CALR 6 0.00012358 0.00066811 8 4 -2.7166 
RBM4B 6 0.00012466 0.00067226 9 6 -2.6964 
MAPK3 6 0.00012767 0.00069071 10 5 -1.8917 
hsa-mir-4717 4 0.00014428 0.00058232 11 4 -1.6209 
LCMT1 6 0.00014459 0.00078895 12 4 -2.087 
AK7 6 0.00015873 0.00086552 13 5 -3.1668 
TSSK2 6 0.00017627 0.00096284 14 5 -3.5813 
EARS2 6 0.00017874 0.00097898 15 5 -1.8177 
LINGO1 6 0.00018208 0.0010034 16 6 -1.8333 
hsa-mir-6892 4 0.0002222 0.00087659 17 4 -2.8944 
ATG2B 6 0.0002298 0.001234 18 2 -3.6526 
SH3GLB2 6 0.00024589 0.0013161 19 5 -2.6298 
HYPK 6 0.00024814 0.0013304 20 4 -2.1598 
GSG1L 6 0.00025317 0.0013581 21 5 -2.3702 
ACBD3 6 0.00026187 0.0014052 22 6 -2.2593 
MTMR12 6 0.00026917 0.0014388 23 4 -2.1953 
SLC3A2 6 0.00027914 0.0015002 24 6 -2.2157 
TMEM215 6 0.00028086 0.0015108 25 5 -1.1434 
AK6 6 0.00028655 0.0015366 26 4 -2.1069 
MAMDC2 6 0.00030754 0.0016413 27 5 -1.4796 
CHMP1A 6 0.00032762 0.0017373 28 5 -1.7902 
ERMN 6 0.00033192 0.0017585 30 6 -0.97693 
MAPK9 6 0.00033748 0.0017885 31 4 -2.8254 
MYOG 6 0.00035314 0.0018724 32 5 -1.6799 
TRPC7 6 0.00035559 0.0018839 33 4 -2.3862 
PHB2 6 0.00035575 0.0018844 34 4 -2.1601 
TM6SF2 6 0.00038298 0.0020278 35 4 -1.4028 
DICER1 6 0.00039301 0.0020754 36 5 -2.072 
C1orf95 6 0.00041291 0.0021828 37 6 -2.4832 
hsa-mir-4270 4 0.00041852 0.0015906 38 3 -2.5061 
DMGDH 6 0.00042055 0.0022183 39 5 -2.2022 
BCAS3 6 0.0004259 0.0022432 40 4 -2.3394 
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Supplementary Table 20: Genes ranked by Maximum 
Likelihood Estimate comparing all APAP samples to T0. 
Gene sgRNA Beta Z value P-value 
hsa-mir-519c 3 0.62184 7.8712 0.001873 
hsa-mir-611 4 -0.38341 -5.5104 0.002795 
ATXN7L1 6 0.5016 10.354 0.0041 
hsa-mir-6729 4 0.49166 7.1337 0.004305 
ZNF776 6 -0.31595 -6.2515 0.005069 
PKD2 6 -0.30637 -5.9898 0.005618 
PGM5 6 0.45058 9.2391 0.005618 
hsa-mir-3667 4 0.44758 7.4561 0.005693 
hsa-mir-548i-4 3 0.44338 6.0099 0.005888 
hsa-mir-4745 4 -0.30223 -4.5899 0.005926 
hsa-mir-8088 4 -0.30191 -4.3664 0.005935 
LOC388813 5 0.44244 7.0175 0.005935 
CYB5R3 6 0.43842 8.3189 0.006149 
hsa-mir-940 4 -0.29317 -4.9592 0.006597 
hsa-mir-3929 4 -0.28944 -4.5263 0.00682 
hsa-mir-6839 4 -0.28804 -4.7414 0.006904 
CTDP1 6 0.41036 7.9603 0.007519 
hsa-mir-346 4 -0.27647 -4.2813 0.007882 
PDSS2 6 0.40502 7.9945 0.007892 
SHC3 6 0.40446 8.1923 0.00792 
CXADR 6 0.40409 7.9601 0.007938 
NR1I3 6 0.40377 8.0512 0.007975 
hsa-mir-2392 4 0.40319 6.2329 0.008013 
hsa-mir-6719 4 0.39518 6.0495 0.008553 
PTPRT 6 0.39483 7.5349 0.008553 
PDLIM7 6 0.39414 7.6306 0.008665 
hsa-mir-3151 4 0.39175 6.1599 0.008823 
GPRIN1 6 -0.26558 -4.9772 0.008842 
hsa-mir-506 4 0.39113 6.5232 0.008851 
hsa-mir-6845 4 -0.26173 -4.0798 0.009159 
OSBPL9 4 0.38179 5.8574 0.009541 
NUP62CL 6 0.38158 7.9489 0.009541 
hsa-mir-548f-4 3 -0.25804 -3.3301 0.009569 
PXDN 6 -0.25612 -5.1054 0.009783 
MAPK10 6 0.37439 7.6531 0.010286 
hsa-mir-4270 4 -0.2537 -4.2933 0.010295 
hsa-mir-4466 4 -0.25314 -3.8864 0.010379 
GHRH 6 0.36919 7.5375 0.010836 
hsa-mir-504 4 0.36901 6.4193 0.010845 
hsa-mir-4313 4 -0.24881 -3.8792 0.010892 
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Supplementary Table 21 Significant gene hits from the APAP time points 
(p<0.05) were compared with a list of 48 genes with known roles in NAD 
metabolism. 
4d pos 
p<0.05 
4d neg 
p<0.05 
24h pos 
p<0.05 
24h neg 
p<0.05 
30min-24h 
pos 
p<0.05 
30min-24h 
neg 
p<0.05 
all pos 
p<0.05 
all neg 
p<0.05 
NADK2 NMNAT1 HSD11B1 NMNAT1 HSD11B1 NMNAT1 NADK2 NMNAT1 
SIRT3  NADSYN1  SIRT1    
NADSYN1        
SLC36A4        
NUDT9        
SLC25A17        
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Supplementary Table 22: Most significant genes 
differentially expressed with and without APAP 
treatment from RNA-sequenced mice (p<0.05). 
Gene log2(fold_change) Test statistic p-value 
Dnajc12 1.8521 3.78614 5.00E-05 
Tff3 2.67264 3.70363 5.00E-05 
Abcc4 1.81514 3.36102 5.00E-05 
Gsta1 1.66224 3.07492 5.00E-05 
Derl3 1.75233 2.95514 5.00E-05 
Nipal1 1.86904 2.90845 5.00E-05 
Tcf24 2.46792 2.81794 5.00E-05 
Socs2 1.60733 2.78214 5.00E-05 
Scara5 1.44466 2.75335 5.00E-05 
Arntl 1.66518 2.6448 5.00E-05 
Asns 1.71814 2.52692 5.00E-05 
Gm6484 1.56456 2.47812 5.00E-05 
Tnfrsf12a 1.3779 2.43612 5.00E-05 
Csf2rb2 1.96996 2.41819 5.00E-05 
Srxn1 1.15006 2.40386 5.00E-05 
Creld2 1.26828 2.39791 5.00E-05 
Slc1a4 1.4146 2.38864 5.00E-05 
Dhrs9 1.38945 2.38317 5.00E-05 
Hes1 1.54994 2.3744 5.00E-05 
Igfbp1 0.98216 2.34434 5.00E-05 
Socs3 1.484 2.31186 5.00E-05 
Efna1 0.981277 2.27729 5.00E-05 
Sept11 1.08833 2.2209 5.00E-05 
Abhd2 0.979515 2.17504 5.00E-05 
Slc41a2 1.25408 2.12833 5.00E-05 
Chka 1.59289 2.04586 5.00E-05 
Kcnq1ot1 0.868679 2.04195 5.00E-05 
Litaf 0.859747 2.03045 5.00E-05 
Gas6 0.808195 1.9904 5.00E-05 
Fndc3b 1.11942 1.68965 5.00E-05 
Tef -1.05904 -1.61622 5.00E-05 
Pklr -1.63238 -1.66792 5.00E-05 
Gys2 -1.30449 -1.70762 5.00E-05 
Dpp4 -0.905014 -1.86888 5.00E-05 
Galm -0.775005 -1.89618 5.00E-05 
Slc1a2 -2.4172 -1.90821 5.00E-05 
Homer2 -0.814433 -1.90821 5.00E-05 
Acy3 -0.778139 -1.91211 5.00E-05 
Ddah1 -0.856776 -1.95112 5.00E-05 
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Supplementary Table 23: Description of participants used in the GSE70784 
analysis. 
Group 
Number of 
participants 
Gender (% 
male)* 
Age 
(years) Ethnicity** 
Responder 12 6 (50%) 32.8 C:8, H:4, C/H:0, A:0, AA:1 
non-
responder 32 20 (62.5%) 33.8 
C:8, H:13, C/H:1, A:1, AA: 
9 
Placebo 10 7 (70%) 25.8 C:4, H:5, C/H:0, A:0, AA:1 
Total 54 33 (61.1%) 32.1 
C: 20, H: 22, C/H: 1, A:1, 
AA:1 
*, number males    
**, ethnicity: c= caucasian, h=hispanic, aa=african american, a=asian 
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Supplementary Table 24: Significant gene hits from the APAP time points (p<0.05) were compared with significantly 
associated genes from other datasets studying the effects of APAP (GSE74000, ALF healthy liver sample microarray 
data; GSE70784, d1 and d8 APAP responder and non-responder blood sample microarray data; GSE70784, d1 and d8 
APAP responder and placebo blood sample microarray data; and mouse 24h +/- APAP RNA-seq data). 
Dataset 4d positive 
p<0.05 
4d negative 
p<0.05 
24h 
positive 
p<0.05 
24h 
negative 
p<0.05 
T30min-24h 
positive p<0.05 
T30min-24h 
negative p<0.05 
All positive 
p<0.05 
All negative 
p<0.05 
GSE70784 d1 APAP responder vs. non-
responder p<0.05 
12 11 15 12 12 19 18 10 
GSE70784 d8 APAP responder vs. non-
responder p<0.05 
98 101 117 94 111 96 100 108 
GSE70784 d1 APAP responder vs. 
placebo p<0.05 
22 30 34 20 40 21 31 25 
GSE70784 d8 APAP responder vs. 
placebo p<0.05 
91 89 86 68 82 72 72 81 
GSE74000 ALFp<0.05 67 63 70 60 81 61 67 57 
GSE110787 mouse 24h +/- APAP p<0.05 86 57 63 55 64 58 73 67 
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Supplementary Table 25: Top 100 significantly associated genes (p<0.05) from other datasets 
studying the effects of APAP (GSE74000, ALF healthy liver sample microarray data; GSE70784, d1 
and d8 APAP responder and non-responder blood sample microarray data; GSE70784, d1 and d8 
APAP responder and placebo blood sample microarray data; and mouse 24h +/- APAP RNA-seq 
data) were queried in pubmatrix to determine novelty. 
Dataset Analysis type APAP Acetaminophen Hepatotoxic Hepatotoxicity Acute 
liver 
injury 
Acute 
liver 
failure 
GSE110787 mouse RNA-
Seq top 100 genes 
Gene expression LFC 15 15 12 24 26 17 
GSE74000 top 100 genes Gene expression LFC 12 12 9 15 15 10 
GSE70784 d1 responder vs. 
nonresponder top 100 genes 
Gene expression LFC 8 8 7 14 14 10 
GSE70784 d8 responder vs. 
nonresponder top 100 genes 
Gene expression LFC 7 7 4 9 9 7 
GSE70784 d1 responder vs. 
placebo top 100 genes 
Gene expression LFC 9 9 6 10 13 8 
GSE70784 d8 responder vs. 
placebo top 100 genes 
Gene expression LFC 10 10 14 17 17 13 
genes in all top 100 lists 600 
unique genes in all top 100 
lists 
586 
unique genes with APAP 
hits 
60 
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Supplementary Table 26: Summary of 147 APAP-associated SNPs. 
SNP Position* Alleles# MAF^ Reference Reference 
p-value 
rs10110651 Chr8:36989597 T/C 0.278754 Moyer 2011 2.14E-05 
rs10144421 Chr14:95445498 T/C 0.384385 Moyer 2011 8.77E-05 
rs10186482 Chr2:151625463 A/G 0.45647 Moyer 2011 6.87E-05 
rs1042640 Chr2:233772898 C/G 0.178914 Court 2013  
rs10485114 Chr6:115807742 C/T 0.222444 Moyer 2011 4.01E-05 
rs10508010 Chr13:94974756 A/C 0.30012 Moyer 2011 2.50E-03 
rs10511137 Chr3:88463052 A/G 0.330671 Moyer 2011 3.18E-07 
rs10515465 Chr5:134931867 G/C 0.157348 Moyer 2011 5.69E-05 
rs10849421 Chr12:6217842 G/A 0.394968 Moyer 2011 4.15E-05 
rs10852886 Chr17:6789522 A/T 0.475439 Moyer 2011 7.50E-05 
rs10929303 Chr2:233772770 C/T 0.247604 Court 2013  
rs11070109 Chr13:95111572 C/T 0.0565096 Moyer 2011 3.80E-02 
rs11129122 Chr3:23671125 A/G 0.220847 Moyer 2011 4.97E-05 
rs11153350 Chr6:112257182 G/A 0.153554 Moyer 2011 2.54E-05 
rs11248859 Chr16:1191997 G/A 0.276358 Moyer 2011 6.18E-05 
rs11611637 Chr12:97291586 T/C 0.285343 Moyer 2011 8.78E-05 
rs11766607 Chr7:49480023 A/G 0.136581 Moyer 2011 2.06E-05 
rs1189434 Chr13:95084938 G/A 0.0972444 Moyer 2011 6.00E-03 
rs1189436 Chr13:95084146 G/A 0.0986422 Moyer 2011 9.00E-03 
rs1189437 Chr13:95083350 T/G 0.125799 Moyer 2011 1.11E-02 
rs1189439 Chr13:95082712 C/T 0.194089 Moyer 2011 3.09E-02 
rs11909987 Chr21:42402293 C/A 0.413139 Moyer 2011 3.62E-05 
rs12107308 Chr3:88433203 C/G 0.193291 Moyer 2011 4.09E-06 
rs12120268 Chr1:52587287 C/A 0.0551118 Moyer 2011 3.98E-02 
rs12267329 Chr10:1633353 A/G 0.400559 Moyer 2011 6.71E-05 
rs12584534 Chr13:95103296 C/T 0.175319 Moyer 2011 4.37E-02 
rs12700386 Chr7:22723390 C/G/A 0.133187 Moyer 2011 6.20E-05 
rs13015146 Chr2:202197380 T/C 0.434305 Moyer 2011 9.49E-05 
rs13101122 Chr3:88458699 T/C 0.463259 Moyer 2011 8.35E-06 
rs13204006 Chr6:21946381 A/G 0.165735 Moyer 2011 7.85E-05 
rs13326165 Chr3:52498102 G/A 0.197284 Moyer 2011 7.92E-05 
rs1343151 Chr1:67253446 G/A 0.337859 Moyer 2011 1.91E-05 
rs1354510 Chr1:165206278 A/G 0.280351 Moyer 2011 7.78E-05 
rs1356553 Chr6:53424785 T/G 0.451677 Moyer 2011 2.12E-02 
rs1372940 Chr18:30437953 C/T 0.0700879 Moyer 2011 5.74E-05 
rs1377392 Chr6:53433687 C/T 0.345048 Moyer 2011 8.80E-03 
rs1380292 Chr8:21246897 A/G 0.236821 Moyer 2011 7.64E-05 
rs1467558 Chr11:35208126 C/T 0.0609026 Court 2014, 
Harrill 2009 
4.50E-02 
rs1532815 Chr1:165210852 A/T 0.33147 Moyer 2011 6.04E-07 
rs1536343 Chr13:39101284 C/T 0.0541134 Moyer 2011 7.28E-05 
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Supplementary Table 26. –Continued. 
rs1599096 Chr8:21260713 C/T 0.263578 Moyer 2011 6.86E-05 
rs16851554 Chr2:214159668 T/G 0.149561 Moyer 2011 2.46E-05 
rs16900696 Chr5:31113307 C/G 0.0760783 Moyer 2011 7.12E-05 
rs16950155 Chr13:94799401 C/G 0.0636981 Moyer 2011 4.16E-02 
rs16950190 Chr13:94809909 C/T 0.0539137 Moyer 2011 1.27E-02 
rs17310467 Chr20:34957813 A/G/T 0.0810703 Moyer 2011 4.20E-03 
rs17413355 Chr7:78356266 C/T 0.142173 Moyer 2011 8.50E-05 
rs17469886 Chr8:27725811 C/A 0.0419329 Moyer 2011 3.52E-05 
rs1751043 Chr13:95076266 G/A 0.0972444 Moyer 2011 6.00E-03 
rs17559005 Chr3:88463389 T/C 0.330471 Moyer 2011 3.18E-07 
rs17640676 Chr2:154791307 G/T 0.227835 Moyer 2011 2.09E-05 
rs1764425 Chr13:95352239 G/A 0.189696 Moyer 2011 3.20E-02 
rs1766908 Chr13:95352874 C/T 0.186901 Moyer 2011 1.88E-02 
rs1876381 Chr8:82046088 T/C 0.159944 Moyer 2011 9.60E-06 
rs1902023 Chr4:68670366 C/A 0.453474 Court 2017  
rs1925851 Chr13:94968444 C/T 0.491613 Moyer 2011 2.28E-02 
rs1925856 Chr13:94964357 A/G 0.491214 Moyer 2011 4.00E-03 
rs1925860 Chr13:94993427 C/T 0.327276 Moyer 2011 2.00E-03 
rs1982562 Chr3:88459217 G/A 0.463259 Moyer 2011 1.28E-05 
rs1989983 Chr17:50633170 G/A 0.199481 Moyer 2011 3.84E-02 
rs2031920 Chr10:133526341 C/T 0.0670926 Ueshima 1996  NA 
rs2064504 Chr20:45775071 G/A 0.389976 Moyer 2011 8.52E-05 
rs2074451 Chr19:1107036 G/T 0.391973 Moyer 2011 7.90E-03 
rs2082603 Chr4:178754241 C/T 0.329673 Moyer 2011 3.43E-05 
rs2089515 Chr8:57014167 C/T 0.230431 Moyer 2011 9.91E-05 
rs2209631 Chr13:39100885 A/G 0.0541134 Moyer 2011 7.28E-05 
rs2218988 Chr7:134879612 T/C 0.24361 Moyer 2011 9.50E-05 
rs2344953 Chr3:88483065 G/A 0.272564 Moyer 2011 5.59E-06 
rs2397105 Chr6:52788526 A/G 0.276757 Moyer 2011 4.80E-02 
rs2397132 Chr6:52877418 A/G 0.138778 Moyer 2011 2.80E-02 
rs2524290 Chr11:61920202 G/A 0.308906 Moyer 2011 6.19E-05 
rs2567513 Chr17:72696601 T/C 0.161142 Moyer 2011 6.66E-05 
rs2720666 Chr8:128071213 A/G 0.24401 Moyer 2011 6.93E-05 
rs2720667 Chr8:128071338 A/G 0.244209 Moyer 2011 5.73E-05 
rs2737844 Chr14:64941791 A/G 0.428315 Moyer 2011 2.97E-02 
rs2748991 Chr6:52731718 C/T/A 0.485224 Moyer 2011 2.08E-02 
rs279874 Chr9:953057 G/C 0.394968 Moyer 2011 9.13E-05 
rs2880961 Chr3:88475025 C/T 0.333666 Moyer 2011 1.88E-07 
rs319590 Chr5:134919098 T/G 0.162939 Moyer 2011 2.76E-05 
rs319594 Chr5:134914456 T/C 0.16274 Moyer 2011 6.51E-05 
rs3208829 Chr6:112252087 C/G 0.160144 Moyer 2011 2.54E-05 
rs33966381 Chr3:88463472 C/T 0.330871 Moyer 2011 3.18E-07 
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Supplementary Table 26. –Continued. 
rs3744198 Chr17:74960029 G/A 0.244209 Moyer 2011 3.40E-05 
rs3746165 Chr19:1102212 G/A 0.433706 Moyer 2011 2.78E-02 
rs3746923 Chr21:42406235 C/T 0.429313 Moyer 2011 2.56E-05 
rs3749166 Chr2:240598004 A/G 0.488219 Harrill 2009  
rs3795578 Chr1:204143856 G/A 0.403754 Moyer 2011 7.18E-06 
rs3799732 Chr6:125253363 T/C 0.48103 Moyer 2011 6.49E-05 
rs3825924 Chr15:100905695 G/A 0.213458 Moyer 2011 1.73E-05 
rs3828599 Chr5:151022235 G/A 0.416933 Moyer 2011 1.80E-03 
rs3857596 Chr6:50937354 C/T 0.176318 Moyer 2011 7.75E-05 
rs3957358 Chr6:53446762 G/T 0.284345 Moyer 2011 4.18E-02 
rs4148411 Chr17:50656384 G/C 0.149161 Moyer 2011 3.41E-02 
rs4289753 Chr7:49516998 G/A 0.146565 Moyer 2011 7.19E-05 
rs4495049 Chr4:126017998 C/A 0.0926518 Moyer 2011 9.43E-05 
rs4563418 Chr3:88430636 G/A 0.211861 Moyer 2011 3.87E-05 
rs4585742 Chr8:67822534 A/G 0.282348 Moyer 2011 6.05E-05 
rs4710625 Chr6:66787937 C/G 0.464257 Moyer 2011 8.39E-05 
rs4715210 Chr6:50929538 C/T 0.176118 Moyer 2011 7.75E-05 
rs4715359 Chr6:52876817 A/G 0.272564 Moyer 2011 6.80E-03 
rs4764486 Chr12:6218823 C/T 0.392971 Moyer 2011 5.27E-05 
rs4773861 Chr13:95254618 C/T 0.0726837 Moyer 2011 3.34E-02 
rs4869233 Chr5:95089838 T/C 0.322284 Moyer 2011 2.28E-05 
rs5936441 ChrX:148242736 C/T 0.445828 Moyer 2011 5.38E-06 
rs6032545 Chr20:45794066 G/T/A 0.495008 Moyer 2011 6.48E-05 
rs6083315 Chr20:23883158 A/G 0.416933 Moyer 2011 7.52E-05 
rs6124741 Chr20:45776008 T/C 0.493211 Moyer 2011 8.31E-05 
rs6502555 Chr17:2826358 T/C 0.452875 Moyer 2011 3.11E-05 
rs6553786 Chr4:174379453 C/T 0.197085 Moyer 2011 8.16E-05 
rs6737742 Chr2:239294326 G/A 0.164537 Moyer 2011 5.53E-05 
rs6789170 Chr3:107870704 G/T 0.072484 Moyer 2011 3.63E-05 
rs6795028 Chr3:88431940 A/G 0.480831 Moyer 2011 6.05E-06 
rs6809413 Chr3:88463299 G/A 0.463858 Moyer 2011 5.47E-06 
rs6810790 Chr4:20514047 A/G 0.208466 Moyer 2011 8.17E-05 
rs6852435 Chr4:174379628 T/C 0.226837 Moyer 2011 5.71E-06 
rs6878801 Chr5:116872209 C/T 0.479832 Moyer 2011 6.77E-05 
rs6922172 Chr6:53441156 C/T 0.0964457 Moyer 2011 2.60E-02 
rs6949916 Chr7:49494648 A/G 0.11881 Moyer 2011 8.53E-05 
rs707148 Chr5:151010686 T/G 0.319888 Moyer 2011 1.73E-02 
rs718068 Chr8:21245385 T/C 0.247604 Moyer 2011 5.25E-05 
rs7329514 Chr13:95264546 G/A 0.0792732 Moyer 2011 2.39E-02 
rs7526132 Chr1:205584957 G/C 0.425919 Moyer 2011 3.87E-06 
rs7665426 Chr4:174404535 G/T 0.214856 Moyer 2011 2.17E-05 
rs766606 Chr13:95001913 A/C 0.335463 Moyer 2011 1.21E-02 
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rs7726138 Chr5:86826950 A/G 0.332069 Moyer 2011 5.44E-05 
rs7738812 Chr6:88206884 A/T 0.0940495 Moyer 2011 8.52E-05 
rs776746 Chr7:99672916 C/T 0.378594 Court 2014 3.40E-02 
rs777952 Chr3:104727844 C/T 0.255192 Moyer 2011 5.73E-05 
rs7987903 Chr13:94818417 T/C 0.0780751 Moyer 2011 4.80E-03 
rs8001657 Chr13:95091793 C/T 0.184305 Moyer 2011 3.34E-02 
rs8081984 Chr17:6783247 T/G 0.1252 Moyer 2011 7.46E-05 
rs8177426 Chr5:151023379 G/A 0.249401 Moyer 2011 1.94E-02 
rs8191438 Chr11:67583625 C/G 0.0469249 Moyer 2011 2.70E-02 
rs8191439 Chr11:67583826 G/A 0.0469249 Moyer 2011 3.40E-02 
rs8330 Chr2:233772999 C/G 0.254992 Court 2013 2.70E-02 
rs908262 Chr2:239295827 C/A 0.186502 Moyer 2011 3.71E-05 
rs9367532 Chr6:53446041 G/A 0.278554 Moyer 2011 1.57E-02 
rs943005 Chr6:50898107 C/T 0.174321 Moyer 2011 7.78E-05 
rs9473924 Chr6:50866444 G/T 0.356629 Moyer 2011 8.49E-05 
rs9473932 Chr6:50890282 G/A 0.354633 Moyer 2011 3.26E-05 
rs948999 Chr11:130828644 T/C 0.405351 Moyer 2011 6.95E-05 
rs9508207 Chr13:28984557 C/T 0.216853 Moyer 2011 6.79E-05 
rs9590150 Chr13:94978603 A/T 0.490615 Moyer 2011 2.78E-02 
rs9590154 Chr13:94999100 T/G 0.311901 Moyer 2011 2.80E-02 
rs9784215 Chr21:42403627 C/A 0.4373 Moyer 2011 2.73E-05 
rs9984523 Chr21:41512104 C/T 0.0555112 Moyer 2011 8.76E-05 
rs9997440 Chr4:31206989 A/T 0.116414 Moyer 2011 3.83E-05 
*, GRCh38.p5; #, Major Allele/ Minor Allele; ^, 1000 Genome Phase 3 
 109 
 
Supplementary Table 27: Summary of Ensembl GrCh38.p5 transcripts of 147 APAP-
associated SNPs. 
SNP Transcripts* 
rs10110651 ENST00000495560               
rs10144421 ENST00000557275, ENST00000334258, ENST00000554873, ENST00000555759, 
ENST00000553340             
rs10186482 ENST00000409198, ENST00000604864, ENST00000603639, ENST00000427231, 
ENST00000618972, ENST00000397345, ENST00000172853, LRG_202t1            
rs1042640 ENST00000430892, ENST00000428446, ENST00000454283, ENST00000610772, 
ENST00000482026, ENST00000344644, ENST00000373445, ENST00000373450, 
ENST00000354728, ENST00000373414, ENST00000373424, ENST00000446481, 
ENST00000305139, ENST00000406651, ENST00000305208, ENST00000360418, 
ENST00000373426, ENST00000373409, ENST00000450233, LRG_733t1 
rs10485114                
rs10508010                
rs10511137                
rs10515465 ENST00000254908, ENST00000512783, ENST00000504352, ENST00000510013, 
ENST00000454092, ENST00000509243, ENST00000498999, ENST00000580862            
rs10849421 ENST00000382518, ENST00000543916, ENST00000536586, ENST00000382519, 
ENST00000546073, ENST00000538834, ENST00000538418, ENST00000009180, 
ENST00000382515, ENST00000610354, ENST00000617871          
rs10852886 ENST00000321535, ENST00000572251, ENST00000575022, ENST00000571744              
rs10929303 ENST00000430892, ENST00000428446, ENST00000454283, ENST00000610772, 
ENST00000482026, ENST00000344644, ENST00000373445, ENST00000373450, 
ENST00000354728, ENST00000373414, ENST00000373424, ENST00000446481, 
ENST00000305139, ENST00000406651, ENST00000305208, ENST00000360418, 
ENST00000373426, ENST00000373409, ENST00000450233, LRG_733t1 
rs11070109 ENST00000376887, ENST00000536256, ENST00000629385              
rs11129122                
rs11153350 ENST00000230538, ENST00000522006, ENST00000389463, ENST00000424408, 
ENST00000521398, ENST00000519932, ENST00000431543, ENST00000243219, 
ENST00000521690, ENST00000368638, ENST00000453937, ENST00000455073, 
ENST00000433684, ENST00000588837, ENST00000590293, ENST00000585450, 
ENST00000629766, ENST00000590804, ENST00000590584, ENST00000627025, 
ENST00000585504, ENST00000590673, ENST00000585611, ENST00000587816, 
LRG_433t1, LRG_433t2   
rs11248859 ENST00000348261, ENST00000565831, ENST00000564954, ENST00000358590              
rs11611637                
rs11766607                
rs1189434 ENST00000376887               
rs1189436 ENST00000376887               
rs1189437 ENST00000376887               
rs1189439 ENST00000376887               
rs11909987 ENST00000635189, ENST00000291535, ENST00000635108, ENST00000635325, 
ENST00000634453, ENST00000634718, ENST00000319294, ENST00000398367, 
ENST00000473381           
rs12107308 ENST00000384586               
rs12120268                
rs12267329 ENST00000381312               
rs12584534 ENST00000376887, ENST00000536256, ENST00000629385              
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rs12700386 ENST00000325042, ENST00000404625, ENST00000426291, ENST00000401651, 
ENST00000485300, ENST00000407492, ENST00000401630, ENST00000406575, 
ENST00000258743           
rs13015146 ENST00000498697, ENST00000469462, ENST00000541917, ENST00000475212              
rs13101122                
rs13204006 ENST00000606851, ENST00000607048, ENST00000444265              
rs13326165 ENST00000321725, ENST00000481607, ENST00000479355              
rs1343151 ENST00000347310, ENST00000425614, ENST00000473881, ENST00000395227              
rs1354510 ENST00000457106, ENST00000342310, ENST00000294816, ENST00000489443, 
ENST00000367893             
rs1356553                
rs1372940                
rs1377392                
rs1380292                
rs1467558 ENST00000510619, ENST00000528869, ENST00000263398, ENST00000415148, 
ENST00000528086, ENST00000428726, ENST00000526669, ENST00000425428, 
ENST00000433892, ENST00000278386, ENST00000434472, ENST00000352818, 
ENST00000442151, ENST00000525211, ENST00000526000, ENST00000279452, 
ENST00000527889, ENST00000531873, ENST00000531110, ENST00000525685, 
ENST00000534296, ENST00000525688, ENST00000278385, ENST00000533222, 
ENST00000525241, ENST00000526553, ENST00000534082, ENST00000525293, 
ENST00000528672, ENST00000532339 
rs1532815 ENST00000457106, ENST00000342310, ENST00000294816, ENST00000489443, 
ENST00000367893             
rs1536343 ENST00000614005               
rs1599096                
rs16851554 ENST00000331683, ENST00000406979, ENST00000452556, ENST00000451561, 
ENST00000480494             
rs16900696 ENST00000523584               
rs16950155                
rs16950190                
rs17310467 ENST00000216951               
rs17413355 ENST00000354212, ENST00000419488, ENST00000629359, ENST00000626691, 
ENST00000522391, ENST00000519748, ENST00000520379, ENST00000630991, 
ENST00000628781, ENST00000634996, ENST00000535697, ENST00000628980, 
ENST00000450028, ENST00000421208         
rs17469886                
rs1751043 ENST00000376887, ENST00000474158, ENST00000467685              
rs17559005                
rs17640676 ENST00000295101, ENST00000493505, ENST00000544049              
rs1764425                
rs1766908                
rs1876381                
rs1902023 ENST00000338206 
rs1925851                
rs1925856 ENST00000563184               
rs1925860                
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rs1982562                
rs1989983 ENST00000502435, ENST00000505699, ENST00000502426, ENST00000285238, 
ENST00000515707, ENST00000513511, ENST00000427699            
rs2031920 ENST00000622716, ENST00000488261, ENST00000463117, ENST00000541261, 
ENST00000477500, ENST00000541080, ENST00000421586, ENST00000418356, 
ENST00000480558, ENST00000252945           
rs2064504 ENST00000481847, ENST00000337205, ENST00000243938, ENST00000474942, 
ENST00000372632, ENST00000372630, ENST00000471401, ENST00000493693, 
ENST00000487343, ENST00000462017, ENST00000467679, ENST00000490877, 
ENST00000408119         
rs2074451 ENST00000631948, ENST00000622719, ENST00000634172, ENST00000631689, 
ENST00000632999, ENST00000612198, ENST00000361757, ENST00000438103, 
ENST00000587024, ENST00000587673, ENST00000586109, ENST00000354171, 
ENST00000589115, ENST00000611653, ENST00000593032, ENST00000588919, 
ENST00000585362, ENST00000614791, ENST00000587648, ENST00000592940, 
ENST00000587932, ENST00000585480, ENST00000622390, ENST00000616066    
rs2082603                
rs2089515                
rs2209631 ENST00000614005               
rs2218988 ENST00000417172, ENST00000436461, ENST00000422748, ENST00000454108, 
ENST00000430085, ENST00000482470, ENST00000361675, ENST00000361901, 
ENST00000489019, ENST00000445569, ENST00000435928          
rs2344953                
rs2397105 ENST00000493331, ENST00000334575               
rs2397132 ENST00000616666, ENST00000412182               
rs2524290 ENST00000394836, ENST00000301773, ENST00000531922              
rs2567513 ENST00000255559, ENST00000542342, ENST00000579988, ENST00000582769              
rs2720666 ENST00000513868, ENST00000512617, ENST00000521600, ENST00000522875, 
ENST00000523190, ENST00000616386             
rs2720667 ENST00000513868, ENST00000512617, ENST00000521600, ENST00000522875, 
ENST00000523190, ENST00000616386             
rs2737844 ENST00000267512, ENST00000533601, ENST00000552941, ENST00000549987, 
ENST00000553743, ENST00000551823, ENST00000553522, ENST00000389614, 
ENST00000557049, ENST00000557323, ENST00000612794, ENST00000551947, 
ENST00000551093         
rs2748991                
rs279874 ENST00000382276, ENST00000569227               
rs2880961                
rs319590 ENST00000254908, ENST00000512783, ENST00000504352, ENST00000510013, 
ENST00000501056             
rs319594 ENST00000254908, ENST00000512783, ENST00000504352, ENST00000510013              
rs3208829 ENST00000230538, ENST00000522006, ENST00000389463, ENST00000424408, 
ENST00000521398, ENST00000519932, ENST00000431543, ENST00000243219, 
ENST00000521690, ENST00000368638, ENST00000453937, ENST00000455073, 
ENST00000433684, ENST00000588837, ENST00000590293, ENST00000585450, 
ENST00000629766, ENST00000590804, ENST00000590584, ENST00000628122, 
ENST00000627025, ENST00000585504, ENST00000590673, ENST00000585611, 
ENST00000587816, LRG_433t1, LRG_433t2  
rs33966381                
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rs3744198 ENST00000425042, ENST00000534480, ENST00000578002, ENST00000532894, 
ENST00000318565, ENST00000583244, ENST00000530857, ENST00000528902, 
ENST00000532900, ENST00000581676, ENST00000530904, ENST00000525128, 
ENST00000579818         
rs3746165 ENST00000354171, ENST00000589115, ENST00000611653, ENST00000593032, 
ENST00000588919, ENST00000585362, ENST00000614791, ENST00000587648, 
ENST00000592940, ENST00000587932, ENST00000585480, ENST00000622390, 
ENST00000616066         
rs3746923 ENST00000635189, ENST00000291535, ENST00000635108, ENST00000635325, 
ENST00000634453, ENST00000634718, ENST00000319294, ENST00000398367, 
ENST00000473381           
rs3749166 ENST00000391984, ENST00000404753, ENST00000270364, ENST00000352879, 
ENST00000357048, ENST00000416591, ENST00000354082, ENST00000270361, 
ENST00000391983, ENST00000494738, ENST00000465943, ENST00000483602, 
ENST00000493058, ENST00000426297         
rs3795578 ENST00000433869, ENST00000367201, ENST00000367202, ENST00000367197, 
ENST00000422072, ENST00000472340, ENST00000492392, ENST00000422699, 
ENST00000452983, ENST00000444817, ENST00000477125          
rs3799732 ENST00000304877, ENST00000534000, ENST00000368402, ENST00000368388, 
ENST00000527711, ENST00000392483, ENST00000528193, ENST00000532978, 
ENST00000532429, ENST00000534199, ENST00000392482, ENST00000524679, 
ENST00000532423, ENST00000530868, ENST00000608456, ENST00000609477        
rs3825924 ENST00000329841, ENST00000346623, ENST00000558869, ENST00000560351              
rs3828599 ENST00000388825, ENST00000521722, ENST00000521650, ENST00000519214, 
ENST00000517973, ENST00000625178, ENST00000521632, ENST00000520597, 
ENST00000520059, ENST00000614343, ENST00000622181, ENST00000624359          
rs3857596                
rs3957358                
rs4148411 ENST00000515585, ENST00000505699, ENST00000502426, ENST00000285238, 
ENST00000513511, ENST00000427699             
rs4289753                
rs4495049                
rs4563418 ENST00000384586               
rs4585742                
rs4710625                
rs4715210                
rs4715359 ENST00000616666, ENST00000412182               
rs4764486 ENST00000382518, ENST00000543916, ENST00000536586, ENST00000382519, 
ENST00000546073, ENST00000538834, ENST00000538418, ENST00000009180, 
ENST00000382515, ENST00000610354, ENST00000617871          
rs4773861 ENST00000376887, ENST00000536256, ENST00000629385              
rs4869233 ENST00000515393, ENST00000503301, ENST00000513695              
rs5936441                
rs6032545 ENST00000372622, ENST00000449078, ENST00000456939, ENST00000415790, 
ENST00000435014, ENST00000481847, ENST00000337205, ENST00000243938, 
ENST00000372632, ENST00000372630, ENST00000471401, ENST00000493693, 
ENST00000487343, ENST00000462017, ENST00000467679, ENST00000490877, 
ENST00000465935       
rs6083315 ENST00000304710               
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rs6124741 ENST00000481847, ENST00000337205, ENST00000243938, ENST00000474942, 
ENST00000372632, ENST00000372630, ENST00000471401, ENST00000493693, 
ENST00000487343, ENST00000462017, ENST00000467679, ENST00000490877, 
ENST00000408119         
rs6502555 ENST00000540393, ENST00000254695, ENST00000366401, ENST00000542807              
rs6553786 ENST00000508815               
rs6737742 ENST00000345617, ENST00000463007, ENST00000493582, ENST00000535493, 
ENST00000446876, ENST00000544989, ENST00000543185            
rs6789170 ENST00000464359, ENST00000488852, ENST00000464823, ENST00000466155, 
ENST00000612802, ENST00000608110, ENST00000601930, ENST00000596110, 
ENST00000608306, ENST00000601385, ENST00000600749, ENST00000608647, 
ENST00000608137, ENST00000475362, ENST00000600240, ENST00000473528, 
ENST00000608307, ENST00000609429, ENST00000607880      
rs6795028 ENST00000384586               
rs6809413                
rs6810790 ENST00000503823, ENST00000504154, ENST00000273739, ENST00000503837, 
ENST00000622093             
rs6852435 ENST00000508815               
rs6878801                
rs6922172                
rs6949916                
rs707148                
rs718068                
rs7329514 ENST00000376887, ENST00000536256, ENST00000629385              
rs7526132 ENST00000475956, ENST00000367147, ENST00000539267, ENST00000489709, 
ENST00000616173, ENST00000536357, ENST00000621216, ENST00000614644            
rs7665426                
rs766606                
rs7726138                
rs7738812                
rs776746 ENST00000222982, ENST00000469887, ENST00000461920, ENST00000463364, 
ENST00000481825, ENST00000466061, ENST00000480723, ENST00000463907, 
ENST00000439761, ENST00000469622, ENST00000456417, ENST00000489231, 
ENST00000339843         
rs777952                
rs7987903                
rs8001657 ENST00000376887, ENST00000536256, ENST00000629385              
rs8081984 ENST00000321535, ENST00000572251, ENST00000575022              
rs8177426 ENST00000388825, ENST00000521722, ENST00000521650, ENST00000519214, 
ENST00000517973, ENST00000625178, ENST00000521632, ENST00000520597, 
ENST00000520059, ENST00000614343, ENST00000622181          
rs8191438 ENST00000398606, ENST00000398603, ENST00000494593, ENST00000489040, 
ENST00000498765, ENST00000467591, ENST00000495996, LRG_723t1            
rs8191439 ENST00000398606, ENST00000398603, ENST00000494593, ENST00000489040, 
ENST00000498765, ENST00000467591, ENST00000495996, LRG_723t1            
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rs8330 ENST00000373424, ENST00000446481, ENST00000305139, ENST00000406651, 
ENST00000354728, ENST00000373414, ENST00000482026, ENST00000373409, 
ENST00000450233, ENST00000430892, ENST00000428446, ENST00000454283, 
ENST00000610772, ENST00000373426, ENST00000305208, ENST00000360418, 
ENST00000344644, ENST00000373445, ENST00000373450, LRG_733t1      
rs908262 ENST00000345617, ENST00000463007, ENST00000493582, ENST00000535493, 
ENST00000446876, ENST00000544989, ENST00000543185            
rs9367532                
rs943005 ENST00000402760               
rs9473924                
rs9473932                
rs948999                
rs9508207 ENST00000612955               
rs9590150                
rs9590154                
rs9784215 ENST00000635189, ENST00000291535, ENST00000635108, ENST00000635325, 
ENST00000634453, ENST00000634718, ENST00000319294, ENST00000398367, 
ENST00000473381           
rs9984523 ENST00000332149, ENST00000458356, ENST00000454499, ENST00000424093, 
ENST00000497881, ENST00000463138, ENST00000398585            
rs9997440 ENST00000515292               
*GRCh38.p5 
  
 
1
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Supplementary Table 28: Summary of Ensembl GrCh38.p5 regulatory annotation of 147 APAP-associated SNPs. 
SNP Regulatory 
Features* 
GrCh38 Compiled ENSEMBL Variant 
Consequence 
Non-coding 
RNA 
biotype* 
Non-coding 
RNA gene* 
SIFT 
prediction 
PolyPhen 
prediction 
Amino 
acid 
rs10110651   upstream  gene  variant    processed 
pseudogene 
AC090453.1-001       
rs10144421   intron  variant, non  coding  transcript  variant              
rs10186482   intron  variant              
rs1042640   upstream  gene  variant, 3  prime  UTR  variant, 
downstream  gene  variant, NMD  transcript  variant 
          
rs10485114                 
rs10508010                 
rs10511137       misc RNA Y  RNA.529-201       
rs10515465   intron  variant, NMD  transcript  variant, non  coding  
transcript  variant, upstream  gene  variant, 
downstream  gene  variant  
          
rs10849421   intron  variant, non  coding  transcript  variant              
rs10852886   downstream  gene  variant, NMD  transcript  variant, 
intron  variant   
          
rs10929303   upstream  gene  variant, 3  prime  UTR  variant, 
downstream  gene  variant, NMD  transcript  variant 
          
rs11070109   intron  variant              
rs11129122       snRNA,          
miRNA 
RNU6-788P-
201, MIR548AC 
      
rs11153350   upstream  gene  variant, non  coding  transcript  
variant, intron  variant, non  coding  transcript  exon  
variant   
antisense RP11-506B6.6        
rs11248859   intron  variant, upstream  gene  variant              
rs11611637       linc RNA,       
ncRNA 
RP11-541G9.2-
001, RMST 
      
rs11766607       linc RNA AC010971.1-001       
rs1189434   intron  variant              
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rs1189436 ENSR0000
1619905, 
ENSR0000
1036605 
intron  variant, regulatory  region  variant              
rs1189437 ENSR0000
1036605 
intron  variant, regulatory  region  variant              
rs1189439   intron  variant              
rs11909987   upstream  gene  variant              
rs12107308   downstream  gene  variant    misc RNA Y  RNA.529-201       
rs12120268                 
rs12267329   intron  variant              
rs12584534   intron  variant              
rs12700386   downstream  gene  variant, upstream  gene  variant    antisense AC073072.5-001       
rs13015146   downstream  gene  variant, non  coding  transcript  
variant, non  coding  transcript  exon  variant   
processed 
pseudogene 
DAZAP2P1-001       
rs13101122                 
rs13204006 ENSR0000
1213359 
non  coding  transcript  variant, regulatory  region  
variant, intron  variant   
linc RNA RP11-377N20.1,      
CASC15 
     
rs13326165 ENSR0000
1479196 
intron  variant, regulatory  region  variant, non  coding  
transcript  variant   
          
rs1343151   intron  variant, NMD  transcript  variant              
rs1354510   upstream  gene  variant, intron  variant, non  coding  
transcript  variant   
          
rs1356553                 
rs1372940       linc RNA,      
miRNA 
RP11-675P14.1-
001, MIR302F 
      
rs1377392 ENSR0000
1496109 
regulatory  region  variant    misc RNA RN7SKP256-
201 
      
rs1380292 ENSR0000
1387319 
regulatory  region  variant    linc RNA, 
ncRNA 
RP11-24P4.1-
001, RP11-
24P4.1-002, 
LOC286114 
      
  
 
1
1
7
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rs1467558   upstream  gene  variant, downstream  gene  variant, 
intron  variant, missense  variant, non  coding  
transcript  variant, NMD  transcript  variant, non  
coding  transcript  exon  variant,  
    tolerated benign I/T 
rs1532815   non  coding  transcript  variant, non  coding  transcript  
exon  variant, intron  variant   
antisense RP11-38C18.2       
rs1536343 ENSR0000
1508952 
non  coding  transcript  variant, regulatory  region  
variant, intron  variant   
linc RNA RP11-50D16.4       
rs1599096       linc RNA, 
ncRNA 
RP11-24P4.1-
001, RP11-
24P4.1-001, 
LOC286114 
      
rs16851554   intron  variant, NMD  transcript  variant, non  coding  
transcript  variant   
          
rs16900696 ENSR0000
1408138 
non  coding  transcript  variant, regulatory  region  
variant, intron  variant   
antisense RP11-152K4.2-
001 
      
rs16950155       antisense SOX21-AS1       
rs16950190       antisense SOX21-AS1       
rs17310467   upstream  gene  variant              
rs17413355   intron  variant, non  coding  transcript  variant, 
upstream  gene  variant   
pseudogene RPL13AP17       
rs17469886 ENSR0000
1720964 
regulatory  region  variant              
rs1751043   intron  variant, upstream  gene  variant              
rs17559005                 
rs17640676   intron  variant, non  coding  transcript  variant              
rs1764425       misc RNA RNY4P27-201       
rs1766908       misc RNA RNY4P27-201       
rs1876381       linc RNA RP11-99H20.1-
001, RP11-
99H20.1-002 
      
rs1902023   missense  variant     tolerated benign Y/D 
  
 
1
1
8
 
Supplementary Table 28. –Continued. 
rs1925851 ENSR0000
0518959 
regulatory  region  variant    linc RNA LINC00557       
rs1925856   downstream  gene  variant    linc RNA LINC00557       
rs1925860       snRNA RNU6-62P-201       
rs1982562       misc RNA Y  RNA.529-201       
rs1989983   upstream  gene  variant    antisense CTB-22K21.2       
rs2031920   non  coding  transcript  variant, non  coding  transcript  
exon  variant, downstream  gene  variant, intron  
variant, upstream  gene  variant  
          
rs2064504   non  coding  transcript  variant, intron  variant, 
downstream  gene  variant, upstream  gene  variant   
          
rs2074451 ENSR0000
0640654 
downstream  gene  variant, regulatory  region  variant              
rs2082603       snoRNA,   
ncRNA 
SNORD65.1-
201, LINC01098 
      
rs2089515 ENSR0000
1722376 
regulatory  region  variant              
rs2209631   non  coding  transcript  variant, intron  variant    linc RNA RP11-50D16.4       
rs2218988 ENSR0000
1564179 
intron  variant, regulatory  region  variant, NMD  
transcript  variant, non  coding  transcript  variant   
          
rs2344953       misc RNA Y  RNA.529-201       
rs2397105 ENSR0000
1704513 
downstream  gene  variant, regulatory  region  variant              
rs2397132 ENSR0000
1704518, 
ENSR0000
1496077 
intron  variant, regulatory  region  variant, non  coding  
transcript  variant   
          
rs2524290 ENSR0000
0319346 
upstream  gene  variant, regulatory  region  variant, 5  
prime  UTR  variant   
          
rs2567513   intron  variant, non  coding  transcript  variant              
rs2720666 ENSR0000
1401713 
non  coding  transcript  variant, regulatory  region  
variant, intron  variant, downstream  gene  variant   
          
rs2720667   non  coding  transcript  variant, intron  variant, 
downstream  gene  variant   
          
  
 
1
1
9
 
Supplementary Table 28. –Continued. 
rs2737844 ENSR0000
0419397 
downstream  gene  variant, regulatory  region  variant, 
NMD  transcript  variant, intron  variant   
         
rs2748991 ENSR0000
1218546 
regulatory  region  variant    pseudogene GSTA7P       
rs279874   intron  variant              
rs2880961       misc RNA Y  RNA.529-201       
rs319590   intron  variant, NMD  transcript  variant, non  coding  
transcript  variant, downstream  gene  variant   
         
rs319594   intron  variant, NMD  transcript  variant, non  coding  
transcript  variant   
          
rs3208829 ENSR0000
1224733 
intron  variant, regulatory  region  variant, 
downstream  gene  variant, non  coding  transcript  
variant   
          
rs33966381       misc RNA Y  RNA.529-201       
rs3744198   synonymous  variant, 3  prime  UTR  variant, NMD  
transcript  variant, upstream  gene  variant, 
downstream  gene  variant  
        A 
rs3746165   upstream  gene  variant              
rs3746923 ENSR0000
0185890 
intron  variant, regulatory  region  variant, NMD  
transcript  variant, non  coding  transcript  variant   
          
rs3749166   synonymous  variant, intron  variant, 3  prime  UTR  
variant, NMD  transcript  variant, non  coding  
transcript  variant, non  coding  transcript  exon  
variant, downstream  gene  variant, upstream  gene  
variant 
        A 
rs3795578   downstream  gene  variant, intron  variant, upstream  
gene  variant, non  coding  transcript  variant   
          
rs3799732 ENSR0000
1499510 
intron  variant, regulatory  region  variant, 
downstream  gene  variant, non  coding  transcript  
variant, non  coding  transcript  exon  variant, NMD  
transcript  variant  
          
rs3825924   splice  region  variant, intron  variant, non  coding  
transcript  variant   
          
  
 
1
2
0
 
Supplementary Table 28. –Continued. 
rs3828599 ENSR0000
1294023 
intron  variant, regulatory  region  variant, non  coding  
transcript  variant, NMD  transcript  variant, 
downstream  gene  variant, upstream  gene  variant  
          
rs3857596                 
rs3957358       ncRNA AL591034.1       
rs4148411   upstream  gene  variant, NMD  transcript  variant, 
intron  variant   
          
rs4289753                 
rs4495049       lincRNA,         
miRNA 
RP11-318I4.1-
001, MIR2054 
      
rs4563418   upstream  gene  variant    misc RNA Y  RNA.529-201       
rs4585742                 
rs4710625       snRNA,        
pseudogene 
RNU7-66P-201,  
MCART3P 
      
rs4715210                 
rs4715359 ENSR0000
1496077 
intron  variant, regulatory  region  variant, non  coding  
transcript  variant   
unprocessed 
pseudogene 
GSTA10P       
rs4764486 ENSR0000
0425731 
intron  variant, regulatory  region  variant, non  coding  
transcript  variant   
          
rs4773861 ENSR0000
1511482 
intron  variant, regulatory  region  variant              
rs4869233   intron  variant, non  coding  transcript  variant              
rs5936441                 
rs6032545   intron  variant, upstream  gene  variant              
rs6083315   upstream  gene  variant              
rs6124741   non  coding  transcript  variant, intron  variant, 
upstream  gene  variant   
          
rs6502555 ENSR0000
1339172 
intron  variant, regulatory  region  variant              
rs6553786   upstream  gene  variant    linc RNA,      
miRNA 
RP11-51M24.1-
001, MIR4276 
      
rs6737742   intron  variant, non  coding  transcript  variant              
  
 
1
2
1
 
Supplementary Table 28. –Continued. 
rs6789170   non  coding  transcript  variant, intron  variant    linc RNA RP11-631B21.1,    
LINC00635  
      
rs6795028   downstream  gene  variant    misc RNA Y  RNA.529-201       
rs6809413       misc RNA Y  RNA.529-201       
rs6810790   intron  variant              
rs6852435   upstream  gene  variant    linc RNA,      
miRNA 
RP11-51M24.1-
001, MIR4276 
      
rs6878801       linc RNA CTC-472C24.1-
001 
      
rs6922172 ENSR0000
1218714 
regulatory  region  variant    ncRNA 
AL591034.1 
      
rs6949916       linc RNA AC010971.1-001       
rs707148                 
rs718068       lincRNA,          
ncRNA 
RP11-24P4.1-
001, RP11-
24P4.1-002,  
LOC286114 
      
rs7329514   intron  variant              
rs7526132 ENSR0000
0671996 
3  prime  UTR  variant, regulatory  region  variant, 
NMD  transcript  variant, missense  variant, 
downstream  gene  variant  
    tolerated benign G/A 
rs7665426       miRNA MIR4276       
rs766606       snRNA RNU6-62P-201       
rs7726138       linc RNA CTC-493L21.2-
001 
      
rs7738812                 
rs776746   intron  variant, splice  acceptor  variant, non  coding  
transcript  variant, non  coding  transcript  exon  
variant, NMD  transcript  variant, downstream  gene  
variant  
          
rs777952       miRNA MIR548A3       
rs7987903                 
  
 
1
2
2
 
Supplementary Table 28. –Continued. 
rs8001657   intron  variant, downstream  gene  variant              
rs8081984   intron  variant, upstream  gene  variant              
rs8177426 ENSR0000
1294023, 
ENSR0000
1698982 
intron  variant, regulatory  region  variant, non  coding  
transcript  variant, NMD  transcript  variant, 
downstream  gene  variant, upstream  gene  variant  
          
rs8191438 ENSR0000
0564238 
5  prime  UTR  variant, regulatory  region  variant, 
upstream  gene  variant   
          
rs8191439 ENSR0000
0564238 
5  prime  UTR  variant, regulatory  region  variant, 
non  coding  transcript  variant, non  coding  transcript  
exon  variant, upstream  gene  variant  
          
rs8330   downstream  gene  variant, 3  prime  UTR  variant, 
NMD  transcript  variant, upstream  gene  variant   
          
rs908262 ENSR0000
0610600 
intron  variant, regulatory  region  variant, non  coding  
transcript  variant   
          
rs9367532       ncRNA AL591034.1       
rs943005   non  coding  transcript  variant, non  coding  transcript  
exon  variant    
processed 
pseudogene 
RP4-753D5.3-
001 
      
rs9473924                 
rs9473932                
rs948999 ENSR0000
1608376 
regulatory  region  variant    linc RNA RP11-890B15.2-
001, RP11-
890B15.2-001 
      
rs9508207   intron  variant              
rs9590150       linc RNA LINC00557-001       
rs9590154       snRNA RNU6-62P-201       
rs9784215   intron  variant, upstream  gene  variant              
rs9984523   upstream  gene  variant, intron  variant              
rs9997440   non  coding  transcript  variant, intron  variant    linc RNA RP11-617I14.1-
001 
      
*, GRCh38.p5 
  
 
1
2
3
 
Supplementary Table 29: Summary of HaploReg v4.1 annotations of 147 APAP-associated SNPs. 
SNP GERP 
cons° 
SiPhy 
cons° 
Promoter 
histone 
marks 
Enhancer 
histone 
marks 
DNAse Proteins 
bound 
Motifs 
changed 
NHGRI
/EBI 
GWAS 
hits 
GRASP 
QTL 
hits 
eQTL 
hits 
GEN 
CODE 
genes 
RefSeq 
genes 
dbSNP 
func. 
Annot.+ 
rs10110651                 3 hits 53kb 3' 
of 
KCNU
1 
53kb 3' 
of 
KCNU1 
  
rs10144421       SKIN,A
DRL,MU
S 
GATA2 Nrf-
2,TCF11:
:MafG 
  1 hit 9 hits SYNE
3 
C14orf4
9 
intronic 
rs10186482           6 altered 
motifs 
    14 
hits 
NEB NEB intronic 
rs1042640         CTCF,R
AD21 
BCL,TH
AP1,YY
1 
      UGT1
A1 
UGT1A
1 
3'-UTR 
rs10485114           Eomes     1 hit 134kb 
3' of 
FRK 
134kb 
3' of 
FRK 
  
rs10508010           NRSF       13kb 3' 
of 
RP11-
74A12.
2 
45kb 3' 
of 
ABCC4 
  
rs10511137           4 altered 
motifs 
      32kb 3' 
of 
Y_RN
A 
305kb 
3' of 
C3orf38 
intronic 
rs10515465           CTCF,Ra
d21,SMC
3 
    9 hits PCBD
2 
PCBD2 intronic 
rs10849421       BRST,S
KIN 
  Gfi1,Hdx
,STAT 
    1 hit CD9 CD9 intronic 
  
 
1
2
4
 
Supplementary Table 29. –Continued. 
 
rs10852886       BRST,S
KIN,BR
ST 
  4 altered 
motifs 
  1 hit 11 
hits 
TEKT
1 
1.9kb 3' 
of 
FBXO3
9 
  
rs10929303         CTCF,R
AD21 
6 altered 
motifs 
      UGT1
A1 
UGT1A
1 
3'-UTR 
rs11070109     LNG PANC   TCF11::
MafG,V
DR 
  1 hit   ABCC
4 
ABCC4 intronic 
rs11129122     LNG     5 altered 
motifs 
      30kb 5' 
of U6 
64kb 3' 
of 
MIR548
AC 
  
rs11153350     ESDR, 
ADRL, 
HRT 
ESDR,E
SDR,AD
RL 
  Spz1     1 hit RP11-
506B6.
6 
2.6kb 5' 
of 
LAMA
4 
intronic 
rs11248859     4 tissues     BHLHE4
0,STAT 
      CACN
A1H 
CACN
A1H 
intronic 
rs11611637           4 altered 
motifs 
      15kb 5' 
of 
RP11-
541G9.
2 
173kb 
5' of 
RMST 
  
rs11766607     6 tissues SKIN   RBP-
Jkappa 
      225kb 
3' of 
AC010
971.1 
294kb 
5' of 
VWC2 
  
rs1189434     BLD, 
VAS, 
SKIN 
    Myc,XB
P-1 
      ABCC
4 
ABCC4 intronic 
rs1189436     4 tissues 9 tissues   Hand1   1 hit   ABCC
4 
ABCC4 intronic 
 
  
 
1
2
5
 
Supplementary Table 29. –Continued. 
rs1189437     BLD, 
VAS 
BLD   AP-
1,Pax-8 
  1 hit   ABCC
4 
ABCC4 intronic 
rs1189439   BLD BLD     4 altered 
motifs 
      ABCC
4 
ABCC4 intronic 
rs11909987   BLD 4 tissues BLD         5 hits 1.6kb 
5' of 
UBAS
H3A 
1.6kb 5' 
of 
UBASH
3A 
  
rs12107308     BLD     5 altered 
motifs 
      1.9kb 
3' of 
Y_RN
A 
275kb 
3' of 
C3orf38 
intronic 
rs12120268     ESDR     HNF4   1 hit 5 hits 15kb 5' 
of 
GPX7 
15kb 5' 
of 
GPX7 
  
rs12267329           Cdx,HN
F4,TCF4 
      ADAR
B2 
ADAR
B2 
intronic 
rs12584534     ESDR     8 altered 
motifs 
      ABCC
4 
ABCC4 intronic 
rs12700386   6 tissues 18 tissues 29 
tissues 
  Smad       2kb 3' 
of 
AC073
072.5 
3.8kb 5' 
of IL6 
  
rs13015146     BLD, 
ADRL, 
SPLN 
    Hdx   2 hits   AC079
354.1 
8.8kb 3' 
of 
SUMO1 
  
rs13101122           4 altered 
motifs 
  1 hit   27kb 3' 
of 
Y_RN
A 
301kb 
3' of 
C3orf38 
intronic 
rs13204006     13 tissues 6 tissues   5 altered 
motifs 
      34kb 3' 
of 
RP11-
377N2
0.1 
FLJ225
36 
intronic 
  
 
1
2
6
 
Supplementary Table 29. –Continued. 
rs13326165   4 tissues 12 tissues BLD,BL
D 
    1 hit 3 hits 12 
hits 
STAB
1 
STAB1 intronic 
rs1343151             2 hits 1 hit 1 hit IL23R IL23R intronic 
rs1354510     ESDR     Myf,RP5
8 
      LMX1
A 
LMX1
A 
intronic 
rs1356553     BLD     Ik-1,Ik-
2,PLZF 
      9.2kb 
5' of 
7SK 
73kb 3' 
of 
GCLC 
  
rs1372940                   275kb 
5' of 
RP11-
675P1
4.1 
139kb 
3' of 
MIR302
F 
  
rs1377392   FAT, LIV, 
BLD 
15 tissues   4 bound 
proteins 
        18kb 5' 
of 7SK 
64kb 3' 
of 
GCLC 
  
rs1380292       31 
tissues 
CTCF,R
AD21,S
MC3 
Arid5b,E
vi-1 
      51kb 5' 
of 
RP11-
24P4.1 
252kb 
3' of 
LOC28
6114 
  
rs1467558 yes yes   4 tissues BLD,SKI
N,BLD 
POL2       9 hits CD44 CD44 missens
e 
rs1532815             1 hit 1 hit   RP11-
38C18.
2 
LMX1
A 
intronic 
rs1536343     4 tissues 6 tissues   14 
altered 
motifs 
      50kb 3' 
of 
NHLR
C3 
51kb 3' 
of 
NHLRC
3 
  
rs1599096     BRST     6 altered 
motifs 
      37kb 5' 
of 
RP11-
24P4.1 
266kb 
3' of 
LOC28
6114 
  
rs16851554 yes yes                 SPAG
16 
SPAG1
6 
intronic 
  
 
1
2
7
 
Supplementary Table 29. –Continued. 
rs16900696   STRM 7 tissues 10 
tissues 
ERALP
HA_A,G
R 
AP-
1,Arid5a,
Hoxa5 
    5 hits RP11-
152K4.
2 
80kb 5' 
of 
CDH6 
  
rs16950155     4 tissues SKIN,L
NG 
  8 altered 
motifs 
      85kb 3' 
of 
SOX2
1-AS1 
87kb 5' 
of 
SOX21 
  
rs16950190       ADRL   Maf       95kb 3' 
of 
SOX2
1-AS1 
98kb 5' 
of 
SOX21 
  
rs17310467     IPSC, 
MUS, 
LIV 
  ZNF274 8 altered 
motifs 
1 hit   12 
hits 
2kb 5' 
of GSS 
MYH7
B 
intronic 
rs17413355     ESDR, 
BRN 
            MAGI
2 
RPL13
AP17 
intronic 
rs17469886     5 tissues SKIN   Rad21   2 hits 8 hits 7.5kb 
3' of 
CCDC
25 
7.5kb 3' 
of 
CCDC2
5 
  
rs1751043     ESDR MUS   5 altered 
motifs 
      ABCC
4 
ABCC4 intronic 
rs17559005           7 altered 
motifs 
      32kb 3' 
of 
Y_RN
A 
305kb 
3' of 
C3orf38 
intronic 
rs17640676     PANC     NRSF   1 hit   KCNJ
3 
KCNJ3 intronic 
rs1764425   ESDR CRVX   STAT1,S
TAT3 
LXR,ST
AT 
    1 hit 16kb 5' 
of 
RNY4
P27 
51kb 5' 
of 
ABCC4 
  
rs1766908     LNG, 
CRVX 
BRST,C
RVX 
JUND GR,Nkx2
,Nkx3 
    1 hit 17kb 5' 
of 
RNY4
P27 
51kb 5' 
of 
ABCC4 
  
  
 
1
2
8
 
Supplementary Table 29. –Continued. 
rs1876381   ESC, 
IPSC 
ESC, 
ESDR, 
IPSC 
    8 altered 
motifs 
      52kb 3' 
of 
RP11-
99H20.
1 
204kb 
5' of 
SNX16 
  
rs1902023   LIV, 
BRN, GI 
LNG     Dbx1,Ho
xd8,Zfp1
05 
      UGT2
B15 
UGT2B
15 
missens
e 
rs1925851   15 tissues 8 tissues 13 
tissues 
  BCL,NF-
kappaB 
      7.1kb 
3' of 
RP11-
74A12.
2 
51kb 3' 
of 
ABCC4 
  
rs1925856 yes yes   ESDR ESDR,E
SDR 
  Pitx2       3kb 3' 
of 
RP11-
74A12.
2 
55kb 3' 
of 
ABCC4 
  
rs1925860     7 tissues     Irx,RP58       26kb 5' 
of 
RNU6-
62 
26kb 3' 
of 
ABCC4 
  
rs1982562                   28kb 3' 
of 
Y_RN
A 
301kb 
3' of 
C3orf38 
intronic 
rs1989983 yes yes   5 tissues LNG,BL
D 
      1 hit 2 hits 1.2kb 
5' of 
CTB-
22K21.
2 
1.7kb 5' 
of 
ABCC3 
  
rs2031920   LIV       7 altered 
motifs 
      CYP2
E1 
1kb 5' 
of 
CYP2E
1 
  
  
 
1
2
9
 
Supplementary Table 29. –Continued. 
rs2064504     GI, 
PLCNT 
BRST,B
RN,GI 
  6 altered 
motifs 
  19 hits 90 
hits 
WFDC
3 
WFDC3 intronic 
rs2074451     17 tissues 28 
tissues 
6 bound 
proteins 
    1 hit 3 hits 248bp 
3' of 
GPX4 
247bp 
3' of 
GPX4 
  
rs2082603     5 tissues     4 altered 
motifs 
      68kb 5' 
of 
SNOR
D65 
763kb 
3' of 
LOC28
5501 
  
rs2089515     8 tissues 5 tissues   BAF155   1 hit   20kb 5' 
of 
IMPA
D1 
20kb 5' 
of 
IMPAD
1 
  
rs2209631     BRN IPSC,BR
N,BRN 
          50kb 3' 
of 
NHLR
C3 
51kb 3' 
of 
NHLRC
3 
  
rs2218988 yes    7 tissues     GCNF,P
ax-6 
      CALD
1 
CALD1 intronic 
rs2344953           8 altered 
motifs 
      52kb 3' 
of 
Y_RN
A 
325kb 
3' of 
C3orf38 
  
rs2397105   LIV 6 tissues   FOXA1,
FOXA2 
Cdc5   1 hit 11 
hits 
3.1kb 
3' of 
GSTA
1 
2.9kb 3' 
of 
GSTA1 
  
rs2397132     11 tissues 20 
tissues 
HDAC2 Pou3f2     1 hit 19kb 3' 
of 
GSTA
3 
19kb 3' 
of 
GSTA3 
  
rs2524290   GI, LNG, 
BLD 
14 tissues 6 tissues 12 bound 
proteins 
LRH1,Pa
x-5,Smad 
  1 hit 1 hit RAB3I
L1 
2.7kb 5' 
of 
RAB3I
L1 
  
  
 
1
3
0
 
Supplementary Table 29. –Continued. 
rs2567513     ESDR, 
SKIN, GI 
GI   AhR,BD
P1,Egr-1 
      SLC39
A11 
SLC39
A11 
intronic 
rs2720666     8 tissues BLD,BL
D,BLD 
6 bound 
proteins 
HNF4,R
XRA,TC
F4 
      PVT1 PVT1 intronic 
rs2720667     8 tissues 6 tissues 4 bound 
proteins 
6 altered 
motifs 
      PVT1 PVT1 intronic 
rs2737844   LIV, GI GI, 
PANC, 
SKIN 
GI   Esr2   10 hits 66 
hits 
GPX2 GPX2 intronic 
rs2748991   BRN 8 tissues IPSC           18kb 3' 
of 
GSTA
2 
7.7kb 3' 
of 
GSTA7
P 
  
rs279874           DMRT1,
Zfp187 
  1 hit   DMRT
1 
DMRT1 intronic 
rs2880961           4 altered 
motifs 
1 hit 1 hit   44kb 3' 
of 
Y_RN
A 
317kb 
3' of 
C3orf38 
  
rs319590 yes yes   4 tissues     Pou3f2,P
ou3f3 
    9 hits PCBD
2 
PCBD2 intronic 
rs319594       BLD   7 altered 
motifs 
  1 hit 9 hits PCBD
2 
PCBD2 intronic 
rs3208829   12 tissues 4 tissues MUS P300 7 altered 
motifs 
    1 hit LAMA
4 
LAMA
4 
intronic 
rs33966381           Foxf2,Fo
xk1,Hox
c10 
      32kb 3' 
of 
Y_RN
A 
306kb 
3' of 
C3orf38 
intronic 
rs3744198     4 tissues ESDR,M
US 
  4 altered 
motifs 
    5 hits C17orf
28 
C17orf2
8 
synony
mous 
rs3746165   8 tissues 20 tissues 33 
tissues 
CTCF ERalpha-
a 
  1 hit 4 hits 1.7kb 
5' of 
GPX4 
1.7kb 5' 
of 
GPX4 
  
  
 
1
3
1
 
Supplementary Table 29. –Continued. 
rs3746923   BLD, GI, 
THYM 
IPSC, 
BLD 
THYM   5 altered 
motifs 
    5 hits UBAS
H3A 
UBASH
3A 
intronic 
rs3749166 yes    GI, 
ADRL, 
LIV 
    4 altered 
motifs 
    8 hits CAPN
10 
CAPN1
0 
synony
mous 
rs3795578   LIV 6 tissues       1 hit     ETNK
2 
ETNK2 intronic 
rs3799732   STRM 9 tissues BRST,S
KIN,MU
S 
  Foxo   5 hits 13 
hits 
TPD52
L1 
TPD52
L1 
intronic 
rs3825924     BLD IPSC   Rad21       ALDH
1A3 
ALDH1
A3 
intronic 
rs3828599   11 tissues 8 tissues SKIN   7 altered 
motifs 
  3 hits 5 hits GPX3 GPX3 intronic 
rs3857596           DMRT5,
Sox,THA
P1 
  2 hits 1 hit 90kb 3' 
of 
TFAP2
B 
90kb 3' 
of 
TFAP2
B 
  
rs3957358   BLD BLD, 
SKIN 
  ZNF263 CEBPB,
Nkx3 
      9.7kb 
3' of 
AL591
034.1 
51kb 3' 
of 
GCLC 
  
rs4148411     LIV, GI, 
LNG 
    Nkx6-
1,Pou4f3
,Pou6f1 
  2 hits 3 hits ABCC
3 
ABCC3 intronic 
rs4289753           Zfp105       257kb 
5' of 
VWC2 
257kb 
5' of 
VWC2 
  
rs4495049           GR   1 hit   53kb 5' 
of 
RP11-
318I4.
1 
511kb 
3' of 
MIR205
4 
  
              
  
 
1
3
2
 
Supplementary Table 29. –Continued. 
rs4563418           HP1-site-
factor,Ho
xa13,Ho
xb13 
  1 hit   554bp 
5' of 
Y_RN
A 
273kb 
3' of 
C3orf38 
intronic 
rs4585742     ESDR, 
LIV 
    Irf,SIX5,
p300 
      76kb 5' 
of 
CPA6 
76kb 5' 
of 
CPA6 
  
rs4710625                   59kb 5' 
of 
RNU7-
66P 
998kb 
3' of 
MCAR
T3P 
  
rs4715210     ESC, 
ESDR, 
BLD 
    11 
altered 
motifs 
    1 hit 82kb 3' 
of 
TFAP2
B 
82kb 3' 
of 
TFAP2
B 
  
rs4715359     13 tissues     5 altered 
motifs 
  1 hit 1 hit 20kb 3' 
of 
GSTA
3 
20kb 3' 
of 
GSTA3 
  
rs4764486     17 tissues 9 tissues   Sox,ZBR
K1 
  1 hit 1 hit CD9 CD9 intronic 
rs4773861   LNG 13 tissues 4 tissues GATA2 14 
altered 
motifs 
    1 hit ABCC
4 
ABCC4 intronic 
rs4869233           6 altered 
motifs 
      MCTP
1 
MCTP1 intronic 
rs5936441             1 hit     216kb 
3' of 
FMR1
NB 
216kb 
3' of 
FMR1N
B 
  
rs6032545     BLD, 
MUS, 
BRST 
BLD,MU
S 
      4 hits 84 
hits 
DNTT
IP1 
DNTTI
P1 
intronic 
rs6083315     PANC     FXR,Nk
x2 
      3.4kb 
5' of 
CST5 
3.4kb 5' 
of 
CST5 
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Supplementary Table 29. –Continued. 
rs6124741     GI     Nanog,O
sr 
  15 hits 84 
hits 
WFDC
3 
WFDC3 intronic 
rs6502555     BLD 19 
tissues 
CTCF,R
AD21 
PU.1,VD
R 
    1 hit RAP1
GAP2 
RAP1G
AP2 
intronic 
rs6553786     ESC, 
IPSC 
        1 hit 1 hit 3kb 5' 
of 
RP11-
51M24
.1 
44kb 5' 
of 
MIR427
6 
  
rs6737742   BLD, GI 17 tissues 6 tissues 5 bound 
proteins 
CCNT2,
GATA,T
AL1 
    1 hit HDAC
4 
HDAC4 intronic 
rs6789170           CIZ,Fox
o,Irf 
      RP11-
631B2
1.1 
LOC15
1658 
intronic 
rs6795028           GATA,H
DAC2 
  1 hit   630bp 
3' of 
Y_RN
A 
274kb 
3' of 
C3orf38 
intronic 
rs6809413           RXRA,Z
ec 
      32kb 3' 
of 
Y_RN
A 
305kb 
3' of 
C3orf38 
intronic 
rs6810790       BLD           SLIT2 SLIT2 intronic 
rs6852435     ESC, 
IPSC 
BLD     1 hit 1 hit 1 hit 3.2kb 
5' of 
RP11-
51M24
.1 
44kb 5' 
of 
MIR427
6 
  
rs6878801           Evi-
1,Pou2f2 
      42kb 5' 
of 
CTC-
472C2
4.1 
297kb 
5' of 
SEMA6
A 
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Supplementary Table 29. –Continued. 
rs6922172     10 tissues 8 tissues PU1 NRSF,R
hox11 
      15kb 3' 
of 
AL591
034.1 
56kb 3' 
of 
GCLC 
  
rs6949916                   240kb 
3' of 
AC010
971.1 
279kb 
5' of 
VWC2 
  
rs707148     LIV     Duxl,Hd
x 
      9.9kb 
5' of 
GPX3 
9.7kb 5' 
of 
GPX3 
  
rs718068     MUS     Zfp691       53kb 5' 
of 
RP11-
24P4.1 
250kb 
3' of 
LOC28
6114 
  
rs7329514     LNG, 
BLD 
    6 altered 
motifs 
    1 hit ABCC
4 
ABCC4 intronic 
rs7526132 yes yes   BLD, GI, 
PANC 
IPSC,BL
D,BLD 
CTCF,R
AD21 
      4 hits MFSD
4 
MFSD4 missens
e 
rs7665426 yes  ESDR ESC, 
IPSC 
LNG   6 altered 
motifs 
    1 hit 19kb 5' 
of 
MIR42
76 
19kb 5' 
of 
MIR427
6 
  
rs766606     IPSC ESDR,T
HYM 
  4 altered 
motifs 
      17kb 5' 
of 
RNU6-
62 
18kb 3' 
of 
ABCC4 
  
rs7726138         CEBPB TCF12       27kb 3' 
of 
CTC-
493L2
1.2 
206kb 
3' of 
COX7C 
  
rs7738812                 3 hits 41kb 5' 
of 
CNR1 
41kb 5' 
of 
CNR1 
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Supplementary Table 29. –Continued. 
rs776746     BLD, GI GI   4 altered 
motifs 
  6 hits 11 
hits 
CYP3
A5 
CYP3A
5 
splice 
donor 
rs777952           GATA,G
fi1 
  6 hits   639kb 
5' of 
ALCA
M 
501kb 
5' of 
MIR548
A3 
  
rs7987903           RBP-
Jkappa 
      104kb 
3' of 
SOX2
1-AS1 
106kb 
5' of 
SOX21 
  
rs8001657     IPSC, 
ESC 
    Foxj2       ABCC
4 
ABCC4 intronic 
rs8081984                 2 hits FBXO
39 
FBXO3
9 
intronic 
rs8177426   10 tissues 16 tissues 17 
tissues 
5 bound 
proteins 
Myb,YY
1 
    4 hits GPX3 GPX3 intronic 
rs8191438   22 tissues   51 
tissues 
26 bound 
proteins 
18 
altered 
motifs 
      GSTP1 GSTP1 5'-UTR 
rs8191439   23 tissues   52 
tissues 
26 bound 
proteins 
ETF,SP1       GSTP1 GSTP1 5'-UTR 
rs8330           PPAR,SP
2 
      UGT1
A1 
UGT1A
1 
3'-UTR 
rs908262   10 tissues 16 tissues 6 tissues   8 altered 
motifs 
    1 hit HDAC
4 
HDAC4 intronic 
rs9367532   BLD ESDR, 
BLD 
BLD   9 altered 
motifs 
  1 hit   10kb 3' 
of 
AL591
034.1 
51kb 3' 
of 
GCLC 
  
rs943005 yes          Foxc1,Po
u3f2 
    1 hit 50kb 3' 
of 
TFAP2
B 
50kb 3' 
of 
TFAP2
B 
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Supplementary Table 29. –Continued. 
rs9473924           PTF1-
beta,VD
R 
1 hit     19kb 3' 
of 
TFAP2
B 
19kb 3' 
of 
TFAP2
B 
  
rs9473932 yes yes   4 tissues             43kb 3' 
of 
TFAP2
B 
43kb 3' 
of 
TFAP2
B 
  
rs948999   MUS 8 tissues SKIN,M
US,MUS 
  AP-
1,ATF3 
    1 hit 16kb 3' 
of 
RP11-
890B1
5.2 
47kb 3' 
of 
SNX19 
  
rs9508207   ESDR 6 tissues HRT   5 altered 
motifs 
      40kb 5' 
of 
MTUS
2 
40kb 5' 
of 
MTUS2 
  
rs9590150     FAT     HP1-site-
factor 
      17kb 3' 
of 
RP11-
74A12.
2 
41kb 3' 
of 
ABCC4 
  
rs9590154       IPSC   Evi-
1,Nkx6-
1,Pou2f2 
      20kb 5' 
of 
RNU6-
62 
21kb 3' 
of 
ABCC4 
  
rs9784215   BLD, 
THYM, 
GI 
5 tissues 5 tissues   PU.1,SP
1,STAT 
    5 hits 271bp 
5' of 
UBAS
H3A 
281bp 
5' of 
UBASH
3A 
  
rs9984523     GI, KID, 
PANC 
GI,KID,
GI 
ERALP
HA_A,G
R 
6 altered 
motifs 
      TMPR
SS2 
3.9kb 5' 
of 
TMPRS
S2 
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Supplementary Table 29. –Continued. 
rs9997440           6 altered 
motifs 
      RP11-
617I14
.1 
60kb 3' 
of 
PCDH7 
  
°, sequence constraint predicted by GREP or SiPhy; +, Canonical Splicing 
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Supplementary Table 30: Summary of GWAVA 
analysis of 147 APAP-associated SNPs. 
SNP Region score TSS score Unmatched score 
rs10110651 0.33 0.14 0.18 
rs10144421 0.21 0.18 0.22 
rs10186482 0.21 0.22 0.14 
rs1042640 0.41 0.77 0.79 
rs10485114 0.44 0.26 0.05 
rs10508010 0.39 0.35 0.14 
rs10511137 0.25 0.12 0.03 
rs10515465 0.45 0.06 0.09 
rs10849421 0.39 0.22 0.16 
rs10852886 0.27 0.33 0.35 
rs10929303 0.37 0.75 0.81 
rs11070109 0.41 0.37 0.22 
rs11129122 0.35 0.23 0.02 
rs11153350 0.19 0.12 0.15 
rs11248859 0.27 0.16 0.2 
rs11611637 0.33 0.17 0.07 
rs11766607 0.3 0.16 0.02 
rs1189434 0.34 0.28 0.14 
rs1189436 0.29 0.27 0.16 
rs1189437 0.41 0.23 0.22 
rs1189439 0.3 0.25 0.17 
rs11909987 0.22 0.35 0.56 
rs12107308 0.28 0.13 0.13 
rs12120268 0.37 0.17 0.16 
rs12267329 0.41 0.1 0.02 
rs12584534 0.3 0.23 0.06 
rs12700386 0.55 0.64 0.69 
rs13015146 0.38 0.28 0.51 
rs13101122 0.27 0.03 0.01 
rs13204006 0.43 0.28 0.19 
rs13326165 0.21 0.35 0.37 
rs1343151 0.47 0.4 0.19 
rs1354510 0.23 0.2 0.09 
rs1356553 0.35 0.31 0.14 
rs1372940 0.49 0.24 0.08 
rs1377392 0.41 0.41 0.23 
rs1380292 0.46 0.44 0.26 
rs1467558 0.45 0.43 0.51 
rs1532815 0.32 0.23 0.68 
rs1536343 0.36 0.42 0.17 
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Supplementary Table 30. –Continued. 
rs1599096 0.37 0.26 0.05 
rs16851554 0.36 0.26 0.04 
rs16900696 0.51 0.43 0.22 
rs16950155 0.43 0.4 0.13 
rs16950190 0.5 0.28 0.07 
rs17310467 0.24 0.43 0.44 
rs17413355 0.29 0.18 0.22 
rs17469886 0.48 0.46 0.12 
rs1751043 0.39 0.1 0.29 
rs17559005 0.24 0.21 0.03 
rs17640676 0.29 0.11 0.04 
rs1764425 0.16 0.2 0.06 
rs1766908 0.2 0.33 0.09 
rs1876381 0.3 0.26 0.16 
rs1902023 0.28 0.16 0.48 
rs1925851 0.25 0.45 0.54 
rs1925856 0.43 0.6 0.36 
rs1925860 0.25 0.25 0.13 
rs1982562 0.23 0.14 0 
rs1989983 0.45 0.65 0.86 
rs2031920 0.71 0.78 0.8 
rs2064504 0.44 0.35 0.44 
rs2074451 0.14 0.51 0.53 
rs2082603 0.52 0.16 0.03 
rs2089515 0.45 0.32 0.14 
rs2209631 0.29 0.23 0.12 
rs2218988 0.31 0.21 0.21 
rs2344953 0.17 0.1 0 
rs2397105 0.4 0.44 0.35 
rs2397132 0.36 0.37 0.36 
rs2524290 0.62 0.75 0.99 
rs2567513 0.18 0.1 0.03 
rs2720666 0.37 0.25 0.25 
rs2720667 0.28 0.19 0.27 
rs2737844 0.29 0.22 0.54 
rs2748991 0.27 0.15 0.09 
rs279874 0.26 0.26 0.05 
rs2880961 0.32 0.09 0.01 
rs319590 0.58 0.52 0.45 
rs319594 0.4 0.1 0.08 
rs3208829 0.38 0.38 0.47 
rs33966381 0.29 0.14 0.03 
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Supplementary Table 30. –Continued. 
rs3744198 0.37 0.54 0.88 
rs3746165 0.19 0.3 0.71 
rs3746923 0.19 0.21 0.34 
rs3749166 0.49 0.43 0.83 
rs3795578 0.36 0.28 0.46 
rs3799732 0.29 0.31 0.5 
rs3825924 0.27 0.22 0.23 
rs3828599 0.18 0.25 0.61 
rs3857596 0.18 0.2 0.01 
rs3957358 0.25 0.27 0.07 
rs4148411 0.34 0.28 0.22 
rs4289753 0.38 0.16 0.03 
rs4495049 0.39 0.13 0.01 
rs4563418 0.35 0.08 0.22 
rs4585742 0.45 0.37 0.13 
rs4710625 0.26 0.23 0.03 
rs4715210 0.31 0.21 0.09 
rs4715359 0.32 0.12 0.16 
rs4764486 0.18 0.29 0.16 
rs4773861 0.29 0.27 0.2 
rs4869233 0.47 0.31 0.15 
rs5936441 0.28 0.17 0.01 
rs6032545 0.1 0.03 0.21 
rs6083315 0.53 0.32 0.33 
rs6124741 0.17 0.39 0.46 
rs6502555 0.31 0.25 0.19 
rs6553786 0.22 0.21 0.1 
rs6737742 0.21 0.18 0.33 
rs6789170 0.3 0.12 0.05 
rs6795028 0.3 0.08 0.14 
rs6809413 0.19 0.16 0.02 
rs6810790 0.1 0.16 0.01 
rs6852435 0.25 0.25 0.17 
rs6878801 0.33 0.21 0.02 
rs6922172 0.35 0.34 0.25 
rs6949916 0.25 0.15 0 
rs707148 0.39 0.32 0.05 
rs718068 0.33 0.27 0.03 
rs7329514 0.19 0.14 0.02 
rs7526132 0.47 0.38 0.55 
rs7665426 0.36 0.34 0.08 
rs766606 0.33 0.38 0.09 
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Supplementary Table 30. –Continued. 
rs7726138 0.3 0.06 0 
rs7738812 0.28 0.13 0.01 
rs776746 0.33 0.19 0.49 
rs777952 0.22 0.09 0.02 
rs7987903 0.24 0.23 0.05 
rs8001657 0.25 0.07 0.05 
rs8081984 0.35 0.06 0.1 
rs8177426 0.3 0.31 0.51 
rs8191438 0.51 0.45 0.95 
rs8191439 0.35 0.46 0.97 
rs8330 0.46 0.76 0.75 
rs908262 0.22 0.24 0.33 
rs9367532 0.17 0.26 0.08 
rs943005 0.43 0.02 0.49 
rs9473924 0.38 0.27 0.16 
rs9473932 0.4 0.46 0.28 
rs948999 0.29 0.38 0.28 
rs9508207 0.48 0.25 0.16 
rs9590150 0.39 0.36 0.14 
rs9590154 0.34 0.21 0.03 
rs9784215 0.38 0.56 0.84 
rs9984523 0.4 0.26 0.15 
rs9997440 0.35 0.09 0.01 
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Supplementary Table 31: Pubmatrix analysis of protein-coding genes containing 
147 APAP-associated SNPs. 
Gene acetaminophen disease drug hepatotoxicity liver metabolism toxicity 
ABCC3 4 53 206 6 100 219 36 
ABCC4 10 103 395 11 105 477 75 
ADARB2 0 8 1 0 1 15 2 
ALCAM 0 114 118 0 35 449 4 
ALDH1A3 0 32 58 0 10 139 9 
C14orf49 0 1 1 0 0 0 0 
C17orf28 0 0 0 0 0 0 0 
C3orf38 0 0 0 0 0 1 0 
CACNA1H 1 59 149 0 1 247 11 
CALD1 0 5 5 0 1 29 0 
CAPN10 0 90 13 0 7 73 0 
CCDC25 0 1 1 0 2 4 0 
CD44 4 3142 4293 7 931 10946 397 
CD9 0 251 288 0 47 1081 19 
CDH6 0 10 6 0 4 34 1 
CNR1 0 172 295 0 34 388 19 
COX7C 0 6 6 0 2 24 1 
CPA6 0 7 5 0 2 14 0 
CST5 0 2 7 0 1 18 1 
CYP2E1 316 1162 3425 506 3675 4943 1524 
CYP3A5 96 817 7719 189 4582 8957 1170 
DMRT1 0 30 77 0 22 351 25 
DNTTIP1 0 0 0 0 0 9 0 
ETNK2 0 2 2 0 2 4 0 
FBXO39 0 1 1 0 0 4 0 
FMR1NB 0 1 1 0 0 1 0 
FRK 0 31 50 0 13 147 10 
GCLC 25 161 409 40 157 604 178 
GPX2 0 53 112 2 65 249 53 
GPX3 3 108 131 3 64 370 26 
GPX4 1 94 148 1 83 356 45 
GPX7 0 10 17 1 6 48 6 
GSS 2 539 267 1 40 524 28 
GSTA1 8 115 243 17 148 431 105 
GSTA3 0 16 36 3 30 65 18 
GSTP1 24 1513 1966 31 791 3948 684 
HDAC4 0 148 269 0 37 647 25 
IL23R 0 524 71 0 19 245 1 
IL6 14 3775 3639 16 782 8378 444 
IMPAD1 0 2 1 0 0 2 0 
KCNJ3 0 15 19 0 1 50 0 
LAMA4 0 22 25 0 8 101 2 
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Supplementary Table 31. –Continued. 
LMX1A 0 92 29 0 1 148 3 
MAGI2 0 32 19 0 4 96 0 
MCTP1 0 1 3 0 1 6 1 
MFSD4 0 3 0 0 1 4 0 
MTUS2 0 2 2 0 0 4 0 
MYH7B 0 7 6 0 1 25 1 
NEB 0 215 255 2 44 509 12 
NHLRC3 0 1 0 0 0 0 0 
PCBD2 0 1 0 0 0 1 0 
PVT1 0 70 23 0 12 77 2 
RAB3IL1 0 0 0 0 0 2 0 
RAP1GAP2 0 1 1 0 0 8 0 
SEMA6A 0 9 12 0 0 65 1 
SLC39A11 0 1 1 0 0 4 0 
SLIT2 0 82 68 0 16 342 7 
SNX16 0 3 3 0 0 8 0 
SNX19 0 7 1 0 1 9 0 
SOX21 0 4 6 0 0 44 1 
SPAG16 0 10 1 0 0 16 0 
STAB1 0 24 14 0 19 74 1 
SUMO1 0 194 245 0 47 1808 27 
TEKT1 0 1 2 0 0 7 0 
TFAP2B 0 44 11 0 3 77 1 
TMPRSS2 1 303 156 0 6 587 12 
TPD52L1 0 3 4 0 0 15 0 
UBASH3A 0 18 0 0 1 8 0 
UGT1A1 47 577 1436 41 905 1769 496 
UGT2B15 6 23 148 2 114 219 14 
VWC2 0 0 0 0 0 4 0 
WFDC3 0 1 1 0 0 1 0 
Pubmatrix returns the number of articles containing both search and modifier terms 
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Supplementary Table 32: Significant gene hits from the APAP time points (p<0.05) were compared to a list of 133 
gene names with 147 known APAP injury-related SNPs.  
4d pos. p<0.05 4d neg. p<0.05 
24h pos. 
p<0.05 
24h neg. 
p<0.05 
30min-24h pos. 
p<0.05 
30min-24h neg. 
p<0.05 all pos. p<0.05 all neg. p<0.05 
ALCAM SUMO1 GSS NEB GSTP1 CPA6 TMPRSS2 RAP1GAP2 
GPX4 KCNJ3 IL23R UGT2B15 GSS GPX2 STAB1 SUMO1 
UGT2B15 SNX16 SNX19 DNTTIP1 STAB1 UGT2B15 ALCAM  
 RAP1GAP2 MAGI2 CPA6 SLIT2  KCNJ3  
   FBXO39   MCTP1  
      TPD52L1  
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Supplementary Table 33: Summary information about the top genes considered for further studies. Genes had to be 
ranked in the top 10 of a CRISPR screen gene list and also be significantly differentially expressed in another dataset 
(all p<0.05). 
Gene Full name 
Protein 
Databa
se ID 
CRISPR gene 
ranking 
(p<0.05) 
sgRN
A 
lfc** Other dataset (p<0.05) Gene expression lfc** 
Essential 
Gene 
(essentialgen
e.org) 
APAP 
public
ations 
LZTR1 Leucine 
Zipper Like 
Transcription 
Regulator 1 
 4d+*, 1.95 70784 D1(responder v non-
responder), D8(responder v 
non-responder) 
0.36 D1, 0.34 D8 no no 
NAAA N-
Acylethanola
mine Acid 
Amidase 
 int-*, all-, 
30min-, 3h-, 
6h- 
-0.5 70784 D8(responder v non-
responder), 70784 
D1(responder v placebo), 74000 
ALF 
0.2 in D8(resp. v nonresp.), 
0.265 in D1(resp. v 
placebo),  -2.99 in ALF 
no no 
PGM5 Phosphogluco
mutase 5 
 24h+*, int+*, 
all+*, 4d+, 3h+, 
6h+, 12h+, 
0.40, 
0.30, 
0.57 
70784 D1(responder v placebo) -0.33759 yes no 
ATG2B Autophagy 
Related 2B 
 NA(4d- #18) -3.65 70784 D1(responder v placebo), 
70784 D8(responder v placebo) 
0.202 D1, 0.218 D8 no no 
MYOZ3 Myozenin 3  24h-*, all-, int-, 
4d-, 3h-, 6h-, 
12h- 
-0.44 70784 D8(responder v non-
responder) 
0.4 no no 
EFNB3 Ephrin B3 4BKF.C 24h-*, int-, 
30min-, 3h+, 
3h-, 6h+, 6h- 
-0.68 70784 D8(responder v non-
responder) 
0.89 no no 
OR5M11 Olfactory 
Receptor 
Family 5 
Subfamily M 
Member 11 
 int-*, all-, 24h-, 
30min-, 3h-, 
6h- 
0.66 70784 D8(responder v non-
responder) 
0.21 no no 
FCGR3A Fc Fragment 
Of IgG 
Receptor IIIa 
3SGJ.C int-*, 24h-, all-, 
30min-, 6h-, 
12h- 
-0.34 70784 D8(responder v non-
responder) 
0.51 no no 
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Supplementary Table 33. –Continued. 
PROZ Protein Z, 
Vitamin K 
Dependent 
Plasma 
Glycoprotein 
3F1S.B int-*, 24h-, 
30min-, 6h-, 
12h- 
-0.56 70784 D8(responder v placebo) -0.34908 no no 
EEF1D Eukaryotic 
Translation 
Elongation 
Factor 1 
Delta 
 24h+*, 3h+ 1.68 74000 ALF 2.525 no no 
ACAD11 Acyl-CoA 
Dehydrogena
se Family 
Member 11 
 24h-*, 3h- -0.4 74000 ALF -2.369 no no 
KIF23 Kinesin 
Family 
Member 23 
3VHX.
B 
all+*, 24h+, 
int+, 6h+, 12h+ 
0.59 70784 D8(responder v placebo) -0.37566 yes no 
C19orf60 Chromosome 
19 Open 
Reading 
Frame 60 
 all-*, int- -1.74 70784 D8(responder v non-
responder), 70784 
D8(responder v placebo) 
0.16, 0.156 yes no 
BMPR1A Bone 
Morphogeneti
c Protein 
Receptor 
Type 1A 
1ES7.B int+*, all+, 
24h+, 6h+, 
12h+ 
0.3 74000 ALF -3.146 yes no 
PDSS2 Prenyl 
(Decaprenyl) 
Diphosphate 
Synthase, 
Subunit 2 
 all+*, int+, 
4d+, 3h+, 12h+, 
24h+ 
0.95 74000 ALF -2.349 yes no 
CXADR Coxsackie 
Virus And 
Adenovirus 
Receptor 
1EAJ.A all+*, int+, 
3h+, 6h+, 12h+ 
0.6 74000 ALF -2.497 yes no 
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Supplementary Table 33. –Continued. 
SSR2 Signal 
Sequence 
Receptor 
Subunit 2 
 24h-*, 30min- -0.23 mouse RNA-Seq 0.41 yes no 
TMCC2 Transmembra
ne And 
Coiled-Coil 
Domain 
Family 2 
 all-* -0.46 mouse RNA-Seq -1.047 no no 
UVRAG UV Radiation 
Resistance 
Associated 
 4d+ *, all- 1.62 mouse RNA-Seq -0.48 yes no 
EGR1 Early Growth 
Response 1 
4X9J.A 24h+*, int+, 
all+, 6h+ 
1.46 mouse RNA-Seq 1.468 yes yes 
VNN1 Vanin 1 4CYF.
A 
24h-*, 6h- -0.51 mouse RNA-Seq -0.851 no yes 
NR1I3 Nuclear 
Receptor 
Subfamily 1 
Group I 
Member 3 
  all+*, int+, 
24h+ 
0.45 70784 D1(responder v placebo), 
mouse RNA-Seq 
-0.183, -0.857 no yes 
*, in top 10 genes; **, lfc=log fold change 
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Supplementary Table 34: All Drug-Gene interactions resultant from analysis of candidate genes by the Drug Gene Interaction 
Database (www.dgidb.org) 
Gene Drug Interaction types Sources PubMed IDs 
ALCAM FLUOROURACIL CIViC 24708484 
BMPR1A CHEMBL3186227 inhibitor GuideToPharmacologyInteract 
FCGR3A GLOBULIN, IMMUNE antagonist DrugBank 20441428|17351760|17911465 
FCGR3A FENTANYL NCI 11772808 
FCGR3A EFALIZUMAB DrugBank 17139284|17016423 
FCGR3A CETUXIMAB PharmGKB|NCI|DrugBank 17139284|17704420|17016423 
FCGR3A INFLIXIMAB PharmGKB 
FCGR3A VINCRISTINE PharmGKB 
FCGR3A PENICILLIN G POTASSIUM NCI 17257217 
FCGR3A NATALIZUMAB DrugBank 17139284|17016423 
FCGR3A TRASTUZUMAB PharmGKB|NCI|DrugBank 18089830|17363544 
FCGR3A ALEMTUZUMAB DrugBank 15217834 
FCGR3A TOSITUMOMAB DrugBank 17139284|17016423 
FCGR3A ABCIXIMAB DrugBank 17139284|17016423 
FCGR3A PREDNISOLONE NCI 17329922 
FCGR3A CHEMBL411250 NCI 1827816 
FCGR3A BEVACIZUMAB DrugBank 17139284|17016423 
FCGR3A EPOETIN ALFA NCI 1300984 
FCGR3A CHONDROITIN SULFATE NCI 18006074 
FCGR3A GEMTUZUMAB OZOGAMICIN DrugBank 7509291|17139284|17016423 
FCGR3A CYCLOSPORINE NCI 17852453 
FCGR3A BASILIXIMAB DrugBank 17139284|17016423 
FCGR3A RITUXIMAB PharmGKB|DrugBank 17324336|15448014|16609067 
FCGR3A CIMETIDINE NCI 11556524 
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Supplementary Table 34. –Continued. 
FCGR3A INDOMETHACIN NCI 17329922 
FCGR3A ETANERCEPT DrugBank 15526004|15457442 
FCGR3A CYCLOPHOSPHAMIDE PharmGKB 
FCGR3A CYTARABINE NCI 17852453 
FCGR3A ALEFACEPT DrugBank 12795239|11970990|17139284|17016423 
FCGR3A LACTULOSE HYDRATE NCI 1418064 
FCGR3A HEPARIN  NCI 18492254 
FCGR3A RIZATRIPTAN NCI 10729215 
FCGR3A PHORBOL MYRISTATE ACETATE NCI 1827816 
FCGR3A THALIDOMIDE NCI 15457133 
FCGR3A PENICILLIN G SODIUM NCI 1371977 
FCGR3A SODIUM CHLORIDE NCI 17187818 
FCGR3A DACLIZUMAB DrugBank 17139284|17016423 
FCGR3A MAFOSFAMIDE NCI 1515095 
FCGR3A PALIVIZUMAB DrugBank 17139284|17016423 
FCGR3A DIMETHYL SULFOXIDE NCI 16896803 
FCGR3A TESMILIFENE HYDROCHLORIDE NCI 11556524 
FCGR3A MUROMONAB-CD3 NCI|DrugBank 11599102|17139284|17016423 
FCGR3A GELDANAMYCIN NCI 7662976 
FCGR3A HYDROGEN PEROXIDE NCI 2138680 
FCGR3A DOXORUBICIN NCI 1830717 
FCGR3A PUROMYCIN NCI 8423352 
FCGR3A ADALIMUMAB DrugBank 17139284|17016423 
FCGR3A IBRITUMOMAB TIUXETAN DrugBank 17139284|17016423 
FCGR3A BROMOACETIC ACID NCI 1832500 
GPX2 GLUTATHIONE cofactor DrugBank 17510403 
GPX4 GLUTATHIONE cofactor DrugBank 12751792|17503194|17139284|17016423|149679
15 
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Supplementary Table 34. –Continued. 
GSS ACETYLCYSTEINE stimulator DrugBank 2502672 
GSS CYSTEINE  DrugBank 16940754 
GSS CHEMBL460831 DrugBank 10592235|17139284|17016423 
GSS GLUTATHIONE DrugBank 17401648|17607728|17630655|17452339|174677
61 
GSS CHEMBL1230989 DrugBank 10592235|17139284|17016423 
GSS GLYCINE  DrugBank 17401648|16996193|17397529|17452339|171244
97 
GSTP1 EZATIOSTAT 
HYDROCHLORIDE 
inhibitor ChemblInteract|DrugBank 10592235 
GSTP1 GLYCERIN  DrugBank 17139284|17016423 
GSTP1 CIBACRON BLUE DrugBank 17139284|17016423 
GSTP1 IFOSFAMIDE NCI 16282887 
GSTP1 THIOTEPA PharmGKB 
GSTP1 EZATIOSTAT TdgClinicalTrial 
GSTP1 CAMPTOTHECIN NCI 15500952 
GSTP1 EPIRUBICIN PharmGKB 
GSTP1 CHEMBL345292 DrugBank 10592235|17139284|17016423 
GSTP1 DAUNORUBICIN NCI 10050715 
GSTP1 PYRIMETHAMINE PharmGKB 
GSTP1 VERAPAMIL NCI 3566185 
GSTP1 CYTARABINE NCI 3978635 
GSTP1 ALCOHOL  NCI 1302037 
GSTP1 ETOPOSIDE PharmGKB 
GSTP1 BUSULFAN NCI 15779864 
GSTP1 DOCETAXEL NCI 10639573 
GSTP1 MERCAPTOPURINE PharmGKB 
GSTP1 MIFEPRISTONE NCI 1302037 
GSTP1 OXALIPLATIN NCI 12072547 
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Supplementary Table 34. –Continued. 
GSTP1 MISONIDAZOLE NCI 3753520 
GSTP1 PACLITAXEL CIViC 25010864 
GSTP1 CARBOPLATIN NCI|CIViC 25010864|12360105 
GSTP1 CANFOSFAMIDE TdgClinicalTrial|DrugBank 16014111|12738715 
GSTP1 MECHLORETHAMINE HYDROCHLORIDE NCI 2882834 
GSTP1 DROLOXIFENE NCI 11721384 
GSTP1 SULFORAPHANE NCI 1549603 
GSTP1 SODIUM BUTYRATE NCI 12896903 
GSTP1 PERFOSFAMIDE NCI 9382956 
GSTP1 LYCOPENE NCI 10806309 
GSTP1 CURCUMIN NCI 15999103 
GSTP1 OMEPRAZOLE NCI 8529327 
GSTP1 CARBOCYSTEINE DrugBank 10592235|17139284|17016423 
GSTP1 CYCLOPHOSPHAMIDE NCI 9382956 
GSTP1 ETHACRYNIC ACID NCI 10900222 
GSTP1 PRIDINOL  NCI 16127053 
GSTP1 PREDNISONE NCI 11186134|10050715 
GSTP1 IRINOTECAN NCI 10639573 
GSTP1 RESVERATROL NCI 11279601 
GSTP1 MELPHALAN NCI 15779864|1988111 
GSTP1 GLUTATHIONE DrugBank 17465221|17517071 
GSTP1 GARLIC  NCI 11962257 
GSTP1 DECITABINE NCI 11948118|11960994 
GSTP1 VITAMIN E NCI 17029404 
GSTP1 EXATECAN MESYLATE NCI 10639573 
GSTP1 AZACITIDINE NCI 11696442 
GSTP1 SELENOMETHIONINE NCI 1759407 
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Supplementary Table 34. –Continued. 
GSTP1 DITIOCARB NCI 2992773 
GSTP1 DEXAMETHASONE NCI 1302037 
GSTP1 HYDROQUINONE NCI 15141365 
HSD11B1 PREDNISONE ligand DrugBank 20634231 
HSD11B1 CARBENOXOLONE inhibitor DrugBank 11752352 
HSD11B1 CHEMBL222670 inhibitor GuideToPharmacologyInteract 
HSD11B1 CHEMBL2153191 inhibitor GuideToPharmacologyInteract 
HSD11B1 CHEMBL2177609 inhibitor GuideToPharmacologyInteract|TTD 
HSD11B1 PHENYLARSINE OXIDE inhibitor TdgClinicalTrial|DrugBank|TTD 
HSD11B1 CHEMBL495597 DrugBank 10592235 
HSD11B1 CHEMBL392452 DrugBank 10592235 
HSD11B1 CHEMBL427896 DrugBank 10592235 
HSD11B1 CHEMBL1161862 DrugBank 17139284|17016423 
HSD11B1 CHEMBL460962 DrugBank 10592235 
HSD11B1 CORTICOSTERONE DrugBank 10592235 
HSD11B1 CHEMBL455907 DrugBank 10592235 
HSD11B1 CHEMBL406572 DrugBank 10592235 
HSD11B1 CHEMBL1161866 DrugBank 9141556|17139284|8585102|17016423 
HSD11B1 CHEMBL453620 DrugBank 10592235 
HSD11B1 CHEMBL218006 DrugBank 10592235 
KCNJ3 HALOTHANE inhibitor DrugBank 11465552|15175324|11455015 
KCNJ3 CHEMBL2409106 activator GuideToPharmacologyInteract 
KCNJ3 CHEMBL116590 channel blocker GuideToPharmacologyInteract 
KCNJ3 THYROTROPIN NCI 10075694 
KCNJ3 FLUPIRTINE TdgClinicalTrial 
KCNJ3 CLOZAPINE NCI 10780978 
NAAA CARBENOXOLONE inhibitor GuideToPharmacologyInteract 
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Supplementary Table 34. –Continued. 
NAAA FLUFENAMIC ACID inhibitor GuideToPharmacologyInteract 
NADSYN1 L-GLUTAMATE DrugBank 17139284|17016423 
NAMPT TEGLARINAD CHLORIDE inhibitor TdgClinicalTrial|ChemblInteract|DrugBank 
NMNAT1 BETANMN DrugBank 17139284|17016423 
NR1I3 CHEMBL458603 agonist GuideToPharmacologyInteract 
NR1I3 CLOTRIMAZOLE antagonist GuideToPharmacologyInteract 
NR1I3 MECLIZINE antagonist|modulator GuideToPharmacologyInteract|TTD 
NR1I3 PRASTERONE activator DrugBank 17591676 
NR1I3 ANDROSTENOL DrugBank 10592235 
NR1I3 EFAVIRENZ PharmGKB 
NR1I3 CHEMBL486954 DrugBank 10592235 
NR1I3 CARBAMAZEPINE PharmGKB 
NUDT9 DEXTROSE DrugBank 17139284|17016423 
PROZ MENADIONE activator TEND|DrugBank 17139284|17016423 
SIRT1 CHEMBL257991 activator GuideToPharmacologyInteract 
SIRT1 SODIUM LAURYL SULFATE inhibitor GuideToPharmacologyInteract 
SIRT1 CHEMBL420311 inhibitor TdgClinicalTrial|GuideToPharmacologyInteract 
SIRT1 SPLITOMICIN inhibitor GuideToPharmacologyInteract 
SIRT1 RESVERATROL DrugBank  
SIRT3 SODIUM LAURYL SULFATE inhibitor GuideToPharmacologyInteract 
UGT2B15 OXAZEPAM PharmGKB 
UGT2B15 LORAZEPAM PharmGKB 
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